TW314553B - - Google Patents
Download PDFInfo
- Publication number
- TW314553B TW314553B TW080107750A TW80107750A TW314553B TW 314553 B TW314553 B TW 314553B TW 080107750 A TW080107750 A TW 080107750A TW 80107750 A TW80107750 A TW 80107750A TW 314553 B TW314553 B TW 314553B
- Authority
- TW
- Taiwan
- Prior art keywords
- sequence
- vector
- antibody
- group
- ministry
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Γι 1..4.5^3_ 五、發明説明( A 6 B6 經濟部屮央標準局员工消费合作社印製 本發明係1990年9月28日提申的美國專利申請案編號 07/590,219的部份繼績(CIP)申請案。 . 發明背鲁 本發明一般而言僳騮於異體性受器的重組表現,特別 是有鼷於該等受器在絲狀噬菌體的表面上之表現。 抗體是脊椎動物的免疫条統所產生的可輿一抗原結合 的異釀性受器。該分子係由兩傭重鐽與兩鍺輕鏈Μ雙破鍵 - 結合在一起解組成者。抗賺具有一看起來像字形之 結構且其抗原結合部份#位於該Υ形結搆之兩顧短鹫之端 部。已知位於重鐽與輕鏈多跃上對當於抗原結合部份之區 域係為可變區域。抗疆在此區域彼此之藺所生差異主要係 關係到抗髅彼此之間結合專一性的變異性。該等結合專一 性係爲抗原舆重鍵多肽及軽鐽多肽相互反應之一複合物。 免疫糸統具有產生近乎無數的各種不同的抗髏之能力 。生成該一龐大的多樣性主要是透遇重组Μ形成各鍵的可 變區域Μ及透遇重鍵輿輕鏈的差.別配對°模傲天然的免疫 条统並產生可與任何所欲之分子结合的抗體之能力是極有 價值的,因為該等抗嫌可Μ用於診斷及治療。 直到最近,要生成對抗一所欲之分子的抗醯湛能經由 天然免疫反應的搡作。其方法包括實驗動物之正統的免疫 化技術Μ及單株抗籤的製迪。單株抗體的產生係費時且費 力的。其包含了一集列不同的技術並且只能Μ動物細胞上 進行。動物細胞具有相嘗長的世代期間並且較之原核細胞 需要採取額外的預防措施以確保其細胞培餐物的生存力。 先 讀 背 注 意 事 項 再 填 寫 本 裝 fr 線
A 本紙張尺度遑用中鷗S家樣準(〇»S)T 4規格(210X297公at) 3 8】.7 . 20,000張(Η) s___ 經濟部中央標準扃GET:工消費合作社印製 4558 Λ 6 Π 6 五、發明説明( 一種在細蘭驩内產生極多種各式各樣的抗鐮分子之一 方法已載述於 Huse et ah, Science, 246,1275Γ1281 .(1989),該文獻在此併入本案以為參考資料。該方法使用 噬_體λ做潙載黼,該λ載體爲一長形,缔狀的雙股DNA 分子。使用此載讎來製迪抗體渉及將重鍵與輕鏈之DNA族 群殖入各別的載釀内。該等載髏接而被隨機地結合Κ形成 一單一的載醱,其指導重鐽舆輕鋪之共表現Μ形成抗鱅片 段。此方法的'缺點為當產生該共表現載體時會同時產生非 所欲的載體部分之組合。雖然逭些非所欲的組合不能產生 可活的噬齠體,然而其確實谊成序列從該族群潁著的流失 ,而因此減少了可被獲得的介於重鐽與輕鍵之間的各種不 同組合之數目多櫬性。此外,該λ噬菌體基因的大小比碼 编該等抗鰾片段之基因為大。這使得該λ条統先天上比其 它可用的載體条統更難搡作。 因此需要一棰方法Μ產生其棋倣天然免疫糸統的異體 性受器之多樣性族群,該方法快,速且有效並且只產生所欲 之組合而無多槺性之m失。本發明滿足了上述要求並且提 供了相蘭的優點。 本發明之摘要 本發明係鼸於數銪含有第一及第二DNA序列之多樣性 組备的細胞,該第一及第二DNA序列各自碼编會形成一異 腥性受器之第一及第二多肽,該異蠢性受器被表現在一細 胞的表面上,最好該細胞是一能生成諸如M13之絲狀噬菌 賸者。本發明亦提供了載體,蘧殯条统及製通和篩壤該異 請 先 ik 背 注 意 事 項 再 m 窩 本
I 裝 η * 本紙張尺.度遑用中國困家楳毕(CNS) f 4規格(210_x297公釐) 4 81. 7 . 20,000^(11) Λ 6 iU4553----— 五、發明説明() 體性受器的方法。 圖忒簡沭 , .第1團為兩健用於從重鏞及輕鍵存庫構建表面表現存 庫的載鼸之一备構画f M13IX30 (第1A画)是用於遴殖重 鋪序列(空心白框區)的載鰻,單頭箭號代表Lac p/o表 現序列而雙頭箭頭代表其被用來與M13IX11結合的M13IX30 之部份β琥珀(a*ber)終止密碼子及相鼸的限制位置亦有 顯示出。MlllXll (第1B豳)是用於遵殖輕鰱序列(實心 黑框s的媒髏。粗線代表假-野生型uvm)及野生型( gVIII)基因VIII序列。雙頭箭頭代表其被用來與M13IX30 結合的M13IXII之部份。亦有顯示出相關的限制位置。第 1C圖顯示源自重鍵與輕鏈存摩之載腱族群的结合Μ形成有 功能的表面表現載體《13IXHL。第1D圖顯示在一非-抑制 子菌株內一表面表現存庫的產生及噬菌饞的產生。該噬菌 體被用來感染一抑制子齠株(第1S圈)以供表面表現及存 庫之篩蘧。 . 第2圖係為Μ13ΙΧ30之核苷酸序列。 第3圏係為Μ13ΙXII之核苷酸序列。
經濟部中央標準局s:工消费合作社印II (請先_讀背.Φ之注意事項再填寫本I}f" . 第4躧係潙Μ13ΙΧ13之核苷酸序列。 第5圖係為MH3IΧ34之核苷酸序列。 第6圏係為Μ13ΙΧ60之核苷黢序列。 龙發萌海細櫺沭 本發明係針對簡單且有效的方法Μ產生極多種各式各 樣的異體性受器之組合。本案方法是有好處的因為只有適 本紙班尺本逍《中《«家樣竿(C»S) T4規格(210X297公釐) 5 81. 7 . 20,000¾ (II) Η 6 丘、發明説明()、 經濟部屮央標準局貞工消費合作社印製 當的媒鱧部份之組合被隨機地集合Μ供不同的DNA序列之 共表現而無族群大小或多樣性之損失。該等受器可虔表現 在細胞的表面上,該等細胞例如那些可生成絲狀噬菌豔者 ,該曬_體可被大量地篩遴出。碼编該等受器之核酸序列 可被容易地鑑定出持微因為該絲狀噬菌饅生成單股DNA以 供有效的序列分析及突變誘發方法。如此所製得之異匾性 受器可用在無數的診斷及治療程序。 1 在一實瘡例中,兩舾各式各樣的重鏈(Hc>舆輕鐽(Lc) 序列之族群藉由聚合酶鍵反應(PCR)被合成之。這些族群 被殖入各別的M13-基底的載讎(含有表現所需因子)內。 該重繾載醱含有一基因VI11 (gVI Π )外套蛋白序列以致於 該等He序列之轉薄產生gVIII-Hc融合蛋白質。隨機地组合 二載體之族群K致於只有含有該笄He及Lc序列的載體部份 被結合成一單一的環形載鑼。該結合的載體指導He及Lc此 二序列之共表現為Μ供該二多fe之組合以及M13上之表面 表現。同時存在一俪機制Μ於存.庫構建及篩選期間内控劁 gVIII-Hc融合蛋白質的表現Q 在此所用之“異饅性受器”一詞係指其由兩健或更多 的次單位所構成之蛋白質,該等次單位合在一起可對一特 定分子展現結合活性。據了解,只要多呔的組合及該组合 的複合物之功能可被滄持,該名詞即涵括次單位片段。例 如,異餵性次單位包括抗膜及其片段(如:Fab及(Fab)e 部份),T細胞受器,整合子(integrins),荷爾蒙受器 及傅遞子受器。 先 J竭 請 背 注 意 事 項 再 璜 寫 本 1 裝 訂 線 本紙Λ尺度逍用中a B家槔準(C«S)甲4規格(210x297公*) 6 81. 7 . 20,000張(II) -514553_ 五、發明説明() 經濟部中央摞準局员工消费合作社印製 在此所用之“預定的分子”一詞係指一選自於多種選 擇之分子。例如,該分子可為一蛋白質或胜fe,或r-有機 分子(諸如藥)。苯左代雜潘(benzodiazapaa)為一預定 的分子之待例。 在此所用之“共表現”一詞係指2衡或Μ上的通常被 表現如同各別的多fe之核酸序列的表現。鼸於異體性受器 ,該等共表現的多呔聚合形成該異釀物(heteroior ),因 - - ' 此,在此所#之“表現因子” 一詞係指有蘭形成該等異體 性受器之被表現的多肽的轉錄、轉譯、調節及分類所必須 的序列。該名詞亦包含了兩傭被連結在一起但可組合成一 異蘐性受器的次單位多fe之表現。經連結的多呔之共表現 的一健特例爲He和Lc多呔與一將該二次單位結合成一單鏈 的可擦性胜呔或多fc連結子一起被表現。該連結子係為可 撓曲的而可使He和Lc部分聯結成一有功能的Fab車段。 本發明提供一種物質組成物,其包含有數個含有第一 及第二DNA序列之多樣性組合的.細胞,該第一及第二DNA 序列各自碼编會形成一異體性受器之第一及第二多fe,.該 異體性受器對一預定的分子展現結合活性,該異體性受器 被表現在絲狀噬菌體的表面上。 碼繙號異膿性受器多呔的DNA序列可藉由熟於此藝人 士所知的方法獲得之。該等方法包括,例如,eDNA合成及 聚合_鐽反應(PCR) 〇視其需要而決定使用何種方法或那 些方法的組合Μ得到所欲之序列的族群。該表現可於任何 可相容的載蘐少宿主糸統内進行之。該等条統包括,例如 -先 %閲 讀 背 注 意 事 項 再 填 % 本 \ 裝 订 線 本紙張尺度遑用.中® 家樣华(.C,NS) Τ4規格.(210χ2!)7公龙) 7 81. 7 . 20,000¾ (II) 14hiZ- 五、發明説明( Λ 6 Π 6 經濟部中央櫺準局员工消费合作社印製 ,原核生物(如大膦桿《)、酵母籲条統Μ及其他的有核 生物条統(如晡乳動物細胞)體内之質體或噬菌驩載鑲( Phageaides),但在本察中將以其目前最佳的具體實例( 亦即在絲狀噬菌髅之表面上的表現)予Μ描述之。絲狀噬 菌镰包括,例如,Μ13,F1和f d。此外,該異體性受器亦 可視需要和所使用的載體/宿主条統而以可溶性或經分泌 的形式被表現之。 異鼸性#器諸如抗體或其功能性片段在M13的表面上 之表現,可Μ,例如,使用第1圖所示之載體条統而予以 完成。在實施例1中清楚地說明如何構建具一般技術之人 士可做出的載_。完整的核苷酸序列見於第2圖和第3麵 。此条統製馇,出被功能性址聯結至表現因子之被隨機地組 合之童鍵.(He)舆輕鏈(Lc)抗證片段族群。該He多呔被製成 有如一帶有爲基因VIII所碼編之M13外套蛋白質的融合蛋 白。該gVIII-Hc融合蛋白質因而將該經組合的He和Lc多呔 固定於M13的表面上。由此糸統.所得之He舆Lc組合之多樣 性可達5X 10τ或更离。亦可獲得小於5 X 1〇7的多樣性且此 視需要及所欲予Μ表現的異讎性受器之型式而定。 欲予Μ結合至一載體Μ供表現的He和Lc碼编序列之族 群各被殖入不同的載體内。鼸於第1圖中所示之載髅,各 種癘编He多fe之序列被殖入ΜΪ3ΙΧ30。碼编Lc多汰之序列 被殖入M13IX11。該等族群被插入M13IX30的Xho I-Spe I 或Stu I限制酶作用位置之間以及M13IX11的Sac I-Xbal 或Eco RV位置之間(分別為第1A圔及第1B圖)。 ? 先 二閲 ik 背 — 注 意 事 項 再 填 % 本 Μ 本紙張遑用中國興家樣毕(CNS)T4規格(210x297公;¢) 81. 7: 20,000^(11) 號專利申請案 中文說明書修正頁(86年5月) ΚΊ B7 五、發 —------=®Γ 經濟部中央橾準局貝工消費合作社印製 插入該等載體内之He及Lc序列的族群可被合成帶有 該碼编序列之.相對端側翼的適當限制辨識序列,但此並非 必需的。該等位置容許這些序列(與骨架中的表現因子) 之煅化.(annealing〉及聯結有這些序列的表現元素煮Μ成 為一被適當的限制酶的限制之雙股的載體。任擇地,Μ及 一較佳的具體實施例,該等He和Lc序列可Μ被插入載髅中 而不需DNA.的限制。此捶選殖方法是較有利的,因為天然 碼编的限制酷’位置可能存在於該等序列中,因此當Κ 一限 制酶處理時會引起該序列的破壊。對於不具限制的選殖, 該序列主要係以一 3'至5’外核酸酶(如T4DNA聚合酶或外 核酸酶I 11)予Η處理之。一痼5 ’至Υ外核酸酶亦可達到 相同的功能。所產生的突出5’端應互補於該載體內於殖入 位置之限制和外核酸酶處理後所產生的單股突出物。將該 等外核酸酶處理過的揷入物Μ熟于此技人士所知之方法和 经限制的載體一起黏合<3 η n ea Ud)。該外核酸酶法降 低了背景並較容易操作.。 . 用於He族群之載髏M13IX30 (第1A圖)除了表現因子 外還包含一位在下游並與該等殖入位置形成骨架之碼编, 假-野生型gVIIl產物的序列。此基因碼编野生型M13 VIII 胺基酸序列密碼但已在核苷酸级上予Μ改變K減少與包含 在相同載塍内之野生型svni之ΙΪΓ源性戛组。該野生型 gViII存在Μ確保至少一些有功能的,非融合外套蛋白可 虔生成。因此包含一野生型gVin可降低生成不可栝的噬( 菌體之可能性以及對抗某種胜fe融合蛋白質的生物性選擇 — ---I Is-·-, m· --i-1 i- --- Hi 「裝— X請先閱讀背面之注意事項再填寫本頁) 訂 ---- 1^- ^ --- 私紙張尺度適用中國國家標準(CNS ) A4规格(210X297公釐)-9 rSMSM" Λ 6 B6 五、發明説明 經濟部中央櫺準局tS:工消费合作社印製 。該二基因的差別調節亦可用來控制鍰野生型舆野生型蛋 白質的相對比例。 , 一琥珀終止密碼子亦被包含在下游並舆該等殖入位置 形成骨架。該终止密碼位於該等被插入的He序列與gVI II 序列之間且骨架之中。有如野生型gVIII之功能,當組合 載體部分Μ生成有功能的表面表現載體時,該珑珀終止密 碼子亦降低生物性選擇。此乃經由使用一非-抑制子(sup - · t 0)宿主《株ΐϊί完成,因爲該等非-抑制子菌株會在He序列 之後但在假gv III序列之前終止表現。因此,該假gVI II 基本上在這些情況下不會被表現在該在噬菌體的表面上。 相反地,只有可溶性He多ft會被生成。當希望製迭抗體片 段的大量族群時,可有利地利用在一非-抑制子宿主菌株 內之表現。琥珀Μ外之終止密碼子(如卵白(opal)和豬石 (ochre)終止密碼子),或分子開醑(如可誘發的阻遏子 因子)亦可用來解開源自表面表現之多呔表現。 用於Lc族群之載鱧M13IX11,.含有Lc序列所需表現因 子及選殖位置(第1B圃)。如使用M13IX30, 一供分類 至該噬菌體表面的引導序列位在上游並與該等殖入位置形 成骨架。此外,亦存在一核糖體結合位置及Lac Z起動子 /操作子因子Μ供該等DNA序列的轉錄及轉譯。 該二載體含有兩對的Mlu I-Hind III限制酶位置(第 1A及B國)以將He和U碼编序列及相關的載體序列連結在 一起。Ml u I和Hi nd 111為非-相容的限制位置。此二配 對在該殖入位置左右被對稱地定位因此只有含有該等欲予 ? 先 讀 背 U而 之 注 意 項 再 填 寫 本 頁 本紙張尺度速用中《國家«毕(CNS)亨4規格(210X297公;it) 10 81. 7 . 20,000¾ (il) 五、發明説明() Μ表現之序列之該等載體水部份被確實地合併成為一單一 的載鎳。該二對位置在該二載髏上被定位於同於另广者處 並且介於該二位置間的DNA在該二載髅間必須有足夠的同 源性Μ容許煅化’。此定位容許各環形載髏分裂成兩Μ部份 Μ及位於各載體的内基本成份組合成為一單一環形載鑲, 其中該被碼编的多呔可被共表現之(第1C圖)。. 可使用住二對的限制酶位置,只要其在該殖入位置左 , .1 右被對稱地索’位且在該二載體上是位置相同的。然而,位 於各對内之該等位董必須是不相同的或能被做成被差別地 辨識成有如一斷裂基質。例如,第1圈中所示之包含在該 等載髏内的兩對限制位置爲Ml u I和H i nd I Π。該等位置 各別可被Ml u I和Hind III差別地切斷。熟于此技之人士 知道如何Μ其它配對之限制位置取代上述之Mlu I-Hind III配對。又,舉例而言,除了兩锢Hind ΠΙ和兩锗Ml u I 位置M外,亦可將一 Hind I和Not I位置舆一 Mlu I和一 Sal I位置配對。 . 經濟部中央標準局is;工消費合作社印製 隨機地將該二多樣性族群内之He和Lc碼编序列集合在 一起K形成一單一載睡(第1C圏:M13IXHL )。由各別獨 立的載體(M13IX30和Μ13Π11)所提供的該等載體序列像 為生成可存活的噬蘭體所霈者。又,因為該假απι序列 係包含在M13IX30內,有功能的抗鼸片段(如Lc聯結的 gVI II-He融合蛋白)之共表現只有在該等載體序列被建結 成如M13IXHL中所示時才能於該噬菌鑲表面上被達成。 該结合步揉係MMlu I和Hind III分別地限制各锢含 本紙張尺度逡用中釅®家楳準(CHS) T 4規格(210x297公;¢) 81. 7. 20,_張(11) 經濟部中央標準局貞工消费合作社印製 4咖 五、發明説明( A 6 η 6 有He和Lc之載體族群。各櫥經限制的載鼸族群之3’端Μ上 述用於將序列插入殖入位置内的3’至5’外核酸酶予Κ消化 之。混合該等載廣族群容許其煅化並將之引入一適當的宿 主内。該存庫之初期構建期間内最好使用一非-抑制子宿 主(第1D圖)以確保該等序列不會因為差現如融合蛋白質 而不被遴擇。從在一非-抑制子Β株建立的存庫中分離出 的噬菌賭可用來感染一抑制子菌株Μ供抗斷片段的表面表 , ·· /«« 現。 一種從一多樣性的異體性受器族群中選出一對預定的 分子展現結合活性的異體性受器之方法包括:(a)將一第 一多樣性DNA序列族群(碼编一多樣性的第一多呔族群) 可操作地連結至一笫一載翳(其具有兩對於一殖人位置左 右被對稱地定位之限制位置;(b)將一第二多樣性DNA序 列族群(碼編一多樣性的第二多fe族群)可操作地連結至 一第二載體(其具有兩對於一殖入位置左右被對稱地定位 之限制位置且其方向同於該第一.載髏上者;(c)在只允許 含有該等第一和第二DNA序列的載髏序列之操作性結合的 情況下組合步驟U)和(b)的載疆產物;(d)在足供表現該 j 等第一和第二DNA序列族群的情況下將該等組合遏的載體 之族群引人一可相容的宿主髅內;Μ及(e)測定可结合該 預定的分子之異鼸性受器。本發明亦提供用Μ澍定碼编該 等多呔之核酸序列之方法。 該抗鼸存庫的表面表現係於一琥珀抑制子a株内進行 的。如上所述,介於該He序列和《VIII序列之間的琥珀終 先 :閲 讀 背 之 注 意 事 項 再 填 寫 本 頁 本紙張疋尽遑用中« β家櫺毕(CNS) Τ4辑格(210X297公:¢) 81. 7. 20,000張(II) B6 * 五、發明説明( 請 讀 背 之 注 意 事 項 # 寫 本 止密碼子解開一非-抑制子菌株内之該二成份。分離由該 非-抑制子Μ株所產生之噬β體並Μ之感染一抑制子菌株 會在表現時將He序列與gVIII序列連起來(第3Ε國)。在 .感染後培餐該抑制子齠株容許該M13之表面上該存庫中所 有抗體種類之共表現如同gVIII融合蛋白質(gVIII-Pab) 融合蛋白質般共同表現。任擇地,該DNA可由非-抑制 子_株中分_出並隨而引入一抑制子菌株Μ達到相同的效 / A-fr, 巣0 一 - 經濟部屮央標準局Μ工消費合作社印褽 gVIII-Fab融合蛋白其表現的位準還另外可於轉錄级 位予Μ控制。該gVill-Fab融合蛋白的兩齒多呔係在Lao Z 起動子/操作子条统之可誘發性控制之下。其它可誘發的 起動子亦可使用且為熟於此技人士所熟知者。為達高位準 的表面表現,該抑制子存库在有Lac Z起動子之誘發物〔 諸如異丙镟基- /3 -半乳糖苷(IPTG)〕的存在下培餐之。 可誘發性控制是有利的因為藉由在非-表現狀況下培養該 存庫可使針對無功能的gVIII-Fa.b融合蛋白的生物性選擇 減至最低。於是只有在篩選之時才誘發表現以確保該存庫 中整锢抗震族群被準確地表现在該噬菌髏表面上。又,此 可用於控制該噬菌齷表面的抗體的效價。 該表面表現存庫Μ檷準親和性分離方法篩選會結合預 定的分子之專一性Fab片段。該等方法包括,例如,平盤 法(panning)、親和力餍析法和固相吸墨法。平盤法係載 於 Paraley and Snith,Gene 73:305-318 (1988)(該論 文在此併入本案M為參考文獻),其係較為適宜的因為噬 遑用中《«家樣毕(CHS)T4規格(210><297公此) 81. 7 . 20,0003t (II) S14553_ 五、發明説明() η 6
0體的高滴定度可Μ小容積被容易、快速地篩選出。進一 步言,此方法可於該族群中遴擇較小的Fab片段棰類,不 然,其將為偵测不到的並被擴增至實質上均質的族群。該 等經邃擇的Fab片段可藉由於該噬®體族群之擴增後序列 分析碼编該等多呔之核酸序列而予Μ特撳趣定之。 Μ下實施例僳用來例示本發明而非限制本發明。 富施例1 Μ1 3表而h的髏Η段的棲裁、弄斑ft餾珑 此實施例顯示一多樣性的重鏈(He)和輕鏈(Lc)抗體片 段族群之合成及其有如基因VIII-Fab融合蛋白在M13表面 上之表現。該等被表現的抗體係衍生自一 He和Lc配對的隨 機混合和共表現,同時予Μ證明的是其結合苯左代雜潘( benzodiazapan, _B_DP)的被表現的Fab片段的分離和待擻 鑑定及其對應的核苷酸序列。 mRNA的分離和杭鶄Η段的PCR镲增 該表面表現存庫係由一已接受過KLH -偶合的苯左代 雜潘(BDP)免疫的小白鼠所分離出的aRNA而予Μ建立者。 BDP舆鑰孔血蘭素(Κ0Η)之配對僬使用載於Antibodies:A 請 先 m ih 背 之 ’/主 意 事 項 再 填 寫 本 頁 裝 订 線 Λ 經 濟 部 中 央 標 準 局 员 工 消 β 合 作 社 印 製
Laboratory Manual. Har1 os and Lane, eds., Cold Spring Harbor,New York (1988)之技術,該文獻在 ft 併 入本案以為參考文獻。簡單地說,10.0毫克的鍮孔血蘭 素和0.5毫克的帶有戊二醸基間隔子之BDP接枝Ν-羥基琥 珀酿亞胺連結子附肢。偶合的進行係如Jonda et a 1 ., Science. 241: 1188 (19S8)所述者,該文獻在此併入本案 本紙.張凡度遑用中BH家掭準(ε.Ν5)Τ4規格(210X297公贤) 81. 7 . 20,000¾ (II) 314553 經濟部屮央標準局员工消费合作社印製 五、發明説明( Μ為參考文獻。該KLH- BDP缀合物藉由凝膠遇濂層析法通 SephadexG-25 而被移出。. , 藉由將lOOwg的KLH-BDP缀合物加到250/ig的磷酸 鹽鑀衝的生理鹽水(PBS〉内來製備該綴合物以供注射至小 白鼠證內。加入等鑛積的完全弗羅因德氏佐剤(Freund’s adjuvant)並使整掴溶液乳化5分鐘。使用300w 1的該乳 化液注入小白鼠饑内。該等注射係使用21號注射針於數値 位置皮下注妨'之。第二次的BDP免疫係於兩週後進行。這 次注射係如下製備:将50W 1的BDP於250 w 1的PBS内稀 釋並以等體積的明礬與該混合。使用23號注射針將500 1 的該瘠液注入小白鼠腹膜腔内。一個月之後,M50ug的 綴合物(於PBS内稀釋至200 /il)給小白鼠最後一次注射 。此次注射係使用30號注射針靜脈內注射倒尾靜嚴。在此 最後注射的5天後,犧牲小白鼠並從其脾臓分離出總細胞 RNA 〇 總 RNA 係藉由 Chofflczynski ,and Sacchi , Anal . Biochei, , 162 :156-159 (1987)(該文獻在此併入本案 M 為參考文獻)之方法從單隻如上述了以免疫的小白鼠之脾 臟分離出者。簡短而言,在從該經免疫的小白鼠髑内取出 脾臓之後即刻使用一玻璃均質器在10ml的含有4.0M的鳥_ 昤異硫氮酸鹽、0.25M檸檬酸納(pH 7.0)及0.1M 2-擁基乙 醇的變性溶液內將组雜均質化。取lal的2M醋酸納(pH 4.0) 與該均質化的脾臟組雜混合。亦將1b1的飽和酚混入該含 有均質化的脾組鏃之變性溶液内。將2b1的氯仿:異戊醇 請14 ifi 背 之 注 意 事 項 再 構 % 本 頁 .裝 訂 線
A 表紙張尺度遑用中鼷《家楳毕(CNS) T4規格(210X297公法) 81. 7 . 20,000¾ 0〇 五、發明説明() (24:1 v/v)之混合物加到該均質物內。劇烈混合該均 質物10秒鐘並將之放在冰上15分鐘。接著將該均質,物移入 一厚壁的50al聚異丙烯離心管(Fisher Scientific Company, Pittsburgh, PA)中―。在 4 Ό, 10, OOOxg 下離 心該溶液。将上層含有MA之水雇移至一新的50il聚丙烯 離心管内並與等體積的異丙醇混合。此溶液予Μ放在-20 下達至少1小時Μ沉澱RNA。將含沉澱的RNA之溶液在4 t:下M10,0(f〇xg離心20分鐘。收集該沉澱的總細胞RNA並 將之溶於3ml上逑的變性溶液中。將的異戊醇加入該再 次散浮的總細胞RNA中並劇烈地混合。將此溶液放在-20 t下達至少1小時Μ沉穀BNA。將含有沉澱的BNA之溶液在 4 t:下M 10,000xg離心10分鐘。該沉濺的RNAK—含有75 %乙醇的溶液清洗一次。該沉瀑的RNA在真空下予Μ乾燥 15分鐘然後再散浮於二甲基焦碳酸酯(DEPC)處理過的水( DEPC- Ha0)中。 經濟部屮央標率局β工消費合作社印製 供用於第一股cDNA合成的Poly A* RNA係由以上所分 離的總RNA所製備者,其乃使用一旋轉-管柱澍試組( spin-coluan Kit, Pharaacia,Piscataway,NJ)並依據 製造商之建議而行。基本的方法載述於Aviv and Leder, Pron. Natl. Acad. . . USA.叹:1408-1412 (1972), 該文獻在此併入本案以為參考文獻。簡短而言,將一半的 總RNA (如上述從單隻經免疫過的小白鼠脾臓予K分離出 而製備者)再散浮於U1的DEPC- Ha〇中並维持在65Ό下5 '分鐘。將1«1的兩倍高鑒裝載缓衝液〔PH7.5之100bM的 81. 7. 20,000.張(I!)
i •先 讀 背 ^而 之 注 意 事 項 再 本 I
A t紙Λ尺度遑用中《 Η家楳準(CNS) f 4規格(210X297公龙) 五、發明説明() 經濟部中央搮準扃员工消費合作社印製
Tris-HCl,1M的氮化納,PH8.0之2_〇tM的乙二胺四醋酸 (EDTA)二鈉及0.2%的十二烷基磅酸納(SDS)〕加入該再散 浮之RNA中,並容許該1合物在室溫下冷郤。然後將該混 合物施加至一 oligodT (Collaborative Research Type 2 或Type 3 Bedfore, HA〉管柱中,該管柱係事先以一含有 0· 1M之氫氧化銷及5aM之EDTA的溶液淸洗該〇lig0-dT並接 而MDEPC-處理的水平衡該管柱而製得者。將洗出物收集 在一無豳的寶'異丙烯管中,並於6510下加熱該洗出物5分 鐘後將之再施加至相同的管柱中。接而用2®1的由pH7.5之 50bM 之 Tris-H:Cl、及 500eiM 之氯化納及 PH8.0 之 1·Μ 的 EDTA 及0· 1%的SDS所組成之高»裝載緩衝液清洗該〇lig〇-dT管 柱。然後,M2b1的一倍中度鹽緩衝液(PH7.5之50mM的 Tris-HCl、100aM氮化鈉,ρΗ8·0之 laM 的 EDTA 及 0.1% 的 SDS 清洗該 olig0-dT 管柱。以 U1 的由 10al Tris-HCl (pH 7.5)、laM EDTA (ΡΉ8·0)和0·05% SDS所構成之鍰衝液洗 提該*RNA。該*RNA之純化係藉电K酚/氣仿萃取此溶液並 接著M100%的氯仿萃取一次乙醇沉穀之並再散浮於 KDEPC處理的dHs0中。 在有關PCR擴增之製備中,aRNA被用來作為cDNA合成 的模板。在一典型的250 // 1的反轉錄反應混合物中,首 先在65¾下將5-配於水中的膊bRNA與500ng (0.5 paol)的3’V 引子(引子12,表I ),或是3’V引子( 引子9,表I)煅化5分鏡。接著將該混合物調整至含有 0.8fflM dATP> 0.8«M dCTP . 0.8nH dGTF» 〇.8eM dTTP> (請先閲讀背而之注意事項再填寫本頁) -4 --4 -I---Γ < 本纸張尺本逡用中BS家樣準(CNS)T4規格(210X297公*) - 17 - 81. 7_ 20,000張《11) Λ 6 Π 6 314553 五、發明説明() IOObM Tris-HCl (ρΗ6.8),ΙΟβΜ氣化鎂,40ιΜ氯化鉀Μ及 20·Μ 2-ΜΕ。將26簞位的冥洛尼氏(Moloney)-小白鼠白血 病病毒(Bethesda Research Laboratories (BRL), Gaithersburg, P)反轉錄酶加至該溶液中並於40t:下培 育1小時。所形成的第一股cDNAK酚萃取之,Μ乙醇沉澱 之,並接而將之於下逑有蘭重鏈輿輕鐽序列之擴增的聚合 酶反應程序中。 表I顯者用於有關Μ13ΙΧ30存庫之構建的重鏈Fd片段 的擴增之引子。擴增於八個各別的反應内進行,此係依據 Saiki et al . , Science, m: 487-491 (1988〉(該論文 在此併入本案M為參考文獻),每一個反應包含表I中所 列的一ft 5’引子(引子2到9中一者)及一値3’引子(引 子12)。其餘的5’引子(供一單一反應的擴增之用)為 一簡並引子(引子1)或一在其四儲簡並位置處併入次黃 苷的引子(引子10)。剩下的3’引子(引子11)係用於 構建Fv片段。該等5’引子晝有底.線的部份併入了一锢Xh〇 I位置,而該3’引子畫有底線的部份則併入了一德Spe ί 位置,俥以一供表現之預定的閲讀架構方式將該等經擴增 的片段殖入Μ13ΙΧ30載饈中。
弟I 重舖引芊 (請先閲請背而之注意事項再填寫本頁)、 ____/ Λ 經濟部中央標準局货工消費合作社印製 本紙張尺度遑用中 Η家標毕(CNS)甲4規格(210x297·*;«:) 18 - 81. 7 . 20,000¾ (1Π A 6 B 6 五、發明説明() - · CC G G T 1) 5 1 -AGGT A CT CTCGAGTC GG ; GA A T A 3 , 2) 5' -AGGTCCAGCTGCTCGAGTCTGG - 3言 3) 5' -AGGTCCAGCTGCTCGAGTCAGG - 3 1 4) 5 1 -AGGTCCAGCTTCTCGAGTCTGG - 3 1 5) 5* -AGGTCCAGCTTCTCGAGTCAGG - 3 1 6) 5' -AGGTCCAACTGCTCGAGTCTGG - 3 1 7) 5' -AGGTCCAACTGCTCGAGTCAGG - 3 1 8) 5' t -AGGTCCAACTTCTCGAGTCTGG - 3 1 9) 51 -AGGTCCAACTTCTCGAGTCAGG - 3 1 10) 5言 T 一 AGGTIIAICTICTCGAGTC GG - A 3 1 11) 5' -CTATTAACTAGTAACGGTAACAGT GGTGCCTTGCCCCA - 3 r - 12) 51 -AGGCTTACTAGTACAATCCCTGG GCACAAT - 31 - (請先閲讀背而之注意事項再填寫本頁)11 經濟部中央櫺準局貝工消費合作社印製 表1顯示用於有關M13IX11存庫之構建的小白鼠K輕 鍵序列的擴增之引子。所選擇的這些引子含有可舆載體相 容且不存於該小白鼠輕鍵《RNA的守恒序列上的限制位置。 擴增如上所述於五個各別的反應内進行,每一個反應包含 表I中所列的一锢5'引子(引子3至7中一者)及一摑3’ 引子(引子9)。剩下的3’引子(引子8)被用來構建Fv 片段。該等5’引子畫有底線的部份描述一餾Sac I限制位 置,而該3’引子輋有底線的部份則併入了一個Xba I限制 位置,俥以一供表現务預定的閲讚架構殖入方式將該等經 < 本紙張尺度遑用中®興家標準(CHS)?4規格(210父297公袋) -19 - 81. 7. 20,000張(1丨) 314553 Λ 6 Β6 經濟部中央櫺準局β工消费合作杜印製 五、發明説明() 擴增的片段M13IX30載體中。 表I g舖引平 ' -- · - — - -· — - - · — ---· - -- . ... . .... - . - - -- - -- 1) 5' - CCAGTTCCGAGCTCGTTGTGACTCAGGAATCT — 3 ' | 2) 5' - CCAGTTCCGAGCTCGTGTTGACGCAGCCGCCC - 3' 3) 5' - CCAGTTCCGAGCTCGTGCTCACCCAGTCTCCA - 3' ;4) 5' - CCAGTTCCGAGCTCCAGATGACCCAGTCTCCA - 3' 5) 5' - CCAGATGTGAGCTCGTGATGACCCAGACTCCA - 3 ' 6) ' 5' - CCAGATGTGAGCTCGTCATGACCCAGTCTCCA - 31 7) 5' - CCAGTTCCGAGCTCGTGATGACACAGTCTCCA- 3 ' 8) 5' - GCAGCATTCTAGAGTTTCAGCTCCAGCTTGCC - 3 ' 9) 5' - GCGCCGTCTAGAATTAACACTCATTCCTGTTGAA - 3' 有關重鏈及輕鐽片段的PCR擴增反應係在一 100/zg的 反應混合物中進行,該混合物含有上述反轉錄反應之產物 (約5w g 的cDNA-RNA 雜交物),300naol 的3’V 引子( 引子12,表I )和一供重鏈擴增之5’V引子(引子2-9, 表I ),或者300naol的3’V引子(引子9,表E )和一 供各嫡輕鍵擴增之5’ V引子(引子3-7,表I ),一由200 mM 的 dNTPs,50hM 的氯化鉀、lOiaM Tris-HCi (PH8.3)、15 aM的氯化鎂、0.1%的明膠和2單位的Thermus aguaticus 一種好熱菌屬細_〇~丸聚合酶的混合物。該反應混合物覆 以一層礦物油並將之引至40傭循環的擴增。每値擴增循環 包含在92它下變性1分鐘,在52它下煅化2分鐘Μ及在72 它下增長1.5分鐘。等經擬增之產物Κ酚/氯仿萃取兩次 ,Μ氯仿萃取一次,以乙醇沉澱,並在-701:下貯存於10
先閲背 而 之 注意 事項再填 %本 I Λ 本紙張尺度遑用+闽鐲家搮毕(CNS)甲4規格(21(^29_/_公没) -20 - 81. .7. 20,000¾ (JI) Λ 6 ____Β6__ 五、發明説明() nM的Tris-HCl (pH7_5)及1®M的EDTA中。所形成的產生被 用來楕建M13IX30及M13IX11存庫(參照下面)。 載鶼:> 嫌建 兩健M13-基底的載鳢(M13IX30及M13IX11)分別被構 建出以供He和Lc抗體片段族群之選殖與增殖。該等媒鰻被 構建出Μ加速抗體片段族群之隨機接合及隨後的表面表現 0 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁)> -e-Γ-Ml Λ Μ13ΙX3CT或He載饋被構建來容置多樣性的He抗體片段 族群。M13mpl9 (Phanaacia, Piscataway, NJ)係為起始 載體。此載體被修飾Μ使之除了該經碼編的野生型M13基 因VIII之外尚含有(1): 一假-野生型基因VIII序列,其 帶有一位在其舆該等用於選殖寡核苷酸的限制位置之間的 琥珀終止密碼子;(2)供用於藉由雜交Κ插入序列之Stu I 限制位置,及與該假-野生型基因VI Π形成架構並供用於 S^lHc序列的Spe I和Xho I限制位置;(3)表現所必須之 序列,例如一起動子,倍號序列及轉譯起始訊號;(4)兩 對的Hind III-Mlu I位置Μ供He和Lc載體部份之隨機連接 ;和(5)各種其他的突變種Μ去除重複的限制位置和Lae Z 的胺基末端部份。 M131X30的構建係於四個步驟內進行。在第一値步驄 中,構建一痼含有該假gVill和各種其他的突變之M13-基 底的截驩,M13IX01F。第二锢步驟包含在一分開的M13bp18 載體內構建一小型選殖位置以產生M13IX03。然後,此媒 體被擴大至含有表現序列及供用於He序列的限制位置以形 本紙張尺度遑用中•困家楳毕(CHS)甲4規格(210X297公龙) -21 - 81. 7. 20,_張(11) 314^_ 五、發明説明() Λ 6 Η 6 成M13IX04B ό第四値也是最後一®步驟包含將在M13IX04B 内新構建的序列併入“3^0^之中以形成《13^30〇, M13IX01F的構建首先包含產生一個假野生型gVIII序 列K供抗體片段的表面表規。該假-野生型基因同於該野 生型基因碼编相同的胺基酸序列;但是,其核苷酸序列已 被改變Μ致於此基因和該碼編的野生型基因VIII之間只有 63%的相同淫。該用於表面表現的基因V111核苷酸序列之 ,〆 修飾減少了 #包含在同一値載體內的該野生型基因VIII同 源性重組的可能性。此外,該野生型Μ13基因VIII被保留 在該載醱条統内以確保至少一些有功能的、非融合外套蛋 白可被製造出。包含有野生型基因VIII在有該等多肽之表 面表現的情況下加速了噬_體的生長,而因此減少了不可 活的噬菌體該等融合基因中生成的可能性。 該假野生型基因VIII之構建係藉由化學合成一条列的 «编該基因之兩股的寡核苷酸。該等寡核苷酸見於表I。 (請先IMJ讀背而之注意事項#蜞寫本頁)f" _kr. m.-* 裝- 線- < 經濟部中央標準局Εζ工消费合作社印製 各紙張尺Α遇用中《鷗家樣毕(CHS) Τ 4規格(210父297公龙) 8K 7. 2〇,〇〇〇張0) 五、發明説明( 砉皿 櫥一g牛型某因ντπ宴核苷酴备利 上股寡核苷酸 VIII 03 VIII 04 VIII 05 VIII 06 VIII 07 A 6 η 6 序列(5'至3〇
GATCC TAG GCT GAA GGC GAT GAC CCT GCT AAG GCT GC A TTC AAT AGT TTA CAG GCA AGT GCT ACT GAG TAG A TT GGC TAC GCT TGG GCT ATG GTA GTA GTT ATA GTT GGT GCT ACC ATA GGG ATT AAA TTA TTC AAA AAG TT T ACG AGC AAG GCT TCT TA
ih 閲 背 之 注 意 事 項 再 填 寫 本 I 裝 訂 線 經濟部中央標準局月工消费合作社印製 下股寡核苷酸 VII工 08 VIII 0§viii ίο VIII 11 VIII 12
序列(Y至¥) AGC TTA AGA AGC CTT GCT CGT AAA CTT TTT GAA TAA TTT AAT CCC TAT GGT AGC ACC AAC TAT AAC TAC TAC CAT AGC CCA AGC GTA GCC AAT GTA CTC AGT AGC ACT TG C CTG TAA ACT ATT GAA TGC AGC CTT AGC AGG GTC ATC GCC TTC AGC CTA G 本紙張尺度遑用中《躅家標毕(CTS)f 4規格(210X297公《:) 23 - 81. 7 . 20,000fk〇l) 五、發明説明( Λ 6η 6 經濟部中央標準局員工消费合作社印製 除了該等末端寡核苷酸VIII 03和VIII 08之外,將上 述寡核苷酸(寡核苷酸VIII04-07和09-12)各K 200ng ( 配於l〇Ml最終體積)予Μ混合,MT4聚核苷酸激酶( .Pharmacia)及1·Μ的ΑΤΡ在30C下予Κ磷酸化1小時,於 70它下加熱5分鐘,藉由在65t:下加熱3分鐘之煉化成為 雙股的形式,接著將之冷卻至室溫達30分鐘。該等反應係 K 1_0單位的T4DNA接合酶(BRL)和ImM的ATP在室S下處理 W 逹1小時,#箸加熱至7〇υ達5分鐘。接而將末端寡核苷 酸煅化至該等接合好的寡核苷酸。該等經烺化及接合的寡 核苷酸產生一旁铒MBaa HI位置位在其5’靖及MHind III 位置位在其3’端镅接之雙股的DNA。一轉譯终止密碼子( 琥珀)緊接著該Baa HI位置。該基因VIII序列Μ密碼子 GAA(Glu)開始並舆該終止密碼子3’端隔兩錮密碼子。該雙 股插入物被殖入M13聚連結子中與Eco RI和Sac I位形成架 構,為達此目的,M13npl9MBam HI (NewEngland Biolabs, Beverley, MA)和Hind III (Nei^Englaird Biolabs〉消化, 並將之與該雙股插入物以一為1: 10之冥耳比結合。該等 接合係在室溫下在一含有1.0%單位T4 DNA接合酶(New England Biolabs)之一倍接合酶缀衝液(50 «Μ 的 Tris-HCl (PH7.8),ΙΟβΜ 的氯化鎂,20·Μ的 DTT,laM的 ATP,50 w g /1BSA)中進行過夜。該接合混合物被轉移至一宿主中並 使用此技藝中的檫準方法篩選颺性反應菌株。 於該構建物中生成數镇突變以產生有功能的Μ131X01F 。該等突變之生成係採用Kunkel.et al., Meth. Enzyiol. ki 領ik 背 *而 之 注 意 事 項 再 填 % 本 4 訂 線 Λ 本紙張尺本进用中《國家樣毕(CXS)甲4規格(210 X 297公*) 81. 7. 20,000¾ (11) 經濟部中央標準局员工消费合作社印製 五、發明説明() 154:367-382 (1987)的方法(該文獻在此併入本案Μ爲參 考文獻)Μ供位置-指導的突變誘發。試劑、Β株,及工作 表係得自於一Bio Rad突變誘發試驗組(Bi 〇 Rad, Richmond, CA),且突變誘發之進行係依製造商所建謙者。 使用Μ突變的寡核苷酸5’ - CATTTTTGCAGATGGCTTAGA -3’和5’-TAGCATTAACGTCCAATA-3’從該載髏中移出兩 値Fok I位置及位在該假基因VIII序列之端部的Hind III 位置位置。薪·的Hind III和Mlu I位置亦被引入M13IX01F 的位置3919和3951處。用於此突變誘發之寡核苷酸分別具 有序列 5’ — ATATATTTTAGTAAGCTTCATCTTCT- 3’和 5, - GACA AAGAACGCGTGAAAACTTT-3'。該Lac Z的胺基末端部份之刪 除係藉由寡核苷酸-指導的突變誘發使用突變的寡核苷酸 5’ 一 GCGGGCCTCTTCGCTATTGCTTAAGAAGCCTTGCT- 3’。在構 成上述之突變時,所有在M13碼编區域内所作之改變係如 此進行以致於胺基酸序列維持不變。所形成的載體(M13IX 01F)被用於最後一個步驟以構EM13IX30 (見K下内容)
在第二値步驟中,使Μ13·ρ18產生突變Μ移除該Lac Z 之5’端直至Lac i結合位置並包含Lac Z核耱體結合位萱 和起始密碼子在內。此外,移出該聚連結子並將一 Ml u I 位置引入Lac Z的碼编區域內。一單偁寡核苷酸被用於逭 些突變誘發並包含有序列“5’- AAACGACGGCCAGTGCCAAGTG ACGCGTGTGAAATTGTTATCC-3,”《Hind III 和 Eco RI 的限 制酶位置 K 寡核苷酸 “5’- GGCGAAAGGGAATTCTGCAAGGCGAT 本紙張尺度遑用中《困家樣準(CHS) f 4規格(210><297公釐) 81. 7 . 20,000張⑻ (請先間讀背而之注意事項再填寫本頁)( -V·*-M— Λ 314553 Λ 6 Β 6 五、發明説明( TAAGCTTGGGTAACGCC— 3’ ”將之引入Mlu I位置之下游。 M13uipl8的這些修飾產生前驅載體M13IX03。 - 將該等表現序列和殖入位置引入M13IX03內係藉由使 用化學合成一糸列的碼编該所欲序列之雙股的寡核苷酸。 該寡核苷酸見於表IV。m iv 上股寡核苷酸f 084 027
序列(β至 GGCGTTACCCAAGCTTTGTACATGGAGAAAATAAAG TGAAACAAAGCACTATTGCACTGGCACTCTTACCGT TACCGT
閲 之 注 意 事 項 再 填 寫 本 I 028 029
TACTGTTTACCCCTGTGACAAAAGCCGCCCAGGTCC AGCTGC TCGAGTCAGGCCTATTGTGCCCAGGGATTGTACTAG TGGATCCG 下股寡核苷酸 085 031
序列(β至37 ) TGGCGAAAGGGAATTCGGATCCACTAGTACAATCCCTG GGCACAATAGGCCTGACTCGAGCAGCTGGACCAGGGCG GCTT 經濟部中央櫺準局®:工消费合作社印製 032 033
TTGTCACAGGGGTAAACAGTAACGGTAACGGTAAGTGT GCCA GTGCAATAGTGCTTTGTTTCACTTTATTTTCTCCATGT ACAA Λ 私紙張尺度遑用中_ Η家樣毕(CHS) Ή規格(210X297公龙) 81. 7 . 20,000張(11) Λ 6 Π 6 五、發明説明() 除了末端的寡核苷酸084和085之外,將上述表IV之寡 核苷酸予Μ混合、碟酸化、煅化和接合以形成一如實施例 I中所述之雙股的揷入物,然而,該插入物並非被直接殖 入中間產物載饋,而是先藉由PCR予Μ擴大。該等末端的 寡核苷酸被用來作為PCR的引子。寡核苷酸084含有一掴 Hind III位置,10锢在其5’端內的核苷酸,而寡核苷酸 i 085在其V端属有一個Eco RI ·位置。擴增之後,該等產物 如實施I中所述MHind III和Eco Μ予Μ限制並將之連接 至Μ相同的兩«酵素消化過的Μ13·ρ 18之聚連結子中。所 形成的雙股的插入物含有一核糖體結合位置,一轉譯起始 密碼子其後接著一領導序列和三個供殖入贐機的寡核苷酸 之限制酶位置(Xho I, Stu I, Spe I ),該中間載體被命 名為 M13IX04。 經濟部屮央標準局ts:工消费合作社印31 讀背y注—構寫本頁)Λ 在該雙股揷入物之殖入期間,發現在寡核苷酸028中 一個GCC密碼子及其在031之互補物被鎺除之。由於此一刪 除並不影轡其功能,最後的構建物失去其兩fiGCC密碼子 中之一者。此外,寡核苷酸032在一需要一GAG密碼子之處 含有一 GTG密碼子。突變誘發之進行係使用該寡核苷酸5’ -TAACGGTAAGAGTGCCAGTGC- 3’ K該密碼子轉變為所欲之 序列。所形成的載髏被命名為M131X04B。 Λ1
在構建M13IX30的第三健步驟中包含將獠自M13IX04B 之該等表現及殖入序列挿至>1131\〇117的锿野生型8¥111之 上游。其完成係藉由MDra III和Baa RI消化M13IX04B 本紙張尺度遑Λ + Ηβ家準規格(210X297公St) 81. 7. 20,000張(If) Π 6 五、發明説明( 經濟部中央標準局Μ工消費合作社印製 並凝膠分離出含有該感興趣的序列之700對氮鑛插入物, M13IX01F同樣以Dra ΙΠ和Ba· RI予Μ消化。將該插入物 Κ1: 1的其耳比例與經雙重捎化的載髏結合並如實施例I 所述予Μ接合之。最終梢建物Μ13ΙΧ30的序列見於第2團 。第1Α圆亦顯示了Μ13ΙΧ30,其中檁示出He片段的表面表 現所需之各個因子。應注意的是在該等載體之修飾期間某 些序列與Μ13·ρ18的已公開序列不同。該等新序列被併入 *'· · 此處所記錄的序列中。 Μ13ΙΧ11 (或Lc載醭)被構建來容置多樣性的具有Lc 抗體片段族群。此載體同樣係從《13mpl8所構建的且其包 含:(1)表現所需之序列,如一起動子,信號序列及轉譯 起始倍號;(2) Eco RV限制位置以供_由雜交方法插入序 列Μ及Sac I和Xba I限制位置K供Lc序列的遘殖;(3)兩 對的Hind III - Mlu I位置K供He和Lc載體部份之隨機接 合,和(4)各種其它的突變Μ去除重複的限制位置。 該等表現,轉譯起始訊號、殖入位置和一MMlu I位 置構建係如上述藉由烺化該等重曼的寡核苷酸Μ生成一含 有一 5’Eco RI位置和3’Hind III位置的雙股揷入物。該等 重曼的寡核苷酸見於表V,且被接合成一位在M13bp18的 Eco RI和Hind III位置之間的一雙股揷入物,如同在描述 被插人M13IX03的表現序列時之情況。該核耱髏結合位置 (AGGAGAC)是位於寡核苷酸015內且該轉譯起始密碼子(ATG) 是寡核苷酸016的首三位核苷酸。 先 讀 背 注 意 事 項 再 填 % 裝 訂 線 Λ * 本紙張尺度逍用中輯矚家標毕(CNS)T4規格(210X297公龙) 81. 7 . 20,000張(II) 五、發明説明() Λ 6 η 6 表V 用於機建M13 TX11中的鏞讅信Μ的宴菘苷酸备列 mm 082 015 016 017 018 019 083 021 022 023 序列(fT革:Γ )
CACC TTCATG AATTC GGC AAG GAGACA GTCAT AATT C GCC AAG GAG ACA GTC AT AATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TT ATTA CTC GCT GCC CAA CCA GCC ATG GCC GAG CTC GTG AT GACC CAG ACT CCA GATATC CAA CAG GAA TGA GTG TTA AT TCT AGA ACG CGT C TTCAGGTTGAAGC TTA CGC GTT. CTA GAA TTA ACA CTC ATT CCTGT TG GAT ATC TGG AGT CTG GGT CAT CAC GAG CTC GGC CAT G GC TGG TTG GGC AGC GAG TAA TAA CAA TCC AGC GGC TGC C GT AGG CAA TAG GTA TTT CAT TAT GAC TGT CCT TGG CG 「閲 背 之 注 意 事 項 再 填 寫 本 η 裝 訂 線
A 經濟部中央標準局员工消费合作社印製 寡核苷酸017含有一Sac I限制位置位在ATG密碼子下 游67個核苷酸處,該天然發生的Eco RI位置被移除,而新 的Eco RI和Hind III位置被引入Sac I之下游處。寡核苷 酸 5' - TGACTGTCTCCTTGGCGTGTGAAATTGTTA — 3’和 5’ — TAAC ACTCATTCCGGATGGAATTCTGGAGTCTGGGT — 3’分別用於產生各 個突變。當位在Μ13·ρ19中之原本的Eco RI位置被突變時 私紙張反度遑用中國國家櫺毕(CNS)規格(210X297公龙) 81. 7. 20,000張(Π) Λ 6 Β 6 五、發明説明 該Lac Ζ核糖鱧結合位置被移除。此外,當新的Eco RI和 Hind III位置被生成時,就在這些位置之Y處發現丨00備 對氮鹺之自發性刪除。由於該醑除幸影轡到功能,其被維 持在該最終的載鼸內。 除上述之突變外,各種不同的修飾被做出K併入或移 除某些序列。該用於接合該雙股插入物的Hind III位置利 用寡核苷酸 5’ — GCCAGTGCCAAGTGACGCGTTCTA - 3’予Μ移除 。第二MHinl'III和Mlu I位置分別使用用於Hind III突 變誘發之寡核苷酸 5’ - ATATATTTTAGTAAGCTTCATCTTCT- Y 和用於 Mlu I 突變誘發之 5’- GACAAAGAACGCGTGAAAACTTT-3’而被引入位置3922和3952處。再次地,’在該碼编區域内 之突變並不改變胺基酸序列。 所形成的載體(M13IXII)之序列見於第3圖。第1B圖 亦顯示了 M131X11,其中檁識出在生成一介於U片段之間 的表面表現存庫所霈的每一個因子。 存瘇橇建 . 上述藉由PCR方法合成的各個He和Lc序列族群分別殖 入M13IX30和M13IX11内K生成He和Lc存庫。 \ Μ濟部中央楳準局®:工消費合作社印製 先 妗閲 請 背 hj 注 意 事 項 再 填 寫 本 頁 Λ 混合該等He和U產物(5m g),Μ乙醇沉澱並再散浮於 20;ϋ1的醋酸鈉鑀衝液中(33aM的Tris賭酸(ΡΗ7.9),10 ιιΜ醋酸鎂,66hiM醋酸鉀,0.5mM的DTT)。加入5單位的T4 DNA聚合酶,該反應物在301下培育5分鐘K藉由外核醴 海消化移除3’末端。藉由在70t:下加熱5分鐘Μ終止反應 ,M13IX30MStu 消化而 M13IX11MEco RV 消化。此二載體 本紙張尺/til用中《 S家«毕(CNS) Τ4規格(210x297公*) 30 81. 7. 20,000張(11) 314553 五、發明説明 皆如上所逑地MT4DNA聚合酶處理之,並令其與適當的PCR 產物(10ng/wl) Ml:l的凳耳比例結合,俾在室溫下 於上述缓衝液內煅化過夜。如下所述,將從各個煅化所得 之 DNA電穿透至MK30-3. (Boehringer,Indianapolis, IN) 内,Μ產生He和Lc存庫。
Lcol i MK30-3 為被電穿透的,如 Saith et al., ^.c.us. 1Z: 38-40 (1990)(該論文在此併入本案M為參考 ^ , 文獻)所述,β將大腸桿菌MK30-3電穿透之。該等細胞之製 備係藉由將一新鮮的ΜΚ30-3菌落接種至5ml不含鎂的S0B ( 20克的細菌-胰蛋白臃,5克的細« -酵母萃取物,0.584 克的氯化納,0.186克的氯化鉀,及蒸餾水至1000毫升) 經濟部中央櫺準局貝工消费合作社印製
? 先 .,閲 ή 背 ^ νί& ρ之 注 意 事 項 再 填 寫 本 A Λ * 中,並令其在3710下劇烈振動產氣之情況下生長過夜。 .SOB (500b1)將該過夜培餐物H 1: 1000之比例接種至不含 鎂的SOB (500al),並令其在37C下劇烈振動產氣之情況 下生長直到〇D8BD為0.8 (約2至3小時)。藉由在一GS3 離心機(Sorvall,Newtown,CT),內K 5,000rpn (2,600xg) 在4 t)下離心10分鐘來牧集該等細胞,並再散浮於5D0al 的冰溫10%(V/V)無菌甘油中,離心再Μ同樣的方式予Μ 散浮之。在第三次雛心之後,將該等細胞再散浮於10%的 無豳甘油内至其最终鱧積約為2ial,如此所得之懸浮液的 〇Dee。為200至300。通常,再散浮是在倒掉上澄液後於該 10%的甘油内逹成者。使用乾冰-乙酵浴將細胞(每份40 Ml)冰凍於撤離心管内,並冷凍保存於-70C下。 在使用前將冷凍的細胞慢慢地在冰上溶解並令每40 本紙張尺度边用中國S家樣华(CHS)甲4規格(210X297公釐) -31 - 8】.7* 20,000張(Π) 五、發明説明() 的細胞懸浮液與約10pg至500ng的載體混合以使之被電穿 透。將1份40 w 1部分放置在一〇_ lcm的電穿透室(Bio-Rad, Richmond, CA) 内 ,並在 Ot: 下使用4ΚΩ 並聯電阻 25 F,1 色8 KV予Μ脈衝一次,其生成一脈衝長度(t )為~4 ®s。在一 12-X 75®®的培養試管内將1份lOw 1部份之脈 衝遏的細胞稀釋至lei的SOC (98al的S0B加IbI的2M氮化鎂 和lml的2M«f萄糖)内,並在選擇性培養基內培養之前於 .. 厂 '· 37t下振盪f培餐物達1小時(見下文)。 將各個存庫Μ熟於此技之人士所知之方法予Μ培養之 。該等方法可見於 Sanbfook et al., Molecular Cloning :A Laboratory Manuel, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989,和Arsrbel et al·, Current Protocols in Molecular Biology, John Wiley and Son, New York, 1989,該二文獻在此併入本案K為參考文獻。 經濟部屮央標準局员工消费合作社印Μ 簡短而言,藉由將上述之1®1存庳培餐物條Μ 50倍稀釋至 2ΧΥΤ培養基(16g的胰蛋白臃,l,0g的酵母菌萃取物,5g的 氯化納),並在37¾下培養5至8小時而使之生長。該等 細閨藉由在10, OOOxg下離心而予Μ沉澱。將含有噬菌體的 上淸液轉移至一無龆試管中並存放在4t:下。 將含有He和Lc抗膿片段的雙股媒鼸DNA自各個存庳的 細胞沉澱物中分離出來。簡短而言,該沉澱物在ΤΕ (10·Μ 的Tris (pH 8.0),1·Μ的EDTA)中淸洗,並於Sorval離心 機(Newtown, CT)内在7000rpa下離心5分鐘而再收集之。 將沉澱物再散浮6»1的10%蔗糖、50aM的Tris (ΡΗ8·0)中 本紙張尺Α遑用中SS家楳毕(CNS)T4規格(210X297公货) -32 - 81. 7. 20,000¾ (11) Λ 6 Β 6
31455H 五、發明説明() 。加入3.0毫升的10®g/ y 1溶解酶並在冰上培養速20分 鐘。接著加入.12*升的0.2M氳氧化納,1 %SDS並'在冰上 培育# 10分鐘。在加入7· 5¾升的3M賭酸銷(PH4.6)將該等 懸浮液放在冰上之後,培養達20分鐘。在4 υ下Μ 15,000 rp®離心該等樣品15分鐘,予Κ核酸酶處理並Μ酚/氯仿 萃取之,接著用乙醇沉澱。再散浮該沉澱物,秤重並將等 重的氯化絶溶入各試管中直到密度連1.60 g/al。將EtBr 加入至達600_μ g/al並於一 TV - 1665離心機(Sorval〉內Μ 50,000ι·ρ«藉由平衡離心達6小時Μ收集該雙股DNA。這些 來自於各値左半部和右半部次存庫的DNAs被用來產生40個 存庫,其中該等被隨機化的寡核苷酸之右半部和左半部已 被隨機地接合在一起。 經濟部中央標準局®:工消费合作社印製 該表面表現存庫係藉由將M13IX30其含有He的部份 M13IX11其含有Lc的部份隨機地接合而形成者。從各锢存 庫分離出的DNAs各別地Μ過置的限制酶消化之該Lc族群( 5wg) KHind ΙΠ 消化。該 He 寒群 <5/ig)KMlu I 消化。 藉由酚/氯仿萃取接著用乙醇沉澱來終止反應。沉毅物用 70%的乙醇淸洗,並再散浮於20W1的醋酸銷緩衝液内。 加入5單位的T4DNA聚合酶(Pharmacia),且該反應在30¾ 下培育5分鐘。在70¾下加熱5分鏟Μ終止反應。將該等 He和Lc DNAs混合至一最終濃度為每鶴載體10 ng//zl, 並容許其在室溫下煅化遇夜。將該混合物如上所述地電穿 透至MK30-3細胞内。 弃而宪斑#產的篩黎 本紙張尺Αϋ用中瓤•家《準(CHS)!»4規格(210X297公¢) - 33 - 81. 7. 20,000ft (11) S14553 Λ 6 Η 6 # 經濟部中央楳準局貞工消費合作社印製 五、發明説明() 纯化的噬菌體係從50b1的XL1 Blue™細胞(Stratagene, La Jolla, CA)的液髏培镫物中製備,該細胞已被ip m.o.i. 的嗤菌髏(源自於保存在4 υ下的原種.)所感染。該培養 物M2mM的IPTG誘發之。上淸液藉由兩次離心而被澄清之 ,而該噬®體藉由加入1/1.75體積的PEG溶液(25%PEG -8000 , 2.5M氯化銷)沉裔接著在4¾培育下過夜而使之 .沉澱。藉由崔10, OOOxg下離心90分鐘來回收沉澱物。將噬 V* ®髏沉澱物再'敢浮於25m1的0·01Μ的Tris-HCl (PH7.6), 1·0βΜ的EDTA,和0.1%薩可西(Sarkosyl)內,然後在室溫 下緩慢地振溫30分鏡。將該等溶液調整至0.5M的氯化納及 一最終濃度為5%的聚乙醇。在413下2小時後,該含有 該噬齠體的沉澱物藉由在15,000xg下離心1小時予Μ回收 。將該沉澱物再散浮於l〇Bl的NET緩衝液〔0.1Μ氯化鈉, 1·0βΜ 的 EDTA,和 0.01M 的 Tris-HCl (PH7.6)〕中,均勻混 合,並藉由在170,000xg下離心3小時而再沉澱該噬菌體 。將該噬豳醱沉澱物再散浮於24的NET緩衝液内過夜,並 將之引至在110,000xg下進行氣化絶離心在l〇Bl的鑀衝液 内含3. 86g的氯化絶)18小時。收集噬B體帶,以NET缓衝 液7倍稀釋之,於170,000xg下再離心3小時,再散浮之 ,並於4它下將之存放在含有0.UM的疊氮化鈉的0.3·1 NET缓衝液中。 供用於将抗生物素鏈菌素塗覆之盤平盤化(panning) 的BDP先予Μ生物素化,然後M UV -去活化的阻塞噬菌體 予Κ吸收之(見下文)。將生物素化試劑M2.4 »g固態 (請先閲讀背而之注意事項再填筠本頁)( LI >tl -1
A 本紙張尺度遑用中《國家«毕(CNS) «Τ 4規格(210父297公龙) 81. 7, 20,000張(1'[) 經濟部中央標準局兵工消費合作社印製
UiMS_ 五、發明説明() NHS-SS-生物素(磺基琥珀醸亞胺基2-(生物素胺基) 乙基-1,3’-二蹟基丙酸鹽;Pierce, Rockford, IL)對 1皿1 溶辫之比钶溶入二甲基甲酿胺中,並依製造者所建議之方 .法使用之。小規棋反應係藉由將1m 1已溶解的試劑與43 μ 1的1 eg/al BDP〔稀釋於無_磷酸氫窗緩衝液(0.1M 磺酸氫納,PH8.6)内〕混合。在25Ό下經2小時後,令 殘餘的生物素化試薄舆500 « 1 1M的乙醇胺(pH值Μ氯化 • ·,- ' 氫調至9 ) #反應2小時。將整値樣品M lml含有lng/iil BSA的TBS稀釋之,將之置於一 Centricon 30超過濾器( Aaicon)上濃縮至50/il,並在同一瀘器上以2b1的TBS清 洗三次,Mini含0.02%的叠免化鈉的TBS和7X101SUV-去 栝化的阻塞噬菌偃(見下文)淸洗一次;該最終之滯留物 ( 60-80 Wl)被保存於4=0下。將利用NHS—SS-生物索 試劑予Μ生物素化的BDP經由一含有雙碕之鍵被連接至該 生物素。 UV-輻射的Μ13噬®體通常,被用來阻塞任何偶然地結 合絲狀噬«鼸之被生物素化的BDP。Μ131Ρ18 (Messing and Vieira, Gene 19 : 262-276 (1982),該文獻在此併 入本案Μ為參考文獻)被選擇是因其帶有兩齒琥珀突變, 其確保經輻射仍存活的少數噬®謾不會在其被用於滴定該 表面表現存庫之sup 0 g株中生長。將一 5ml的樣品(含 有5Χ1013Μ13®ρ18噬舖體,傈如上述方法純化者)置放於 一小培養皿中,並Μ —殺菌燈在間隔2英尺的距離下輻射 7分鐘(通量150wW/CMB)。叠氮化鈉被加入至0.02% (請先Μ饋背而之注意事項蒋填寫本頁).5, -4.-7-Γ Λ 本纸張尺羊遑用中β Η家《毕(CKS)f 4規格(210x297公4) 81. 7. 20,000張(11) Λ (5 Β6 五、發明説明() ,並在一 Centricon 30-kDa (Amicon)超遇濾器上將噬菌 髏濃缩至1014顆粒髅/丨1。 , 鬭於平盤法,将加有lal的lag/*1抗生物素鏈《素 (BRL)(配於0·1Η碳酸氳納(ρΗ8·6〉和0.02¾的曼気化納内 )的聚苯乙烯培養皿(60Χ15β·)置於一冷室中之小型不透 Τ 氣之塑膠盒中培育過夜次日除去該抗生物素鏈鰭素,並代 之以至少1〇8^的阻塞溶液(29 1^/现1的85為,3;^8/皿1的 r . 抗生物素鍵#素,0.1M的硝酸氫納(ρΗ8.6),0·02%的曼 氦化鈉),並在室溫下培育至少1小畤。除去該阻塞溶液 並快速地以含有 0.5% Tween 20 (TBS-0.5% Tween 20) 的Tris縝衝的食鹽水洗三次。 篩遴其表現出會結合BDP的抗體片段之噬菌體係利用 5W1 (2.7Wg BDP)的經阻塞的生物素化的BDP舆50W1的 該存庫部份反應而進行的。每一混合物在4t:下予Μ培育 過夜,Mlal的TBS-0.5% Tween 20稀釋之,並將之轉移 至一如上述所製備的抗生物素鐽.菌素塗覆的培餐皿内。在 室溫下搖動10分鐘後,未結合的噬®體被移出,而培餐皿 在一為30-90分鐘之期間内MTBS-0.5% Tween 20洗10次 。將已被結合的噬®»M 800 «1的無菌緩衝液(1衫/通1 BSA、0.1M的氯化氳,pH值Μ甘油調至2.2)從培餐皿中洗 提15分鐘且洗出物Μ48//1 2Μ的Tris (未調pH)中和。在 MK30-3濃縮的細胞上以《入噬菌疆的稀釋物滴定各健滾出 物的一齒20m 1部份。 平盤法其第二回合之進行係藉由5·Μ的DTT處理750 μ 1 ^紙Λ尺束遑用中《«家«毕(CKS) 1Μ規格(210X297公釐) *
ik .先 閲 背 :面. 之' 注 意 項 再 填 寫 本 K Λ 經濟部中央標準局兵工消费合作社印製 81. 7 . 20,000張(il) 經濟部中央標準局貝工消费合作社印製 _ B6_五、發明説明() 的源自該存庫之第一洗出物達10分鐘Μ打斷將生物素基_ 連接至殘餘的經生物索化的結合蛋白質上的雙硫鐽,。該處 .理過的流出物在Centricon 30 (ABicon)超過濾器上予Μ '濃縮之,MTBS-0.5% Tween 20淸洗三次,並將之灕縮至 終體積爲約50 w.l。將最終的滯留物轉移至一含有5.0 W 1 (2.7/ig BDP)經阻塞之生物素化的BDP的試管中並培育過 夜。該溶液Klml的TBS-0.5% Tween 20稀釋之,予以淘 盤洗選,並節'上述在新鮮的抗生物索鍵菌素塗覆遇的培餐 皿上予Μ洗提之。將整偁第二次洗出物(800« 1)M 48« 1 2M的Tris中和之,而其20m1同時Μ第一次洗出物和哏入 噬菌醱的稀釋物予Μ滴定之。如果必要的話,可再進行幾 回合的海盤洗選法Μ得到均質的噬«鼷族群。此外,如果 可獲得供偵測之試劑,噬菌鼸可予人Μ噬菌斑純化。 椹板的靱備驄序利分析 供序列分析之楔板的製備係藉由以一來自經純化·的族 群之各別噬菌斑接種至1·1的2ΧΧΤ培餐物(其含有XL1之一 過夜培餐物的1:100稀釋物)。該等噬豳斑係用一無菌牙 镟來挑。將該培養物於37Ό下拫通培養5-6小時,然後轉 移至一 1.5ml的徼離心管中。加入200 W1的PEG溶液,渦 漩,並置於冰上10分鐘。藉由在12,000xg下離心5分鐘而 回收該噬菌饋沉澱物。丢_上清液,並藉由Μ—黃色的吸 貴管管尖慢慢地抽吸而將該沉澱物再散浮於230^1的ΤΕ (10mMTris-HCl (ρΗ7.5〉,1竄Μ 的 EDTA)內。加入酚( 200 μ 1),接而短暫的渦漩並予Μ撒離心Μ分離成不同的 (請先閲請背面之注意事項再瑱寫本頁) £ < -37 - 81. 7 . 20,000¾ (II) 314553 Λ 6 Π 6 Λ 經濟部中央櫺準局與工消费合作社印製 五、發明説明() 相。將該水溶液相轉移至另一試管中並如上述有鼸酚萃取 者,以2〇〇μ 1的酚,氯仿(1 : 1)萃取之。加入〇· 1择積的 3Μ的醋酸納,接著加入2.5鯉稹的乙酵.,並在-20Ό下沉澱 20分鐘。藉由在12, OOOxg下於一撤離心器內離心8分鐘以 得到該沉澱的棋板。此沉瀑物在70%的乙醇中潸洗,乾燥 .,並再散浮於25w 1 TE中。使用Sequenase™序列·分析試 驗組並依據製造商(U.S. Bioche*ical, Cleveland, 0H) - ‘〆. : 所提供之工#'表來進行序列分析。 音掄例二 不用限制醱消夕童嫌和驊鍊庠列:>«箝 此實施例顯示了利用限制內核酸酶之抗艨重鍵和輕鍵 片段碼纊序列同時併入M13IXHL載髏之中。 關於重鍵和輕鍵片段碼编序列之同時併入一單一的共 表現載體,一ISM13IXHL載體被製造出,該載髁含有一小 白鼠單株抗體(DNA-18H4; Biosite, San Diego, CA)之 重鏈和輕鏈碼編序列。該等被插.入的抗讎片段序列藉由位 置-指導的突變誘發被用來為有鼸He和U的雜交和併入之 互補序列。將該等碼编重鏈和輕鋪多fe的基因分別揷入至 M13IX30和M13IX11内,並如實施例I所述將之合併為一單 個表面表現載體。所形成之M13IXHL·型載讎被命名爲M13IX50 〇 該等組合係在能加速一半的He載體和一半的Lc載體成 為一單個環形載體之狀況下進行者。簡短而言,在M Ml u I或Hind III限制和外核酸酶消化後,於該等限制位置配 (請先閲讀背而之注意事項再填寫本頁) Λ 本紙張尺摩遑Λ中·Η家樣竿(CHS)<H規格(210X297公#:) - 38 - 8】.7 . 20 000張(11) 五、發明説明.() 經濟部中央標準局S工消費合作社印製 對之間所形成的突出物是不相等的(亦即64锢核苷酸相對 於32個核苷酸)。這些不相等的長度造成源自各載醭之互 補端的特定煅化之差別雜交溫度。每半個載體其各端之特 定雜交作用僳藉由在65它下Μ少量(約1〇〇 Wg/Μΐ)進 行第一次锻化K形成一半舾He載體和一半偭Lc載齦的二聚 物而芫成的。該一聚物之環化係藉由稀釋該混合物(至約 20y g/ /i 1^並降低溫度至約25-371C Μ容許煅化。Η接 • ·* ‘ 合酶係存在爵'Μ共價地閉合該瓌形載體。 將Μ13ΙΧ50修飾成不能產生一有關於DAN單株抗體的有 功能的多呔。為達此目的,在各鏈的可變區域之内藉由突 變誘發來改變約8痼胺基酸。該U可變區域使用寡核苷酸 5' - CTGAACCTGTCTGGGACCACAGTTGATGCTATAGGATCAGATCTAG AATTCATTTAGAGACTGGCCTGGCTTCTGC- 3’使之產生突變。該 He序列使用寡核苷酸 5’ - TCGACCGTTGGTAGGAATAATGCAATTA ATGGAGTAGCTCTAAATTCAGAATTCATCTACACCCAGTGCATCCAGTAG CT-3’使之產生突變。一額外的.突變亦被引入M13IX50 K 產生該載體之最終形式。在從一中間產物構建至M13IX50 (M13IX04)逑於實施例I期間,在寡核苷酸027和互補物 032處有一 6齒核苷酸序列被複製。使用寡核苷酸V - GGT AAACAGTAACGGTAAGAGTGCCAG- 3’藉由突變誘發將此序列5’ TTACCG- 3’刪除所形成的載髏名為M13IX53。 M13IX53可被製成如一單股的形式且除了其不能表現 有功能的異醭物之外其含有先前所述M13IXHL媒藤之所有 的有功能的因子。該單股載顦可藉由突變誘發被雜交至單 (請先閲讀背而之注意事項再填寫本頁)
A 本紙張尺本逡用中鼷a家樣毕(CHS) T4規格(210x297公;it) - 39 - 81. 7 . 20,000¾ (II) Λ 6 Π 6 314553 五、發明説明(.) (請先閲讀背而之注意事項再填寫本頁) 股He和Lc碼缠序列的族群,Μ供將之併入該載鱧中。一熟 於此技之人士可由實施例I所述之PCR產物使用其宁所述 之引子及技術來製造覃股He和Lc碼鱔序列的族群。將所形 .成的帶有随機併入的He和Lc碼编序列的載體予Μ增殖並就 實施例I中所述的結合專一性進行篩選。 其它類似於Μ13ΙΧ53的載錶和由其所衍·生的載髏,Μ13 1X11.和Μ13Ι b〇,亦不用银制而被製備出Μ供He和Lc碼编 .. /' 序列之併入$和M13IX53不同的是,這些載體含有人類抗 體序列以供人類He和Lc序列族群之雑交和併入。這些載釀 簡述如下。該等起始載醱可為先前所逑之He載體(M13IX30) 或 Lc媒體(M13IX11)。 < M13IX32藉由自M13IX30移除上述該6侮核苷酸重複序 列5’ - TTACCG - 3’K及該引導序列的突變(M增加產物的 分泌)而生成者。用來除去該重複序列的寡核苷酸係同 於前面所用者。該引導序列內的突變係使用寡核苷酸5’-GGGCTTTTGCCACAGGGGT-3’而產.生的。此突變誘發造成在 Μ13ΙΧ30的位置6353之Α殘基被改為G殘基。 經濟部中央楳準扃β工消费合作社印31 用作抗腥片段的親和力純化的十呔tag被併入M13IX32 內該He表現位置的羧基末端處的適當閲讀架構。用於此突 變誘發的寡核苷酸為 5’- CGCCTT CAGCCTAAGAAGCGTAGTCCG GAACGTCGTACGGGTAGGATCCACTAG- 3’。所形成的載臃被命 名為M131X33。對此載饉或其它載體.的修飾是可想像得到 的,該修飾包含熟於此技人士所知之各棰不同的待撤。例 如,一 fe酶切開位置可被併入在該十fe tag之後,此容許 本紙張尺术遑用中《 «家樣毕(CHS) T 4規格(210><297公徒) 81. 7· 20,000張(H) Λ 6 η 6 經濟部中央櫺準局貞工消費合作社印製 314553五、發明説明() 該抗體可從該融合蛋白的基因VIII部份被切開。 M13IX34係從M13IX33藉由殖入一碼编人類IgGl重鍵的 基因而產生者。該可變區域的閲讓架構被改變且一終止密 碼子被引入Μ確保不會製迪出一有功能的多呔。用於該可 :變區域之突變誘發的寡核苷酸為5’_ CACCGGTTCGGGGAATTA .GTCTTGACCAGGCAGCCCAGGGC-3’.。此載髖之完整的核苷酸 序列見於第2蹰。 , -* · 數βΜ13ΐ'Χ11条列的載謾亦被生成Μ含有類似於在載 體Μ13ΙΧ53和Μ13ΙΧ34中所述的修餘。Μ13ΙΧ11內之啟動子 區域被突變Μ使與 用於此突變的寡核苷酸為5’ — ATTCCACACATTATACGAGCCGGA AGCATAAAGTGTCAAGCCTGGGGTGCC- 3’。一人類 κ 輕鍵序列 被殖入Μ13ΙΧ12,接著刪除其可變區域Μ產生Μ13ΙΧ13。此 載體之完整的核苷酸序列見於第5團。一類似的載體(命 名為Μ13ΙΧ14)亦被生成其中該人類λ輕鍵被揷入Μ13ΙΧ12 內隨而醑除其可變區域的_除之.寡核苷酸分別為5’ - CTGC TCATCAGATGGCG(5GAAGAGCTCGGCCATGGCTGGTTG_3,,和 5’ — GAACAGAGTGACCGAGGGGGCGAGCTCGGCCATGGCTGGTTG - 3' 0 該等He和Lc載體或其修飾過之型式可使用實施例I中 所述之方法予Μ結合Μ產生一單俪載體,其類似於容許藉 由突變誘發產生有效的人類He和Lc碼编序列的併入之Μ13Ι X53。此種載體之一例子為M13IX13和M13IX34的結合。此 載髖M131X60的完整核苷酸序列見於第.6圖。 亦可對先前所述之載膜做額外的修飾Μ產生容許He和 (請先閲讀背而之注意事項再填寫本頁)^s -1-¾-.............................J—t 裝· 線. < 本紙張尺尽遑用中躡國家樣毕(CNS)T4規格(210X297公*) 81. 7 . 20,000張(II) Λ 6 Π 6 經濟部中央標準局貞工消費合作社印製 五、發明説明() Lc序列的有效併入及表面表現。例如,在突變誘發程序當 . 中為緵和使用尿嬸啶選擇K對抗野生型模版,位在載體之 中的可變區域位置可用一糸列的迴折塑限制酶位置(亦卽 兩健位於相反方向之類似位置)予K取代。該等適折型位 置會在突變誘發期間向外形成一Μ環並雜交在一起,因而 形成一供核酸内切酶消化的雙股受質。該位置的切開將馇 成野生型模板的破壞。該等'被插入的He和Lc序列的可變區 域不會受到#鬱,因其受非呈單股的型式。 侬據實施例I的方法,單股的He或Lc族群可藉由熟於 此技人士所知之方法予K製造出。例如,實施例I中所述 之PCR引子可被用於不對稱的PCRK產生該等族群。Gelfand et al., "PCR Protocols: A Guide to Methods and App-lications", Ed by M.A. Innis (1990),該文獻在此併 入本案M為參考文獻。不對稱的PCR為一種僅差別地擴增 該雙股棋板之一覃股的PCR方法。該差別的擴增之完成係 藉由將非所欲之股所需之引子的.量降低至比所欲之股所需 之量的十分之一。另擇地,單股族群可由如實施例I所述 而生成的雙股PCR產物來製造,唯其用於產生該雙股產物 之非所欲之股的引子首先在其5'端先Μ—激酶將之磷酸化 。所形成的產物可接而以一 5 ’至3 ’外核酸酶〔例如λ外核 酸酶(BRL·,Bethesda, MD)予Μ處理Μ切除非所欲之股。 令藉由上述方法或其它熱於此技人士所知之方法所產 生的單股He和Lc族群舆被碼鏞在先前所述載體内之互補序 列雜交。該等序列之族群接著藉由該等經雜交的模板之聚 η 先 閲 &背 之 注 意 事 項 再 填 寫 頁 裝 線
A 本紙張尺度遢用中《困家榣準(MS)肀4規格(210x297公货) -42- 8】· 7 . 20,000張(丨丨) | 五、發明説明() 合酶伸長而被併入一雙股形式之載體中。該等隨機結合的 He和Lc序列的增殖和表面表現係如實施例ϊ中所述者予以 進行之。 雖然本發明係參照目前較佳的具體實施例來描述,但 應可了解各種不同的修飾均可被完成而不脫離本發明之精 ..神。基於此,本發明應由本案申請專利範圍予以限制。 (請先閲讀背而之注意事項再填寫本頁) < 經濟部中央#準局R3:工消費合作社印製 本紙張尺度遑用中BS家樣準規格(210X297公») - 43 - 81 _ 7 . 20,000張(11)
第八〇—〇七七五〇號專利申請案 中文補充説明書1(86年5月、 以取自癌症病人之組織構建如下表以2所示之禮菌體抗體庫· 表1 A4 (1X203)抗體庫之特徵 ,
30 % 1·5χ1〇6 胞來源__ 前列腺腫瘤 (HC : 48-65 %) (LC · 41-56 %) 性:1500純系均無
表2噬菌體表現抗體庫概要 淋巴細胞來源 表現載體 --~ 篩檢方法 Al 腫瘤引流淋巴結(胸部) 1X203 --一 〜«A ~~ -^- 親和力增強 ~1--- 濾、紙印出私y A2 腫瘤引流淋巴結(胸部) 1X203 親和力增強 ^-_ 1X104 濾紙印出物 A3 結腸腫瘤 1X203 —----_ 親和力增強 -— 1X104 滤紙印出物 A4 前列腺腫_ 1X203 ^〜----- 親和力增強 - 濾、紙印出物 ---- 依下表3所示,以ELISA篩檢經固定之腫瘤細胞單層,並依下表4 所不者,以經生物素化之腫瘤細胞萃液探測濾紙溶菌斑印出物,以鑑 定具腫瘤特異性之抗體: 表3 ELISA篩檢概要 抗體庫 載體 次數 師檢之隨機純系 確認之陽性純系 A1 1X203 0 1656 1 1 2760 ,8 2 2024 4 3 1472 5 4 1196+552(SPE) 0 5 1380+552(SPE) 0 A1.1 1X203 F1 0 920 0 F2 6 F3 0 0 F4 0 0 F5 0 0 F6 920 2 A2 1X104 0 920 8 A2 1X203 0 828+2116=2944 2+3=5 A3 1X104 0 4140 39 A3 1X203 0 828+3220=4048 2+11=13 1 1380+4787=6164 2+10=12 2 1656+2024=3680 10+3=13 3 828+3404=4232 3+9=12 4 828 0 5 736 0 A4 1X203 0 0 0 314553 表4濾紙印出物篩檢概要
抗體庫 載體 篩檢之隨機純系 確認爲濾 紙印出物 陽性之純系 比率 H3396-陽性純系 A2 1X104 50600 60 1/843 25 A3 1X104 7000+102400= 109400 -27+38=65 1/1683 32 A3 1X203 13600 21 1/648 ND 1X104及ΓΧ203抗體庫之比例相當 依下示基準,進行腫瘤細胞與正常細胞分類篩檢,選擇最佳純 系,進一步分析特徵: 純系選擇基準 •初次篩檢爲H3396陽性 -固定腫瘤細胞ELISA,或 -以生物素化H3396萃液進行所得溶菌斑印出物 •於H3396細胞上滴定 •正常纖維母細胞活應性評估 •以[Fab] 2 15微克/毫升爲陰性 造行抗體重鏈及輕鏈可變區定序,如下表5所示者,抗體庫中含多 樣性之重鏈: . RR206G.DOC/WA -3 - 表5 純系 纖維母細胞 V片段群 (陰性 < 微克/毫升)_ TA5 18.9 TA50 17.4 VH5 TA60 36.4 ' VH1 TA62 44.8 VH4 TA66 28.1 VH4 TA67 18.1 VH3 TA72 15.5 VH3 TA73 22.6 VH7 TA76 16.8 YH4 TA79 26.7 VH3 TA93 31.4 VH3 TA116 24.9 VH4 TA121 22.8 VH3 F3 16.8 VH3 F13 10.4 . F14 33.2 VH3 F15 14.9 VH3 F19 30.0 VH4 F21 40.8 VH1 F22 -31.8 VH6 F23 97.5 " VH3 F26 38.9 VH3 輕鏈可變區亦可見相同結果。
RR206G.DCX7WA 314553 取TA5及TA50進行H3.396乳癌細胞特異性測試,結果示於圖7 及8。如圖7及8所示者,TA5具腫瘤特異性,且TA5與TA50與 正常細胞之反應性極低。
RF\206<J.DOCyWA
第八〇一〇七七五〇號專利申請案 中文補充説明書II (86年5月) 圖7 TA5與活腫瘤細胞之反應性。_ 圖8 TA5與TA50與活纖維母細胞之反應性。
RR206G.DOC/WA
Claims (1)
- 第80107750號專利申請案 A8 中文申請專利範圍修正本(86年5月)S 7 D8i範圍 2 修正 年月曰、《 、诚5. 29補充 張 紙 ______ I 本 經濟部f央標準局負工消费合作社印裝 .種製備用於共表現兩種不同類DNA序列族群之套组之 方法,該等DNA序列可編碼含一抗體重鏈及輕鏈可變區 域功能郡分之不同類多肽,該等多肽係於Μ13表面上表 現成基因VIII融合蛋白質,該方法包括: ⑻構築第一組Μ13-載體,使其除表現元件外,具有(丨)用 於插入编碼第一多肽不同類族群之不同類DNA序列之 第一族群,(ii)位於該插入部位下游之僞-野生型基因 VIII,( iii)位於該插入部位及gVIII序列間之適當終止 密碼子’及(iv)兩對位與選殖位置方位對稱之Hind ΠΙ-Mlu I限制位置;及 ⑸構築第二組M13_載體,使其除表現元件外,具有㈠) 用於插入编碼第二多肽不同類族群之不同類DNA序列 ^第二族群,及(ii)兩對位與選殖位置方位對稱且方 位同於第一組M-13載體之Hind III- Mlu I限制位置。 •種製備用於共表現兩種不同類序列族群不同類组 β足載體族群之方法,該等DNA序列可编碼含一抗體重 ,及輕鏈可變區域功能部分之兩種不同類多肽族群,該 等夕肽係於M13表面上表現成基因νίπ融合蛋白質,該 方法包括: β ⑻以申清專利範圍第1項步驟·( a)所製之第一組M13-載體 限制位置之限制酶消化該M_13載體,並於該處插入编 碼第—多肽不同類族群之不同類DNA序列之第—族 群; . ⑸以申請專利範圍第1項步驟(b )所製之第二组M13-載體 限制位置之限制酶消化該M_13載體,並於該處插入编 纽適用中國 A4規格(210X297公釐) tea m nfn ^nn In— m ,( 請先闐讀背面之注意事項t^寫本頁) 裝 n-iv n^n mu tmMti- _ 訂--- --線-- 4553 AS B8 C8 D8, 經濟部中央標準局員工消費合作社印製 六、申請專利範圍 碼第二多肽不同類族群之不同類DNA序列之第二族 群;及 (c)依下示方法結合步驟(a)及(b)之載體產物,使僅有含 有該第一及該第二DNA序列之載體序列¥以操作組 合: (cl)以H i n d ΠI及Μ 1 u I限制酶之一切割該第—載 體-,並以該二酶之另一者切割第二載體; (c2)以外核酸酶消化該等經切割之第一及第二載體之 3'端;且 (c3)使該寺第一及弟一載體黏合(annealed)。 3. —種製備组合物之方法,該組合物包含複數個其内含有 第一及第二DN A序列之不同類组合之大腸桿菌細胞, 該第一及第二DN A序列各編碼含一抗體重鏈及輕鏈可 變區域功犯部分之第一及第二多肽,該等多肽係於Mi3 表面上表現成基因νιπ融合蛋白質,嘴方法句括: ㈤利用f穿孔術將巾請㈣範®第2項所製之載體族 群導入複數個大腸捍菌細胞中。 4_ 一種製備抗體之方法,其包括· (a) 培養申請專利範圍第3 $ 固弟J員所製之複數個大腸桿菌細 胞; (b) 提供一種可爲所需抗體結合之分子;及 (c )彳貞測該預選分子鱼該括嘴、 必抚體又結合,以從步驟(a)之 表現產物中篩選抗體。 . , 5 . —種測定可编碼對—預;g么2 a.、、, 謂選为子具有結合活性之抗體之核 酸序列之方法’該方法包括· 本紙張尺度逍用中國國家標準(CNS > m i m· In nn tfn I - ii .m n m I = n nn (請先閱讀背面之注意事項h%寫本頁) * nn fm ms 線丨 ml In ItmMW awmmmu a • t^n m ttm n nn Αδ Βδ C8 D8 六、申請專利範園 (a) 培養申請專利範圍第3項所製之複數個大腸桿菌細 胞; (b) 提供一嘎可爲所需抗體結合之分子; (c )偵測該預選分子與該抗體之結合,以從步驟(a)之 表現產物中篩選抗體;· (d )分離编碼該抗體之核酸序列;及 (e )將該等核酸序列定序。 -fm nm αί ^^VBft 1— . -ii ]! -1 —-· il sli--i 1-i-il {請先閲讀背面之注意事項c%.寫本頁) 訂 線 經濟部中央標準局員工消費合作社印裝 • » .1 I - 本紙張尺度適用中國國家標準(CNS ) A4规格(210X297公釐)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59021990A | 1990-09-28 | 1990-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW314553B true TW314553B (zh) | 1997-09-01 |
Family
ID=24361342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW080107750A TW314553B (zh) | 1990-09-28 | 1991-10-01 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0550645B1 (zh) |
| JP (1) | JP3373510B2 (zh) |
| AT (1) | ATE204607T1 (zh) |
| AU (1) | AU667291B2 (zh) |
| CA (1) | CA2092802A1 (zh) |
| DE (1) | DE69132700T2 (zh) |
| IE (1) | IE63054B1 (zh) |
| IL (1) | IL99552A0 (zh) |
| NZ (1) | NZ239988A (zh) |
| TW (1) | TW314553B (zh) |
| WO (1) | WO1992006204A1 (zh) |
Families Citing this family (857)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US7413537B2 (en) | 1989-09-01 | 2008-08-19 | Dyax Corp. | Directed evolution of disulfide-bonded micro-proteins |
| US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
| US5747334A (en) * | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9206318D0 (en) * | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) * | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| US5858657A (en) * | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en) * | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994005781A1 (en) * | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Phagemids coexpressing a surface receptor and a surface heterologous protein |
| DE69334261D1 (de) * | 1992-11-10 | 2009-03-19 | Applied Molecular Evolution | Lösliche peptide, welche eine erzwungene sekundärstruktur in lösung haben und methode zur herstellung derselben |
| ZA938243B (en) * | 1992-11-12 | 1995-05-04 | Hybritech Inc | Altered affinity polypeptides of metal chelate binding antibodies |
| WO1994018221A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites |
| IT1270939B (it) * | 1993-05-11 | 1997-05-26 | Angeletti P Ist Richerche Bio | Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. |
| US6010861A (en) * | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
| US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| EA199900355A1 (ru) | 1996-10-01 | 2000-08-28 | Джерон Корпорейшн | Теломераза обратная тринскриптаза |
| UA75316C2 (uk) | 1996-10-16 | 2006-04-17 | Займодженетікс, Інк. | Гомологи з фактором росту фібробласта |
| US6310191B1 (en) | 1998-02-02 | 2001-10-30 | Cosmix Molecular Biologicals Gmbh | Generation of diversity in combinatorial libraries |
| CN1246150A (zh) * | 1997-01-31 | 2000-03-01 | 科斯米克斯分子生物有限公司 | 组合文库的多样性的产生 |
| US6555310B1 (en) | 1997-04-04 | 2003-04-29 | Biosite Diagnostics, Inc. | Polyclonal libraries |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| AU1449499A (en) | 1997-10-31 | 1999-05-24 | Maxygen, Incorporated | Modification of virus tropism and host range by viral genome shuffling |
| US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| DE19816129A1 (de) * | 1998-04-09 | 1999-10-14 | Dolores Schendel | T-Zellrezeptor-Expressionskassette |
| EP2284272B1 (en) | 1998-06-10 | 2014-08-13 | Novozymes A/S | Mannanases |
| US6190908B1 (en) * | 1998-08-12 | 2001-02-20 | The Scripps Research Institute | Modulation of polypeptide display on modified filamentous phage |
| DE69939330D1 (de) | 1998-12-07 | 2008-09-25 | Zymogenetics Inc | Wachstumsfaktor-homologe zvegf-3 |
| CZ303272B6 (cs) | 1999-01-07 | 2012-07-11 | Zymogenetics, Inc. | Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid |
| AU3391900A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
| UA84387C2 (ru) | 1999-03-09 | 2008-10-27 | Займодженетикс, Инк. | Человеческий цитокин как лиганд зальфа рецептора и его применение |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| DE60034564T2 (de) | 1999-07-07 | 2007-12-27 | Zymogenetics, Inc., Seattle | Menschlicher cytokinrezeptor |
| US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
| EP2194130A1 (en) | 1999-12-23 | 2010-06-09 | ZymoGenetics, L.L.C. | Cytokine ZCYTO18 |
| ES2279809T3 (es) | 2000-04-05 | 2007-09-01 | Zymogenetics, Inc. | Receptores de citoquina zalfa11 solubles. |
| WO2001087933A2 (en) | 2000-05-11 | 2001-11-22 | Zymogenetics, Inc. | Zsig33-like peptides |
| EP1325115B1 (en) | 2000-06-26 | 2016-07-27 | ZymoGenetics, Inc. | Cytokine receptor zcytor17 |
| JP2005506042A (ja) | 2000-12-12 | 2005-03-03 | ユニヴァーシティー オブ コネティカット | 細胞トランスポーターをコードするポリヌクレオチド、およびその使用方法 |
| US7309783B2 (en) | 2001-05-09 | 2007-12-18 | The University Of Connecticut | Mammalian early developmental regulator gene |
| AU2002311012A1 (en) | 2001-06-06 | 2002-12-16 | Novozymes A/S | Endo-beta-1,4-glucanase from bacillus |
| EP2130919A1 (en) | 2001-11-05 | 2009-12-09 | ZymoGenetics, Inc. | IL-21 antagonists |
| WO2004003140A2 (en) | 2002-01-18 | 2004-01-08 | Zymogenetics, Inc. | Cytokine receptor zcytor17 multimers |
| RU2490276C2 (ru) | 2002-01-18 | 2013-08-20 | Займоджинетикс, Инк. | Новый лиганд рецептора цитокина zcytor17 |
| US7094579B2 (en) | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
| CN1659274A (zh) | 2002-04-19 | 2005-08-24 | 津莫吉尼蒂克斯公司 | 细胞因子受体 |
| MXPA04012116A (es) | 2002-06-07 | 2005-04-19 | Zymogenetics Inc | Uso del il-21 en cancer y otras aplicaciones terapeuticas. |
| AU2003274463B2 (en) | 2002-06-10 | 2009-10-29 | University Of Rochester | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| US7939304B2 (en) | 2002-10-02 | 2011-05-10 | Catalyst Biosciences, Inc. | Mutant MT-SP1 proteases with altered substrate specificity or activity |
| WO2004031733A2 (en) | 2002-10-02 | 2004-04-15 | Catalyst Biosciences | Methods of generating and screenign for porteases with altered specificity |
| EP1947116B1 (en) | 2003-02-10 | 2017-06-21 | 2-BBB Medicines B.V. | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
| ATE471370T1 (de) | 2003-05-02 | 2010-07-15 | Novozymes Inc | Varianten von beta-glukosidasen |
| US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
| EP1653995A1 (en) | 2003-08-08 | 2006-05-10 | Novo Nordisk A/S | Interleukin-20 for treating and diagnosing conditions associated with neovascularisation |
| ES2538824T3 (es) | 2003-08-25 | 2015-06-24 | Novozymes, Inc. | Variantes de glucósido hidrolasas |
| ES2428358T3 (es) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| DK1682656T3 (da) | 2003-10-28 | 2013-11-18 | Novozymes Inc | Polypeptider med beta-glucosidaseaktivitet og polynukleotider, der koder for dem |
| DK1713825T3 (da) | 2004-01-30 | 2012-11-05 | Novozymes Inc | Polypeptider med cellulolytisk forøgende aktivitet og polynukleotider der koder for samme |
| WO2006078256A2 (en) | 2004-02-12 | 2006-07-27 | Novozymes, Inc. | Polypeptides having xylanase activity and polynucleotides encoding same |
| WO2005110453A2 (en) | 2004-04-12 | 2005-11-24 | Catalyst Biosciences, Inc. | Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1 |
| WO2005121351A2 (en) | 2004-05-27 | 2005-12-22 | Novozymes, Inc. | Methods for transforming and expression screening of filamentous fungal cells with a dna library |
| WO2006005032A2 (en) | 2004-06-29 | 2006-01-12 | Novozymes, Inc. | Polypeptides having alpha-glucosidase activity and polynucleotides encoding same |
| US7666630B2 (en) | 2004-09-30 | 2010-02-23 | Novozymes, Inc. | Polypeptides having lipase activity and polynucleotides encoding same |
| EP1809747B1 (en) | 2004-10-04 | 2016-12-14 | Novozymes A/S | Polypeptides having phytase activity and polynucleotides encoding same |
| AR050895A1 (es) | 2004-10-04 | 2006-11-29 | Novozymes As | Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican |
| EP1814996A2 (en) | 2004-11-19 | 2007-08-08 | Novozymes A/S | Polypeptides having antimicrobial activity and polynucleotides encoding same |
| MX2007007107A (es) | 2004-12-22 | 2007-08-08 | Novozymes North America Inc | Polipeptidos que tienen actividad de glucoamilasa y polinucleotidos que los codifican. |
| WO2006086396A2 (en) | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation |
| AR052947A1 (es) | 2005-03-18 | 2007-04-11 | Novozymes As | Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que codifican para los mismos |
| AU2006226192A1 (en) | 2005-03-19 | 2006-09-28 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
| CA2606475C (en) | 2005-04-27 | 2015-06-16 | Novozymes, Inc. | Polypeptides having endoglucanase activity and polynucleotides encoding same |
| EP3683230A1 (en) | 2005-05-12 | 2020-07-22 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| WO2007001677A2 (en) | 2005-05-17 | 2007-01-04 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| AU2006283904B2 (en) | 2005-08-26 | 2012-07-12 | Novozymes Adenium Biotech A/S | Polypeptides having antimicrobial activity and polynucleotides encoding same |
| EP1941023B1 (en) | 2005-09-30 | 2017-04-05 | Novozymes Inc. | Methods for enhancing the degradation or conversion of cellulosic material |
| EP1999257B1 (en) | 2006-03-20 | 2011-06-22 | Novozymes, Inc. | Polypeptides having endoglucanase activity and polynucleotides encoding same |
| EP2004817A2 (en) | 2006-03-30 | 2008-12-24 | Novozymes, Inc. | Polypeptides having endoglucanase activity and polynucleotides encoding same |
| US8106013B2 (en) | 2006-05-19 | 2012-01-31 | Georgia Tech Research Corporation | ABC transporter ligand GATX1 |
| US7932055B2 (en) | 2006-06-22 | 2011-04-26 | Novo Nordisk A/S | Soluble heterodimeric CD94/NKG2 receptors fusion proteins |
| US8324158B2 (en) | 2006-07-14 | 2012-12-04 | Georgia Tech Research Corporation | Methods for inhibiting CLC-2 channel with GATX2 |
| CN101522045A (zh) | 2006-09-29 | 2009-09-02 | 诺维信公司 | 用于动物饲料的木聚糖酶 |
| EP2099818A2 (en) | 2006-11-29 | 2009-09-16 | Novozymes Inc. | Bacillus licheniformis chromosome |
| CN101595214B (zh) | 2006-11-29 | 2013-06-12 | 诺维信股份有限公司 | 改进向细菌细胞中导入dna的方法 |
| PL2662091T3 (pl) | 2006-12-01 | 2019-05-31 | Novartis Ag | Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych |
| DK2129781T3 (da) | 2007-03-26 | 2014-03-31 | Novozymes As | Hafnia-phytase |
| DE102007016139A1 (de) | 2007-03-30 | 2008-10-02 | Jenabios Gmbh | Verfahren zur regioselektiven Oxygenierung von N-Heterozyklen |
| EP2193195B1 (en) | 2007-09-18 | 2014-12-17 | Novozymes A/S | Polypeptides having tyrosinase activity and polynucleotides encoding same |
| US7858759B2 (en) | 2007-10-04 | 2010-12-28 | Zymogenetics, Inc. | Anti-zB7H6 antibody-drug conjugates |
| CN101918437B (zh) | 2007-11-21 | 2013-08-14 | 罗斯基勒大学 | 具有冰结合活性的多肽 |
| US7867745B2 (en) | 2007-11-27 | 2011-01-11 | Novozymes A/S | Polypeptides having alpha-glucuronidase activity and polynucleotides encoding same |
| CA2706639A1 (en) | 2007-11-29 | 2009-06-04 | Novozymes A/S | Synthase inhibitor screening method |
| ES2490608T3 (es) | 2007-12-06 | 2014-09-04 | Novozymes A/S | Polipéptidos con actividad de esterasa de acetilxilano y polinucleótidos que codifican los mismos |
| EP2235173A2 (en) | 2007-12-19 | 2010-10-06 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| NZ586544A (en) | 2007-12-26 | 2012-07-27 | Vaccinex Inc | Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods |
| KR101720760B1 (ko) | 2008-01-25 | 2017-03-28 | 오르후스 우니베르시테트 | Igfbp-4에 대한 papp-a 활성의 선택적 엑소사이트 억제 |
| JP5639039B2 (ja) | 2008-04-11 | 2014-12-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| AU2009254546B2 (en) | 2008-06-06 | 2014-09-25 | Novozymes A/S | Variants of a family 44 xyloglucanase |
| EP4545638A3 (en) | 2008-06-06 | 2025-07-16 | The Procter & Gamble Company | Detergent composition comprising a variant of a family 44 xyloglucanase |
| JP5728380B2 (ja) | 2008-06-12 | 2015-06-03 | シンタクシン リミテッドSyntaxin Limited | 神経内分泌疾患の抑制 |
| BRPI0915142A8 (pt) | 2008-06-12 | 2018-01-02 | Syntaxin Ltd | Polipeptídeos, ácido nucleico e usos dos mesmos |
| WO2009158696A1 (en) | 2008-06-27 | 2009-12-30 | Zymogenetics, Inc. | SOLUBLE HYBRID Fcγ RECEPTORS AND RELATED METHODS |
| CN102159233A (zh) | 2008-07-18 | 2011-08-17 | 诺维信阿德宁生物技术公司 | 使用哺乳动物β防御素的炎性肠病的治疗 |
| MX2011001409A (es) | 2008-08-14 | 2011-03-29 | Cephalon Australia Pty Ltd | Anticuerpos anti-il-12/il-23. |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| WO2010059413A2 (en) | 2008-11-20 | 2010-05-27 | Novozymes, Inc. | Polypeptides having amylolytic enhancing activity and polynucleotides encoding same |
| US7771983B2 (en) | 2008-12-04 | 2010-08-10 | Novozymos, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| WO2010068800A1 (en) | 2008-12-12 | 2010-06-17 | Novozymes, Inc. | Polypeptides having aspartic endopeptidase activity and polynucleotides encoding same |
| US20110296557A1 (en) | 2008-12-12 | 2011-12-01 | Novozymes, Inc. | Polypeptides Having Lipase Activity And Polynucleotides Encoding Same |
| WO2010074972A1 (en) | 2008-12-15 | 2010-07-01 | Novozymes, Inc. | Polypeptides having catalase activity and polynucleotides encoding same |
| US20110271407A1 (en) | 2008-12-16 | 2011-11-03 | Novozymes, Inc. | Polypeptides Having Alpha-Mannosidase Activity And Polynucleotides Encoding Same |
| WO2010074955A1 (en) | 2008-12-16 | 2010-07-01 | Novozymes, Inc. | Polypeptides having carboxypeptidase activity and polynucleotides encoding same |
| EP2379729A2 (en) | 2008-12-19 | 2011-10-26 | Novozymes A/S | Use of enzymes having silicase activity |
| CN102361973B (zh) | 2009-01-21 | 2015-09-02 | 诺维信公司 | 具有酯酶活性的多肽和编码该多肽的核酸 |
| WO2010088387A1 (en) | 2009-01-28 | 2010-08-05 | Novozymes, Inc. | Polypeptides having beta-glucosidase activity and polynucleotides encoding same |
| WO2010087702A1 (en) | 2009-01-30 | 2010-08-05 | Stichting Katholieke Universiteit | TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject |
| WO2010088447A1 (en) | 2009-01-30 | 2010-08-05 | Novozymes A/S | Polypeptides having alpha-amylase activity and polynucleotides encoding same |
| WO2010088463A2 (en) | 2009-01-30 | 2010-08-05 | Novozymes, Inc. | Polypeptides having expansin activity and polynucleotides encoding same |
| US8679814B2 (en) | 2009-02-06 | 2014-03-25 | University Of Chile | Protein and DNA sequence encoding a cold adapted xylanase |
| WO2010091221A1 (en) | 2009-02-06 | 2010-08-12 | Novozymes A/S | Polypeptides having alpha-amylase activity and polynucleotides encoding same |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| WO2010097436A1 (en) | 2009-02-27 | 2010-09-02 | Novozymes A/S | Mutant cells having reduced expression of metallopeptidase, suitable for recombinant polypeptide production |
| EP2408314A1 (en) | 2009-03-17 | 2012-01-25 | Novozymes A/S | Polypeptides having tyrosinase activity and polynucleotides encoding same |
| CN102365360A (zh) | 2009-03-24 | 2012-02-29 | 诺维信公司 | 具有乙酰木聚糖酯酶活性的多肽和编码该多肽的多核苷酸 |
| EP2248893A1 (en) | 2009-05-06 | 2010-11-10 | Novozymes A/S | DFPase Enzymes from Octopus Vulgaris |
| EP2435561B1 (en) | 2009-05-29 | 2018-08-08 | Novozymes Inc. | Methods for enhancing the degradation or conversion of cellulosic material |
| ES2534078T3 (es) | 2009-06-02 | 2015-04-17 | Novozymes Inc. | Polipéptidos con actividad de celobiohidrolasa y polinucleótidos que codifican los mismos |
| WO2010151787A1 (en) | 2009-06-26 | 2010-12-29 | Novozymes North America, Inc. | Heat-stable carbonic anhydrases and their use |
| CA2767169A1 (en) | 2009-07-07 | 2011-01-13 | Novozymes, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| MX2012001060A (es) | 2009-07-24 | 2012-03-14 | Novozymes As | Carbohidrato-oxidasas. |
| WO2011014458A1 (en) | 2009-07-28 | 2011-02-03 | Novozymes, Inc. | Polypeptides having phytase activity and polynucleotides encoding same |
| US8409830B2 (en) | 2009-08-21 | 2013-04-02 | Novozymes A/S | Polypeptides having isoamylase activity and methods of use |
| US8741611B2 (en) | 2009-09-01 | 2014-06-03 | Novozymes, Inc. | Methods for improving malic acid production in filamentous fungi |
| WO2011034421A1 (en) | 2009-09-16 | 2011-03-24 | Stichting Het Nederlands Kanker Instituut | Fra-1 target genes as drug targets for treating cancer |
| DK3269804T3 (da) | 2009-09-17 | 2020-11-23 | Novozymes Inc | Polypeptider med cellulolyseforbedrende aktivitet og polynukleotider, som koder for dem |
| EP2478095A1 (en) | 2009-09-18 | 2012-07-25 | Novozymes Inc. | Polypeptides having beta-glucosidase activity and polynucleotides encoding same |
| EP2305717A1 (en) | 2009-09-21 | 2011-04-06 | Koninklijke Nederlandse Akademie van Wetenschappen | Inhibiting TNIK for treating colon cancer |
| CN102648277B (zh) | 2009-09-25 | 2015-05-20 | 诺维信公司 | 蛋白酶变体的用途 |
| US9598692B2 (en) | 2009-09-25 | 2017-03-21 | University Of Oslo | Multivalent phage display systems and methods |
| EP2480650B1 (en) | 2009-09-25 | 2017-03-22 | Novozymes A/S | Subtilase variants |
| WO2011041397A1 (en) | 2009-09-29 | 2011-04-07 | Novozymes, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| CA2775347A1 (en) | 2009-09-29 | 2011-04-07 | Novozymes A/S | Polypeptides having xylanase activity and polynucleotides encoding same |
| BR112012007375A2 (pt) | 2009-09-30 | 2016-11-22 | Novozymes As | polipeptídeo isolado, polinucleotídeo isolado, métodos para produzir um polipeptídeo, para produzir um mutante de uma célula precursora, para inibir a expressão de um polipeptídeo, para produzir uma proteína, para degradar ou converter um material celulósico, para produzir um produto de fermentação e para fermentar um material celulósico, planta transgênica, parte de planta ou célula de planta transformada, molécula de rna inibitória de filamento duplo, e, composição detergente |
| WO2011039319A1 (en) | 2009-09-30 | 2011-04-07 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| WO2011050037A1 (en) | 2009-10-23 | 2011-04-28 | Novozymes, Inc. | Cellobiohydrolase variants and polynucleotides encoding same |
| WO2011059740A1 (en) | 2009-10-29 | 2011-05-19 | Novozymes, Inc. | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| DK2496692T3 (en) | 2009-11-06 | 2016-06-27 | Novozymes Inc | POLYPEPTIDES WITH xylanase AND POLYNUCLEOTIDES ENCODING THEM |
| CN103068976A (zh) | 2009-11-06 | 2013-04-24 | 诺维信股份有限公司 | 具有纤维二糖水解酶活性的多肽和编码该多肽的多核苷酸 |
| EP2325311A1 (en) | 2009-11-18 | 2011-05-25 | Pierre Fabre Medicament | Novel phage display vector |
| CN102869770B (zh) | 2009-11-30 | 2015-12-16 | 诺维信公司 | 具有葡糖淀粉酶活性的多肽和编码该多肽的多核苷酸 |
| CA2782154C (en) | 2009-11-30 | 2018-10-16 | Novozymes A/S | Polypeptides having glucoamylase activity and polynucleotides encoding same |
| CA2782036C (en) | 2009-12-01 | 2019-01-15 | Novozymes A/S | Polypeptides having glucoamylase activity and polynucleotides encoding same |
| TW201125577A (en) | 2009-12-02 | 2011-08-01 | Novozymes As | Use of defensins for treatment of infective endocarditis |
| WO2011067349A1 (en) | 2009-12-03 | 2011-06-09 | Novozymes A/S | Variants of a polypeptide with lipolytic activity and improved stability |
| US8951770B2 (en) | 2009-12-09 | 2015-02-10 | Novozymes A/S | GH8 xylanase variants |
| US8653024B2 (en) | 2009-12-11 | 2014-02-18 | Adenium Biotech Aps | Use of AMPs for treatment of UTI/cystitis |
| US20120220513A1 (en) | 2009-12-29 | 2012-08-30 | Novozymes A/S | Polypeptides Having Detergency Enhancing Effect |
| CN102884183B (zh) | 2010-01-04 | 2015-09-16 | 诺维信公司 | 趋于钙耗竭和酸性pH的α-淀粉酶的稳定化 |
| EP2354244A1 (en) | 2010-02-04 | 2011-08-10 | Stichting Top Institute Food and Nutrition | MBL2 as a marker of liver-specific insulin resistance |
| EP2354245A1 (en) | 2010-02-04 | 2011-08-10 | Stichting Top Institute Food and Nutrition | MBL2 as a marker of hepatic PPAR- activity |
| JP5833576B2 (ja) | 2010-02-25 | 2015-12-16 | ノボザイムス アクティーゼルスカブ | リゾチームの変異体及びそれをコードするポリヌクレオチド |
| WO2011104284A1 (en) | 2010-02-25 | 2011-09-01 | Novozymes A/S | Polypeptides having antimicrobial activity |
| WO2011109524A2 (en) | 2010-03-03 | 2011-09-09 | Novozymes, Inc. | Xylanase variants and polynucleotides encoding same |
| US9222109B2 (en) | 2010-03-28 | 2015-12-29 | Novozymes A/S | Enzymatic hydroxylation of aliphatic hydrocarbon |
| CN102834521B (zh) | 2010-03-30 | 2018-02-27 | 诺维信公司 | 用于增强来自发酵工艺副产物的方法 |
| WO2011123450A1 (en) | 2010-03-31 | 2011-10-06 | Novozymes, Inc. | Cellobiohydrolase variants and polynucleotides encoding same |
| CA2795806C (en) | 2010-04-14 | 2019-01-08 | Novozymes A/S | Polypeptides having glucoamylase activity and polynucleotides encoding same |
| WO2011153317A1 (en) | 2010-06-04 | 2011-12-08 | Novozymes, Inc. | C4 dicarboxylic acid production in filamentous fungi |
| EP2580238A1 (en) | 2010-06-09 | 2013-04-17 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
| WO2012047324A2 (en) | 2010-06-10 | 2012-04-12 | President And Fellows Of Harvard College | Systems and methods for amplification and phage display |
| US8835604B2 (en) | 2010-06-12 | 2014-09-16 | Adenium Biotech Aos | Antimicrobial peptide variants and polynucleotides encoding same |
| IN2013CN00459A (zh) | 2010-06-21 | 2015-07-03 | Novozymes Inc | |
| AU2011271094B2 (en) | 2010-06-21 | 2015-01-22 | Novozymes, Inc. | Aspergillus aculeatus derived polypeptides having C4-dicarboxylic acid transporter activity and polynucleotides encoding same |
| EP2588604B1 (en) | 2010-06-30 | 2016-06-29 | Novozymes, Inc. | Polypeptides having beta-glucosidase activity and polynucleotides encoding same |
| WO2012021401A1 (en) | 2010-08-12 | 2012-02-16 | Novozymes, Inc. | Compositions comprising a polypeptide having cellulolytic enhancing activity and a bicyclic compound and uses thereof |
| MX2013001843A (es) | 2010-08-17 | 2013-06-28 | Stichting Katholieke Univ | Un metodo novedoso para el diagnostico de fiebre q usando una prueba inmunologica celular. |
| CN107299095B (zh) | 2010-08-24 | 2021-05-11 | 诺维信公司 | 热稳定性Persephonella碳酸酐酶及其用途 |
| WO2012030811A1 (en) | 2010-08-30 | 2012-03-08 | Novozymes A/S | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same |
| WO2012030849A1 (en) | 2010-08-30 | 2012-03-08 | Novozymes A/S | Polypeptides having xylanase activity and polynucleotides encoding same |
| US8629325B2 (en) | 2010-08-30 | 2014-01-14 | Novozymes A/S | Polypeptides having beta-glucosidase activity and polynucleotides encoding same |
| US9303074B2 (en) | 2010-08-30 | 2016-04-05 | Novoyzmes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| WO2012030858A2 (en) | 2010-08-30 | 2012-03-08 | Novozymes A/S | Polypeptides having hemicellulolytic activity and polynucleotides encoding same |
| US9267126B2 (en) | 2010-08-30 | 2016-02-23 | Novozymes, Inc. | Polypeptides having endoglucanase activity and polynucleotides encoding same |
| EP2616483A1 (en) | 2010-09-16 | 2013-07-24 | Novozymes A/S | Lysozymes |
| CA2811678C (en) | 2010-09-21 | 2019-10-01 | Stichting Katholieke Universiteit | Novel method for diagnosing lyme disease using a cellular immunological test |
| EP2622070B1 (en) | 2010-09-30 | 2016-08-03 | Novozymes, Inc. | Variants of polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| EP2622068B1 (en) | 2010-09-30 | 2016-07-20 | Novozymes, Inc. | Variants of polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| MX2013002586A (es) | 2010-10-01 | 2013-03-21 | Novozymes Inc | Variantes de beta-glucosidasa y polinucleotidos que codifican las mismas. |
| RU2583293C2 (ru) | 2010-10-01 | 2016-05-10 | Новозимс А/С | Полипептиды, обладающие эндопептидазной активностью, и кодирующие их полинуклеотиды |
| GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| WO2012058293A1 (en) | 2010-10-26 | 2012-05-03 | Novozymes North America, Inc. | Methods of saccharifying sugarcane trash |
| EP2632943A1 (en) | 2010-10-29 | 2013-09-04 | Novozymes A/S | Polypeptides having succinyl-coa:aceto acetate transferase activity and polynucleotides encoding same |
| MX2013004353A (es) | 2010-10-29 | 2013-06-28 | Novozymes Inc | Produccion recombinante de n-propanol e isopropanol. |
| DK2635689T3 (en) | 2010-11-02 | 2015-07-06 | Novozymes Inc | METHODS OF PREPARATION OF cellulosic material WITH A GH61-POLYPEPTIDE |
| EP2635594B1 (en) | 2010-11-04 | 2017-01-11 | Novozymes Inc. | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same |
| DK2638154T3 (da) | 2010-11-08 | 2017-01-02 | Novozymes As | Polypeptider med glucoamylaseaktivitet og polynukleotider, der koder for dem |
| EP2637515B1 (en) | 2010-11-08 | 2017-09-06 | Novozymes A/S | Polypeptides having glucoamylase activity and polynucleotides encoding same |
| BR112013011442A2 (pt) | 2010-11-12 | 2020-08-11 | Novozymes A/S | polipeptídeo isolado, polinucleotídeo isolado, construto de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, método de produção do polipeptídeo, composição, uso do polipeptídeo ou da composição, métodos de redução do teor de componentes contendo fósforo em um óleo comestível, e para desengomagem de uma composição de óleo |
| BR112013009026A2 (pt) | 2010-11-12 | 2016-07-12 | Novozymes Inc | polipeptídeo isolado, célula hospedeira recombinante, métodos para produzir um polipeptídeo, um mutante de uma célula precursora, uma proteína, e um produto de fermentação, para inibir a expressão de um polipeptídeo, para degradar ou converter um material celulósico, e método para fermentar um material celulósico, planta transgênica, parte de planta ou célula de planta, molécula de rna inibidora de filamento duplo, polinucleotídeo isolado, e, formulação de caldo integral ou composição de cultura de célula |
| WO2012068509A1 (en) | 2010-11-18 | 2012-05-24 | Novozymes, Inc. | Chimeric polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| US8927235B2 (en) | 2010-12-06 | 2015-01-06 | Novozymes A/S | Methods of hydrolyzing oligomers in hemicellulosic liquor |
| EP2465928A1 (en) | 2010-12-16 | 2012-06-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Treatment of Th17-mediated diseases |
| WO2012103322A1 (en) | 2011-01-26 | 2012-08-02 | Novozymes A/S | Polypeptides having endoglucanase activity and polynucleotides encoding same |
| EP2668266B1 (en) | 2011-01-26 | 2018-01-03 | Novozymes A/S | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same |
| US9157075B2 (en) | 2011-01-26 | 2015-10-13 | Novozymes, Inc. | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same |
| DK2668270T3 (en) | 2011-01-26 | 2019-01-07 | Novozymes Inc | Polypeptides with cellobiohydrolase activity and polynucleotides encoding them |
| MX2013007720A (es) | 2011-01-26 | 2013-08-09 | Novozymes As | Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican para los mismos. |
| DK2670853T3 (en) | 2011-01-31 | 2017-08-28 | Novozymes North America Inc | Process for enzymatic refining of pretreated cellulosic material for sugars |
| JP2014511409A (ja) | 2011-02-16 | 2014-05-15 | ノボザイムス アクティーゼルスカブ | 金属プロテアーゼを含む洗剤組成物 |
| JP2014506945A (ja) | 2011-02-16 | 2014-03-20 | ノボザイムス アクティーゼルスカブ | 金属プロテアーゼを含む洗剤組成物 |
| US20140024103A1 (en) | 2011-02-16 | 2014-01-23 | Astrid Benie | Detergent Compositions Comprising Metalloproteases |
| EP2678352B1 (en) | 2011-02-23 | 2017-12-06 | Novozymes, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| WO2012118848A1 (en) | 2011-02-28 | 2012-09-07 | Novozymes, Inc. | Microorganism for c4-dicarboxylic acid production |
| CN103608461B (zh) | 2011-03-09 | 2016-08-03 | 诺维信公司 | 增加多肽的纤维素分解增强活性的方法 |
| WO2012122477A1 (en) | 2011-03-10 | 2012-09-13 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| WO2012127002A1 (en) | 2011-03-23 | 2012-09-27 | Novozymes A/S | Sweet-tasting polypeptide from gram-positive bacteria |
| WO2012127001A1 (en) | 2011-03-23 | 2012-09-27 | Novozymes A/S | Methods for producing secreted polypeptides |
| US9879294B2 (en) | 2011-03-25 | 2018-01-30 | Novozymes A/S | Methods for degrading or converting cellulosic material |
| WO2012135659A2 (en) | 2011-03-31 | 2012-10-04 | Novozymes A/S | Methods for enhancing the degradation or conversion of cellulosic material |
| WO2012135719A1 (en) | 2011-03-31 | 2012-10-04 | Novozymes, Inc. | Cellulose binding domain variants and polynucleotides encoding same |
| DK2702153T3 (en) | 2011-04-28 | 2019-03-18 | Novozymes Inc | Polypeptides with endoglucanase activity and polynucleotides encoding them |
| DK2702162T3 (da) | 2011-04-29 | 2020-05-18 | Novozymes Inc | Fremgangsmåder til forbedring af nedbrydningen eller omdannelsen af celluloseholdigt materiale |
| WO2012150319A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| EP2710132A1 (en) | 2011-05-19 | 2014-03-26 | Novozymes, Inc. | Methods for enhancing the degradation of cellulosic material with chitin binding proteins |
| EP2710133A1 (en) | 2011-05-19 | 2014-03-26 | Novozymes, Inc. | Methods for enhancing the degradation of cellulosic material with chitin binding proteins |
| EP2527432A1 (en) | 2011-05-23 | 2012-11-28 | Novozymes A/S | Bi-directional cytosine deaminase-encoding selection marker |
| EP2527448A1 (en) | 2011-05-23 | 2012-11-28 | Novozymes A/S | Simultaneous site-specific integrations of multiple gene-copies in filamentous fungi |
| CN103620029B (zh) | 2011-06-24 | 2017-06-09 | 诺维信公司 | 具有蛋白酶活性的多肽和编码它们的多核苷酸 |
| EP3421595B1 (en) | 2011-06-30 | 2020-10-07 | Novozymes A/S | Alpha-amylase-variants |
| EP2726500B1 (en) | 2011-06-30 | 2019-03-20 | Novozymes A/S | Method for screening alpha-amylases |
| EP2540824A1 (en) | 2011-06-30 | 2013-01-02 | The Procter & Gamble Company | Cleaning compositions comprising amylase variants reference to a sequence listing |
| MX337984B (es) | 2011-07-06 | 2016-03-30 | Novozymes As | Variantes de alfa amilasa y polinucleotidos que codifican la misma. |
| WO2013004639A2 (en) | 2011-07-07 | 2013-01-10 | Novozymes A/S | Enzymatic preparation of diols |
| JP6219277B2 (ja) | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブDefensin Therapeutics Aps | 炎症性腸疾患の経口治療 |
| CN103827298A (zh) | 2011-07-15 | 2014-05-28 | 诺维信公司 | 脂肪酶变体及其编码多核苷酸 |
| CN109022518A (zh) | 2011-07-22 | 2018-12-18 | 诺维信北美公司 | 用于预处理纤维素材料和改进其水解的方法 |
| BR112014002401B1 (pt) | 2011-08-04 | 2021-08-03 | Novozymes A/S | Célula hospedeira transgênica de fungo filamentoso, métodos para produzir um polipeptídeo e uma proteína, e, construto de ácido nucleico ou um vetor de expressão |
| EP2739728B1 (en) | 2011-08-04 | 2017-07-12 | Novozymes A/S | Polypeptides having endoglucanase activity and polynucleotides encoding same |
| WO2013021065A1 (en) | 2011-08-10 | 2013-02-14 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| WO2013021064A1 (en) | 2011-08-10 | 2013-02-14 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| EP2742129B1 (en) | 2011-08-10 | 2017-08-02 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| US9487761B2 (en) | 2011-08-10 | 2016-11-08 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| US9506044B2 (en) | 2011-08-10 | 2016-11-29 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| WO2013021059A1 (en) | 2011-08-10 | 2013-02-14 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| WO2013021062A1 (en) | 2011-08-10 | 2013-02-14 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| EP2744898A1 (en) | 2011-08-15 | 2014-06-25 | Novozymes A/S | Polypeptides having cellulase activity and polynucleotides encoding same |
| US20140295027A1 (en) | 2011-08-19 | 2014-10-02 | Novozymes A/S | Polypeptides Having Protease Activity |
| BR112014003444A2 (pt) | 2011-08-19 | 2017-03-14 | Novozymes Inc | célula hospedeira recombinante, e, método para produzir um ácido c4-dicarboxílico |
| WO2013026794A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes | Novel immunomodulatory peptide |
| CA2846690A1 (en) | 2011-08-26 | 2013-03-07 | Novozymes A/S | Polypeptides having glucoamylase activity and polynucleotides encoding same |
| GB201115214D0 (en) | 2011-09-02 | 2011-10-19 | Health Prot Agency | Influenza virus antibody compositions |
| CN103930543B (zh) | 2011-09-06 | 2020-11-27 | 诺维信公司 | 葡糖淀粉酶变体和编码它们的多核苷酸 |
| CN103764905A (zh) | 2011-09-09 | 2014-04-30 | 诺维信公司 | 改进纸张材料的特性 |
| CA2847236A1 (en) | 2011-09-09 | 2013-03-14 | Novozymes A/S | Polypeptides having alpha-amylase activity and polynucleotides encoding same |
| EP2756091A1 (en) | 2011-09-13 | 2014-07-23 | Novozymes North America, Inc. | Methods of hydrolyzing and fermenting cellulosic material |
| US20140308705A1 (en) | 2011-09-20 | 2014-10-16 | Novozymes A/S | Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same |
| ES2628190T3 (es) | 2011-09-22 | 2017-08-02 | Novozymes A/S | Polipéptidos con actividad de proteasa y polinucleótidos que codifican los mismos |
| IN2014CN02910A (zh) | 2011-09-23 | 2015-07-03 | Novozymes As | |
| EP2751261B1 (en) | 2011-09-30 | 2018-08-29 | Novozymes, Inc. | Dehydrogenase variants and polynucleotides encoding same |
| WO2013044867A1 (en) | 2011-09-30 | 2013-04-04 | Novozymes A/S | Polypeptides having alpha-amylase activity and polynucleotides encoding same |
| US9353362B2 (en) | 2011-10-11 | 2016-05-31 | Novozymes A/S | Glucoamylase variants and polynucleotides encoding same |
| CA3253390A1 (en) | 2011-10-17 | 2025-06-17 | Novozymes A/S | Variants of alpha-amylase and the polynucleotides encoding them |
| HUE039835T2 (hu) | 2011-10-17 | 2019-02-28 | Novozymes As | Alfa-amiláz variánsok és az azokat kódoló polinukleotidok |
| US10308921B2 (en) | 2011-10-31 | 2019-06-04 | Novozymes, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| WO2013064195A1 (en) | 2011-11-04 | 2013-05-10 | Enel Ingegneria E Ricerca S.P.A. | A new heat-stable carbonic anhydrase and uses thereof |
| EP2794873A1 (en) | 2011-11-08 | 2014-10-29 | Novozymes A/S | Methods for production of archeae protease in yeast |
| HK1200842A1 (zh) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | 具有改进半衰期和其他特性的蛋白质 |
| EP2780449B1 (en) | 2011-11-18 | 2018-04-11 | Novozymes, Inc. | Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same |
| CN103958672A (zh) | 2011-11-21 | 2014-07-30 | 诺维信股份有限公司 | Gh61多肽变体以及编码所述变体的多核苷酸 |
| DK2782998T3 (en) | 2011-11-22 | 2018-04-16 | Novozymes Inc | POLYPEPTIDES WITH BETA-XYLOSIDASE ACTIVITY AND POLYNUCLEOTIDES CODING THEM |
| JP6105615B2 (ja) | 2011-11-25 | 2017-03-29 | ノボザイムス アクティーゼルスカブ | リゾチーム活性を有するポリペプチドおよびそれをコードするポリヌクレオチド |
| US20140342433A1 (en) | 2011-11-25 | 2014-11-20 | Novozymes A/S | Subtilase Variants and Polynucleotides Encoding Same |
| US9624481B2 (en) | 2011-12-01 | 2017-04-18 | Novozymes, Inc. | Polypeptides having beta-xylosidase activity and polynucleotides encoding same |
| US9404093B2 (en) | 2011-12-02 | 2016-08-02 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| US9169469B2 (en) | 2011-12-02 | 2015-10-27 | Novozymes A/S | Polypeptides having peroxygenase activity and polynucleotides encoding same |
| WO2013087027A1 (en) | 2011-12-16 | 2013-06-20 | Novozymes, Inc. | Polypeptides having laccase activity and polynucleotides encoding same |
| WO2013091547A1 (en) | 2011-12-19 | 2013-06-27 | Novozymes, Inc. | Polypeptides having catalase activity and polynucleotides encoding same |
| MX2014007446A (es) | 2011-12-20 | 2014-08-01 | Novozymes As | Variantes de subtilasa y polinucleotidos que las codifican. |
| EP2607468A1 (en) | 2011-12-20 | 2013-06-26 | Henkel AG & Co. KGaA | Detergent compositions comprising subtilase variants |
| DK2794869T3 (en) | 2011-12-20 | 2018-01-02 | Novozymes Inc | CELLOBIO HYDROLASE VARIABLES AND POLYNUCLEOTIDES CODING THEM |
| ES2667318T3 (es) | 2011-12-28 | 2018-05-10 | Novozymes A/S | Polipéptidos con actividad de proteasa |
| US9801398B2 (en) | 2012-01-26 | 2017-10-31 | Novozymes A/S | Use of polypeptides having protease activity in animal feed and detergents |
| DK2623586T3 (da) | 2012-02-03 | 2017-11-13 | Procter & Gamble | Sammensætninger og fremgangsmåder til overfladebehandling med lipaser |
| EP4570895A3 (en) | 2012-02-03 | 2026-01-14 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| MX350713B (es) | 2012-02-17 | 2017-09-14 | Novozymes As | Variantes de subtilisina y polinucleotidos que las codifican. |
| EP2628785B1 (en) | 2012-02-17 | 2016-05-18 | Henkel AG & Co. KGaA | Detergent compositions comprising subtilase variants |
| PT2817325T (pt) | 2012-02-20 | 2019-10-01 | Novozymes As | Polipéptidos que têm atividade da endoglucanase e polinucleotídeos codificando mesmos |
| EP3330283A3 (en) | 2012-03-16 | 2018-07-11 | Albumedix A/S | Albumin variants |
| US9458478B2 (en) | 2012-03-31 | 2016-10-04 | Novozymes A/S | Epoxidation using peroxygenase |
| EP2834353B1 (en) | 2012-04-02 | 2017-07-19 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| US9446102B2 (en) | 2012-04-23 | 2016-09-20 | Novozymes A/S | Polypeptides having alpha-glucuronidase activity and polynucleotides encoding same |
| EP2841570B1 (en) | 2012-04-23 | 2017-12-20 | Novozymes A/S | Polypeptides having glucuronyl esterase activity and polynucleotides encoding same |
| CA2870773A1 (en) | 2012-04-25 | 2013-10-31 | Novozymes A/S | Method of baking |
| CN104245926B (zh) | 2012-04-27 | 2021-05-07 | 诺维信股份有限公司 | Gh61多肽变体以及编码其的多核苷酸 |
| CN113201519A (zh) | 2012-05-07 | 2021-08-03 | 诺维信公司 | 具有黄原胶降解活性的多肽以及编码其的核苷酸 |
| EP2850180A1 (en) | 2012-05-18 | 2015-03-25 | Novozymes A/S | Bacterial mutants with improved transformation efficiency |
| EP2855670A2 (en) | 2012-05-31 | 2015-04-08 | Novozymes A/S | Polypeptides having organophosphorous hydrolase activity |
| WO2013178699A1 (en) | 2012-05-31 | 2013-12-05 | Novozymes A/S | Isopropanol production by bacterial hosts |
| EP2861749A1 (en) | 2012-06-19 | 2015-04-22 | Novozymes Bioag A/S | Enzymatic reduction of hydroperoxides |
| MX364390B (es) | 2012-06-20 | 2019-04-25 | Novozymes As | Uso de polipeptidos que tienen actividad proteasa en alimentos para animales y detergentes. |
| CN104471048B (zh) | 2012-07-12 | 2018-11-16 | 诺维信公司 | 具有脂肪酶活性的多肽及编码它的多核苷酸 |
| EP2875179B1 (en) | 2012-07-18 | 2018-02-21 | Novozymes A/S | Method of treating polyester textile |
| US20150152452A1 (en) | 2012-07-20 | 2015-06-04 | Novozymes A/S | Enzymatic Oxidation of 5-Hydroxymethylfurfural and Derivatives Thereof |
| CN104583394B (zh) | 2012-08-16 | 2019-06-07 | 诺维信公司 | 用内切葡聚糖酶处理纺织品的方法 |
| US9828595B2 (en) | 2012-08-17 | 2017-11-28 | Novozymes A/S | Thermostable asparaginase variants and polynucleotides encoding same |
| US9315791B2 (en) | 2012-08-22 | 2016-04-19 | Novozymes A/S | Metalloproteases from alicyclobacillus |
| MX2015002211A (es) | 2012-08-22 | 2015-05-08 | Novozymes As | Metaloproteasa de exiguobacterium. |
| WO2014029820A1 (en) | 2012-08-22 | 2014-02-27 | Novozymes A/S | Detergent compositions comprising metalloproteases |
| AU2013311668B2 (en) | 2012-09-05 | 2019-02-28 | Novozymes A/S | Polypeptides having protease activity |
| BR112015005884A2 (pt) | 2012-09-19 | 2017-08-08 | Novozymes Inc E Novozymes As | processos para degradação de um material celulósico, para produção de um produto da fermentação, e de fermentação de um material celulósico, composição, e, formulação de caldo inteiro ou composição de cultura de células |
| WO2014052630A1 (en) | 2012-09-27 | 2014-04-03 | Novozymes, Inc. | Bacterial mutants with improved transformation efficiency |
| EP2904099B1 (en) | 2012-10-05 | 2018-12-19 | Novozymes A/S | Preventing adhesion of bacteria |
| EP3586610B1 (en) | 2012-10-08 | 2024-09-25 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| EP2906685B1 (en) | 2012-10-12 | 2018-08-15 | Novozymes A/S | Polypeptides having peroxygenase activity |
| EP2906689B1 (en) | 2012-10-12 | 2018-12-12 | Novozymes A/S | Polypeptides having peroxygenase activity |
| US9453207B2 (en) | 2012-10-12 | 2016-09-27 | Novozymes A/S | Polypeptides having peroxygenase activity |
| EP2906686B1 (en) | 2012-10-12 | 2018-08-29 | Novozymes A/S | Polypeptides having peroxygenase activity |
| CN104718287B (zh) | 2012-10-12 | 2018-02-06 | 诺维信公司 | 具有过氧合酶活性的多肽 |
| WO2014056916A2 (en) | 2012-10-12 | 2014-04-17 | Novozymes A/S | Polypeptides having peroxygenase activity |
| US9404094B2 (en) | 2012-10-12 | 2016-08-02 | Novozymes A/S | Polypeptides having peroxygenase activity |
| WO2014066141A2 (en) | 2012-10-24 | 2014-05-01 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| WO2014068010A1 (en) | 2012-10-31 | 2014-05-08 | Novozymes A/S | Isopropanol production by bacterial hosts |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2014076232A2 (en) | 2012-11-19 | 2014-05-22 | Novozymes A/S | Isopropanol production by recombinant hosts using an hmg-coa intermediate |
| EP2925873B1 (en) | 2012-11-30 | 2017-07-12 | Novozymes, Inc. | 3-hydroxypropionic acid production by recombinant yeasts |
| TR201910918T4 (tr) | 2012-12-07 | 2019-08-21 | Novozymes As | Bakterilerin yapışmasının önlenmesi. |
| EP2740840A1 (en) | 2012-12-07 | 2014-06-11 | Novozymes A/S | Improving drainage of paper pulp |
| US20150307871A1 (en) | 2012-12-07 | 2015-10-29 | Novozymes A/S | Method for generating site-specific mutations in filamentous fungi |
| US20150368627A1 (en) | 2012-12-11 | 2015-12-24 | Novozymes A/S | Polypeptides Having Phospholipase C Activity and Polynucleotides Encoding Same |
| WO2014090940A1 (en) | 2012-12-14 | 2014-06-19 | Novozymes A/S | Removal of skin-derived body soils |
| US9765373B2 (en) | 2012-12-14 | 2017-09-19 | Novozymes A/S | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
| ES2772032T3 (es) | 2012-12-17 | 2020-07-07 | Novozymes As | Alfa-amilasas y polinucleótidos que las codifican |
| WO2014099798A1 (en) | 2012-12-19 | 2014-06-26 | Novozymes A/S | Polypeptides having cellulolytic enhancinc activity and polynucleotides encoding same |
| US9551042B2 (en) | 2012-12-21 | 2017-01-24 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
| EP2938628A4 (en) | 2012-12-24 | 2016-10-19 | Novozymes As | POLYPEPTIDES WITH ENDOGLUCANASE ACTIVITY AND POLYNUCLEOTIDES FOR CODING THEREOF |
| EP3321360A3 (en) | 2013-01-03 | 2018-06-06 | Novozymes A/S | Alpha-amylase variants and polynucleotides encoding same |
| WO2014122109A1 (en) | 2013-02-05 | 2014-08-14 | Novozymes A/S | Enzymatic preparation of indigo dyes and intermediates |
| MX2015010078A (es) | 2013-02-06 | 2016-01-25 | Novozymes As | Uso de polipeptidos con actividad proteasa en alimentos para animales. |
| CN105164254B (zh) | 2013-03-08 | 2019-06-28 | 诺维信公司 | 纤维二糖水解酶变体和编码它们的多核苷酸 |
| WO2014142646A1 (en) | 2013-03-13 | 2014-09-18 | Stichting Katholieke Universiteit | Q-fever diagnostic |
| US9631164B2 (en) | 2013-03-21 | 2017-04-25 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
| EP3533866A1 (en) | 2013-03-21 | 2019-09-04 | Novozymes A/S | Polypeptides having phospholipase a activity and polynucleotides encoding same |
| WO2014170218A1 (en) | 2013-04-18 | 2014-10-23 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
| WO2014173980A2 (en) | 2013-04-23 | 2014-10-30 | Novozymes A/S | Liquid automatic dish washing detergent compositions |
| WO2014177541A2 (en) | 2013-04-30 | 2014-11-06 | Novozymes A/S | Glucoamylase variants and polynucleotides encoding same |
| EP3372680B1 (en) | 2013-04-30 | 2020-11-11 | Novozymes A/S | Glucoamylase variants and polynucleotides encoding same |
| JP2016524697A (ja) | 2013-05-02 | 2016-08-18 | スティッチング カソリーケ ウニベルシテイトStichting Katholieke Universiteit | 個人化医療 |
| CN105164244B (zh) | 2013-05-03 | 2019-08-20 | 诺维信公司 | 洗涤剂酶的微囊化 |
| US9556465B2 (en) | 2013-05-10 | 2017-01-31 | Novozymes A/S | Polypeptides having xylanase activity and polynucleotides encoding same |
| MX392247B (es) | 2013-05-14 | 2025-03-24 | Novozymes As | Composiciones detergentes. |
| US20160083703A1 (en) | 2013-05-17 | 2016-03-24 | Novozymes A/S | Polypeptides having alpha amylase activity |
| CN114634921B (zh) | 2013-06-06 | 2024-09-10 | 诺维信公司 | α-淀粉酶变体以及对其进行编码的多核苷酸 |
| WO2014202089A2 (en) | 2013-06-18 | 2014-12-24 | Roskilde Universitet | Variants of anti-freeze polypeptides |
| US20160122772A1 (en) | 2013-06-21 | 2016-05-05 | Novozymes A/S | Production of Polypeptides Without Secretion Signal in Bacillus |
| WO2014207224A1 (en) | 2013-06-27 | 2014-12-31 | Novozymes A/S | Subtilase variants and polynucleotides encoding same |
| WO2014207227A1 (en) | 2013-06-27 | 2014-12-31 | Novozymes A/S | Subtilase variants and polynucleotides encoding same |
| JP2016523098A (ja) | 2013-07-04 | 2016-08-08 | ノボザイムス アクティーゼルスカブ | 再付着防止効果を有するポリペプチドおよびそれをコードするポリヌクレオチド |
| WO2015004102A1 (en) | 2013-07-09 | 2015-01-15 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
| DK3022300T3 (en) | 2013-07-17 | 2018-10-22 | Novozymes As | : Pullulan chimeras and polynucleotides encoding them |
| EP3027747B1 (en) | 2013-07-29 | 2018-02-07 | Novozymes A/S | Protease variants and polynucleotides encoding same |
| CN105358686A (zh) | 2013-07-29 | 2016-02-24 | 诺维信公司 | 蛋白酶变体以及对其进行编码的多核苷酸 |
| EP2832853A1 (en) | 2013-07-29 | 2015-02-04 | Henkel AG&Co. KGAA | Detergent composition comprising protease variants |
| US9845484B2 (en) | 2013-07-31 | 2017-12-19 | Novozymes A/S | 3-hydroxypropionic acid production by recombinant yeasts expressing an insect aspartate 1-decarboxylase |
| US10010094B2 (en) | 2013-08-15 | 2018-07-03 | Novozymes A/S | Polypeptides having beta-1,3-galactanase activity and polynucleotides encoding same |
| WO2015049370A1 (en) | 2013-10-03 | 2015-04-09 | Novozymes A/S | Detergent composition and use of detergent composition |
| WO2015059133A1 (en) | 2013-10-22 | 2015-04-30 | Novozymes A/S | Cellobiose dehydrogenase variants and polynucleotides encoding same |
| EP2876156A1 (en) | 2013-11-26 | 2015-05-27 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | New enzymes and method for preparing hydroxylated L-lysine or L-ornithine and analogs thereof |
| WO2015079064A2 (en) | 2013-11-29 | 2015-06-04 | Novozymes A/S | Peroxygenase variants |
| CN122012456A (zh) | 2013-12-11 | 2026-05-12 | 诺维信公司 | 角质酶变体以及对其进行编码的多核苷酸 |
| EP2886656A1 (en) | 2013-12-18 | 2015-06-24 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | New enzyme and method for preparing 4-hydroxyl benzyl alcohol and derivatives thereof |
| EP3453757B1 (en) | 2013-12-20 | 2020-06-17 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
| EP3097192B1 (en) | 2014-01-22 | 2018-07-25 | Novozymes A/S | Pullulanase variants and polynucleotides encoding same |
| EP3097112B1 (en) | 2014-01-22 | 2020-05-13 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
| US10155935B2 (en) | 2014-03-12 | 2018-12-18 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
| WO2015143144A1 (en) | 2014-03-19 | 2015-09-24 | Novozymes A/S | Method for enhancing activity of an x143 polypeptide |
| EP3119862B1 (en) | 2014-03-19 | 2022-09-07 | Novozymes A/S | Polypeptides having phospholipase c activity and polynucleotides encoding same |
| WO2015150457A1 (en) | 2014-04-01 | 2015-10-08 | Novozymes A/S | Polypeptides having alpha amylase activity |
| WO2015157656A1 (en) | 2014-04-10 | 2015-10-15 | Novozymes A/S | Alpha-amylase variants and polynucleotides encoding same |
| CN106164236B (zh) | 2014-04-11 | 2021-02-02 | 诺维信公司 | 洗涤剂组合物 |
| US10030215B2 (en) | 2014-04-15 | 2018-07-24 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
| BR112016023769A2 (pt) | 2014-04-17 | 2017-10-17 | Boehringer Ingelheim Rcv Gmbh | célula hospedeira recombinante para a expressão de proteínas de interesse |
| US10865416B2 (en) | 2014-04-17 | 2020-12-15 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Recombinant host cell engineered to overexpress helper proteins |
| CN106459934A (zh) | 2014-05-15 | 2017-02-22 | 诺维信公司 | 包括具有磷脂酶c活性的多肽的组合物及其应用 |
| EP3149178B1 (en) | 2014-05-27 | 2020-07-15 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| CA2950273C (en) | 2014-05-30 | 2022-06-21 | Novozymes A/S | Variants of gh family 11 xylanase and polynucleotides encoding same |
| EP2952584A1 (en) | 2014-06-04 | 2015-12-09 | Boehringer Ingelheim RCV GmbH & Co KG | Improved protein production |
| US20170121695A1 (en) | 2014-06-12 | 2017-05-04 | Novozymes A/S | Alpha-amylase variants and polynucleotides encoding same |
| ES2712402T3 (es) | 2014-06-25 | 2019-05-13 | Novozymes As | Variantes de xilanasa y polinucleótidos que las codifican |
| WO2016001319A1 (en) | 2014-07-03 | 2016-01-07 | Novozymes A/S | Improved stabilization of non-protease enzyme |
| EP3739029A1 (en) | 2014-07-04 | 2020-11-18 | Novozymes A/S | Subtilase variants and polynucleotides encoding same |
| EP3327122B1 (en) | 2014-07-04 | 2021-02-17 | Novozymes A/S | Subtilase variants and polynucleotides encoding same |
| US20170267980A1 (en) | 2014-08-20 | 2017-09-21 | Novozymes A/S | Xyloglucan Endotransglycosylase variants and Polynucleotides Encoding Same |
| EP3189137A1 (en) | 2014-09-05 | 2017-07-12 | Novozymes A/S | Carbohydrate binding module variants and polynucleotides encoding same |
| WO2016062875A2 (en) | 2014-10-23 | 2016-04-28 | Novozymes A/S | Glucoamylase variants and polynucleotides encoding same |
| US10619145B2 (en) | 2014-11-04 | 2020-04-14 | Novozymes A/S | Polypeptides having serine protease activity and polynucleotides encoding same and their application in animal feed |
| WO2016073610A1 (en) | 2014-11-07 | 2016-05-12 | Novozymes A/S | Xylanase based bleach boosting |
| WO2016079305A1 (en) | 2014-11-20 | 2016-05-26 | Novozymes A/S | Alicyclobacillus variants and polynucleotides encoding same |
| WO2016087327A1 (en) | 2014-12-01 | 2016-06-09 | Novozymes A/S | Polypeptides having pullulanase activity comprising the x25, x45 and cbm41 domains |
| WO2016090059A1 (en) | 2014-12-02 | 2016-06-09 | Novozymes A/S | Laccase variants and polynucleotides encoding same |
| EP3227425B1 (en) | 2014-12-04 | 2025-02-12 | Novozymes A/S | Liquid cleaning compositions comprising protease variants |
| MX2017006695A (es) | 2014-12-04 | 2017-08-21 | Novozymes As | Variantes de subtilasa y polinucleotidos que las codifican. |
| EP3227442B1 (en) | 2014-12-05 | 2022-02-16 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| US20180000076A1 (en) | 2014-12-16 | 2018-01-04 | Novozymes A/S | Polypeptides Having N-Acetyl Glucosamine Oxidase Activity |
| MX383142B (es) | 2014-12-19 | 2025-03-13 | Novozymes As | Composiciones que comprenden polipéptidos que tienen actividad xilanasa y polipéptidos que tienen actividad arabinofuranosidasa. |
| WO2016100910A1 (en) | 2014-12-19 | 2016-06-23 | Novozymes A/S | Recombinant host cells for the production of 3-hydroxypropionic acid |
| EP3741849A3 (en) | 2014-12-19 | 2021-03-17 | Novozymes A/S | Protease variants and polynucleotides encoding same |
| WO2016097352A1 (en) | 2014-12-19 | 2016-06-23 | Novozymes A/S | Protease variants and polynucleotides encoding same |
| FI3739045T3 (fi) | 2015-02-24 | 2024-11-13 | Novozymes As | Sellobiohydrolaasivariantteja ja niitä koodittavia polynukleotideja |
| EP3262180A1 (en) | 2015-02-25 | 2018-01-03 | Danisco US Inc. | Alpha-glucosidase, compositions & methods |
| EP3262161B1 (en) | 2015-02-27 | 2021-06-30 | Novozymes A/S | Mutant host cells for the production of 3-hydroxypropionic acid |
| BR112017020007B1 (pt) | 2015-03-19 | 2022-09-20 | Novozymes A/S | Método para preparar um mosto com um nível aumentado de nitrogênio livre aminado (fan) e uso de uma protease |
| WO2016162556A1 (en) | 2015-04-10 | 2016-10-13 | Novozymes A/S | Laundry method, use of dnase and detergent composition |
| CN107636134A (zh) | 2015-04-10 | 2018-01-26 | 诺维信公司 | 洗涤剂组合物 |
| US10125198B2 (en) | 2015-04-17 | 2018-11-13 | Distributed Bio, Inc. | Method for mass humanization of non-human antibodies |
| US11685773B2 (en) | 2015-04-30 | 2023-06-27 | Abcheck S.R.O. | Method for mass humanization of rabbit antibodies |
| JP7175612B2 (ja) | 2015-05-08 | 2022-11-21 | ノボザイムス アクティーゼルスカブ | アルファ-アミラーゼ多様体およびこの多様体をコードするポリヌクレオチド |
| US20180142224A1 (en) | 2015-05-08 | 2018-05-24 | Novozymes A/S | Alpha-amylase variants having improved performance and stability |
| AR105416A1 (es) | 2015-05-08 | 2017-10-04 | Novozymes As | VARIANTES DE a-AMILASA Y POLINUCLEÓTIDOS QUE LAS CODIFICAN |
| CN107532154B (zh) | 2015-05-27 | 2022-09-27 | 国投生物科技投资有限公司 | 具有纤维二糖水解酶活性的多肽以及对其进行编码的多核苷酸 |
| WO2016196202A1 (en) | 2015-05-29 | 2016-12-08 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
| WO2016193420A1 (en) | 2015-06-04 | 2016-12-08 | Novozymes A/S | Use of m4 metalloprotease in wort production |
| EP3310908B1 (en) | 2015-06-16 | 2020-08-05 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
| CN121406620A (zh) | 2015-06-18 | 2026-01-27 | 诺维信公司 | 枯草杆菌酶变体以及编码它们的多核苷酸 |
| US10676727B2 (en) | 2015-06-18 | 2020-06-09 | Novozymes A/S | Polypeptides having trehalase activity and the use thereof in process of producing fermentation products |
| WO2016207373A1 (en) | 2015-06-26 | 2016-12-29 | Novozymes A/S | Polypeptides having peroxygenase activity |
| AU2016282355B2 (en) | 2015-06-26 | 2020-04-09 | Novozymes A/S | Method for producing a coffee extract |
| EP3313990A4 (en) | 2015-06-26 | 2019-01-23 | Novozymes A/S | BIO-finishing system |
| CA2987160C (en) | 2015-07-01 | 2022-12-13 | Novozymes A/S | Methods of reducing odor |
| AU2016286612B2 (en) | 2015-07-02 | 2021-01-28 | Novozymes A/S | Animal feed compositions and uses thereof |
| CN114292829A (zh) | 2015-07-06 | 2022-04-08 | 诺维信公司 | 脂肪酶变体以及编码它们的多核苷酸 |
| CN108138153A (zh) | 2015-07-24 | 2018-06-08 | 诺维信股份有限公司 | 具有阿拉伯呋喃糖苷酶活性的多肽以及编码它们的多核苷酸 |
| WO2017019491A1 (en) | 2015-07-24 | 2017-02-02 | Novozymes Inc. | Polypeptides having beta-xylosidase activity and polynucleotides encoding same |
| BR112018003179A2 (pt) | 2015-08-20 | 2018-09-25 | Albumedix As | conjugados e variantes de albumina |
| WO2017035270A1 (en) | 2015-08-24 | 2017-03-02 | Novozymes A/S | Beta-alanine aminotransferases for the production of 3-hydroxypropionic acid |
| MX2018002183A (es) | 2015-08-27 | 2018-05-28 | Harvard College | Composiciones y metodos para tratamiento del dolor. |
| US10479984B2 (en) | 2015-09-22 | 2019-11-19 | Novozymes A/S | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| WO2017060662A1 (en) | 2015-10-07 | 2017-04-13 | The Secretary Of State For Health | Method for providing a control for use in a screen for pathogenic virus |
| WO2017060475A2 (en) | 2015-10-07 | 2017-04-13 | Novozymes A/S | Polypeptides |
| US20180171318A1 (en) | 2015-10-14 | 2018-06-21 | Novozymes A/S | Polypeptides Having Protease Activity and Polynucleotides Encoding Same |
| EP3362574B1 (en) | 2015-10-14 | 2021-07-07 | Novozymes A/S | Glucoamylase variants and polynucleotides encoding same |
| US10675589B2 (en) | 2015-10-14 | 2020-06-09 | Novozymes A/S | Cleaning of water filtration membranes |
| CN108291212A (zh) | 2015-10-14 | 2018-07-17 | 诺维信公司 | 多肽变体 |
| WO2017070219A1 (en) | 2015-10-20 | 2017-04-27 | Novozymes A/S | Lytic polysaccharide monooxygenase (lpmo) variants and polynucleotides encoding same |
| ES3069936T3 (en) | 2015-10-28 | 2026-06-11 | Novozymes As | Detergent composition comprising amylase and protease variants |
| US11001821B2 (en) | 2015-11-24 | 2021-05-11 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
| EP3384019B1 (en) | 2015-12-01 | 2020-06-24 | Novozymes A/S | Methods for producing lipases |
| US10035995B2 (en) | 2015-12-07 | 2018-07-31 | Eastman Chemical Company | CALB variants |
| ES2932192T3 (es) | 2015-12-07 | 2023-01-16 | Henkel Ag & Co Kgaa | Composiciones para el lavado de vajilla que comprenden polipéptidos que tienen actividad beta-glucanasa y sus usos |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
| CN108603185B (zh) | 2015-12-30 | 2022-05-17 | 诺维信公司 | 酶变体以及编码它们的多核苷酸 |
| US20210171927A1 (en) | 2016-01-29 | 2021-06-10 | Novozymes A/S | Beta-glucanase variants and polynucleotides encoding same |
| US11685911B2 (en) | 2016-02-16 | 2023-06-27 | Monaghan Mushroom S Group | Fungal polypeptides having lysozyme activity |
| BR112018067371A2 (pt) | 2016-03-02 | 2019-01-15 | Novozymes As | variante de celobio-hidrolase, composição de enzimas, formulação de caldo inteiro ou composição de cultura de células, polinucleotídeo, célula hospedeira recombinante, planta, parte de planta ou célula de planta transgênica, métodos para produção e para obtenção de uma variante de celobio-hidrolase, planta trangênica, e, processos para degradação de um material celulósico, para produção de um produto de fermentação e para fermentação de um material celulósico |
| CN109072209A (zh) | 2016-03-24 | 2018-12-21 | 诺维信公司 | 纤维二糖水解酶变体和编码其的多核苷酸 |
| PL3448409T3 (pl) | 2016-04-29 | 2026-02-23 | Defensin Therapeutics Aps | Leczenie chorób wątroby, dróg żółciowych i trzustki defensynami |
| US10626354B2 (en) | 2016-04-29 | 2020-04-21 | Novozymes A/S | Detergent compositions and uses thereof |
| US20240218340A1 (en) | 2016-05-03 | 2024-07-04 | Novozymes A/S | Enzyme Variants and Polynucleotides Encoding Same |
| JP6985295B2 (ja) | 2016-05-09 | 2021-12-22 | ノボザイムス アクティーゼルスカブ | 向上した性能を有する変異体ポリペプチドおよびその使用 |
| EP3246401A1 (en) | 2016-05-20 | 2017-11-22 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | New fatty acid decarboxylase and its uses |
| ES3014057T3 (en) | 2016-05-24 | 2025-04-16 | Novozymes As | Gastric stable polypeptides having alpha-galactosidase activity and polynucleotides encoding same |
| AU2017270269A1 (en) | 2016-05-24 | 2018-11-15 | Novozymes A/S | Compositions comprising polypeptides having galactanase activity and polypeptides having beta-galactosidase activity |
| CN109312321A (zh) | 2016-05-24 | 2019-02-05 | 诺维信公司 | 包含具有半乳聚糖酶活性的多肽和具有β-半乳糖苷酶活性的多肽的组合物 |
| AU2017269498A1 (en) | 2016-05-24 | 2018-11-08 | Novozymes A/S | Polypeptides having alpha-galactosidase activity and polynucleotides encoding same |
| WO2017205535A1 (en) | 2016-05-27 | 2017-11-30 | Novozymes, Inc. | Polypeptides having endoglucanase activity and polynucleotides encoding same |
| WO2017210188A1 (en) | 2016-05-31 | 2017-12-07 | Novozymes A/S | Stabilized liquid peroxide compositions |
| WO2017207762A1 (en) | 2016-06-03 | 2017-12-07 | Novozymes A/S | Subtilase variants and polynucleotides encoding same |
| WO2017211803A1 (en) | 2016-06-07 | 2017-12-14 | Novozymes A/S | Co-expression of heterologous polypeptides to increase yield |
| CN117721095A (zh) | 2016-06-30 | 2024-03-19 | 诺维信公司 | 脂肪酶变体及包含表面活性剂和脂肪酶变体的组合物 |
| WO2018002379A2 (en) | 2016-07-01 | 2018-01-04 | Novozymes A/S | Enzymatic preparation of indigo dyes and in situ dyeing process |
| WO2018002261A1 (en) | 2016-07-01 | 2018-01-04 | Novozymes A/S | Detergent compositions |
| CN109715794A (zh) | 2016-07-05 | 2019-05-03 | 诺维信公司 | 果胶裂解酶变体以及编码它们的多核苷酸 |
| MX2019000139A (es) | 2016-07-08 | 2019-06-10 | Novozymes As | Polipeptidos que tienen actividad xilanasa y polinucleotidos que los codifican. |
| RU2752204C2 (ru) | 2016-07-08 | 2021-07-23 | Новозимс А/С | Варианты ксиланазы и кодирующие их полинуклеотиды |
| WO2018007573A1 (en) | 2016-07-08 | 2018-01-11 | Novozymes A/S | Detergent compositions with galactanase |
| CN109415708A (zh) | 2016-07-13 | 2019-03-01 | 宝洁公司 | 食物芽孢杆菌脱氧核糖核酸酶变体及其用途 |
| CN109790525A (zh) | 2016-07-18 | 2019-05-21 | 诺维信公司 | 脂肪酶变体、编码其的多核苷酸及其用途 |
| WO2018017792A1 (en) | 2016-07-20 | 2018-01-25 | Novozymes A/S | Heat-stable metagenomic carbonic anhydrases and their use |
| CN109661465A (zh) | 2016-07-21 | 2019-04-19 | 诺维信公司 | 丝氨酸蛋白酶变体以及对其进行编码的多核苷酸 |
| FI3487996T3 (fi) | 2016-07-21 | 2024-07-10 | Novozymes As | Seriiniproteaasivariantteja ja niitä koodittavia polynukleotideja |
| WO2018015444A1 (en) | 2016-07-22 | 2018-01-25 | Novozymes A/S | Crispr-cas9 genome editing with multiple guide rnas in filamentous fungi |
| WO2018026868A1 (en) | 2016-08-01 | 2018-02-08 | Novozymes, Inc. | Polypeptides having endoglucanase activity and polynucleotides encoding same |
| EP3504330A1 (en) | 2016-08-24 | 2019-07-03 | Novozymes A/S | Gh9 endoglucanase variants and polynucleotides encoding same |
| WO2018037064A1 (en) | 2016-08-24 | 2018-03-01 | Henkel Ag & Co. Kgaa | Detergent compositions comprising xanthan lyase variants i |
| AU2017317564B2 (en) | 2016-08-24 | 2021-09-30 | Henkel Ag & Co. Kgaa | Detergent composition comprising GH9 endoglucanase variants I |
| US11512300B2 (en) | 2016-08-24 | 2022-11-29 | Novozymes A/S | Xanthan lyase variants and polynucleotides encoding same |
| US20190284647A1 (en) | 2016-09-29 | 2019-09-19 | Novozymes A/S | Spore Containing Granule |
| US20210284933A1 (en) | 2016-10-25 | 2021-09-16 | Novozymes A/S | Detergent compositions |
| WO2018085370A1 (en) | 2016-11-02 | 2018-05-11 | Novozymes A/S | Processes for reducing production of primeverose during enzymatic saccharification of lignocellulosic material |
| JP7645607B2 (ja) | 2016-11-16 | 2025-03-14 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体で乾癬を治療する方法 |
| EP3541954A1 (en) | 2016-11-21 | 2019-09-25 | Novozymes A/S | Yeast cell extract assisted construction of dna molecules |
| CN110072997A (zh) | 2016-11-23 | 2019-07-30 | 诺维信公司 | 具有蛋白酶活性的多肽和编码其的多核苷酸 |
| US20210292723A1 (en) | 2016-11-29 | 2021-09-23 | Novozymes A/S | Alpha-Amylase Variants and Polynucleotides Encoding Same |
| MX2019006122A (es) | 2016-11-30 | 2019-08-14 | Novozymes As | Metodo de hornear. |
| WO2018106792A1 (en) | 2016-12-06 | 2018-06-14 | Novozymes A/S | Improved processes for production of ethanol from xylose-containing cellulosic substrates using engineered yeast strains |
| CA3045079A1 (en) | 2016-12-13 | 2018-06-21 | Defensin Therapeutics Aps | Methods for treating inflammatory conditions of the lungs |
| CN110114465A (zh) | 2016-12-20 | 2019-08-09 | 诺维信公司 | 用于戊糖发酵的重组酵母菌株 |
| AU2017380488B2 (en) | 2016-12-21 | 2023-09-14 | Novozymes A/S | Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof |
| CN110234351A (zh) | 2017-01-30 | 2019-09-13 | 詹森生物科技公司 | 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法 |
| EP3577219B1 (en) | 2017-02-01 | 2023-08-23 | Novozymes A/S | Alpha-amylase variants |
| RU2019123965A (ru) | 2017-02-01 | 2021-02-01 | Дзе Проктер Энд Гэмбл Компани | Очищающие композиции, содержащие варианты амилазы |
| KR20240038148A (ko) | 2017-02-07 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
| MX2019009551A (es) | 2017-02-20 | 2020-01-30 | Novozymes As | Enzima lipolitica para usarse en horneado. |
| CA3055530A1 (en) | 2017-03-07 | 2018-09-13 | Danisco Us Inc. | Thermostable glucoamylase and methods of use, thereof |
| US11479798B2 (en) | 2017-03-29 | 2022-10-25 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Recombinant host cell with altered membrane lipid composition |
| CN110651040A (zh) | 2017-03-31 | 2020-01-03 | 诺维信公司 | 具有dna酶活性的多肽 |
| EP3601549B1 (en) | 2017-03-31 | 2026-07-01 | Novozymes A/S | POLYPEPTIDES WITH DNASE ACTIVITY |
| CN110651041A (zh) | 2017-03-31 | 2020-01-03 | 诺维信公司 | 具有dna酶活性的多肽 |
| US11149233B2 (en) | 2017-03-31 | 2021-10-19 | Novozymes A/S | Polypeptides having RNase activity |
| CN110651029B (zh) | 2017-04-04 | 2022-02-15 | 诺维信公司 | 糖基水解酶 |
| WO2018185152A1 (en) | 2017-04-04 | 2018-10-11 | Novozymes A/S | Polypeptide compositions and uses thereof |
| EP3607039A1 (en) | 2017-04-04 | 2020-02-12 | Novozymes A/S | Polypeptides |
| BR112019021223A2 (pt) | 2017-04-11 | 2020-04-28 | Novozymes A/S | variante de glucoamilase, métodos para aumentar a atividade de hidrólise de amido em bruto de uma glucoamilase e para produzir uma variante de glucoamilase, composição, uso de uma variante de glucoamilase, processos para produzir um produto de fermentação e para produzir um produto de xarope, polinucleotídeo codificando a variante de glucoamilase, construto de ácido nucleico, vetor de expressão, e, célula hospedeira. |
| WO2018202846A1 (en) | 2017-05-05 | 2018-11-08 | Novozymes A/S | Compositions comprising lipase and sulfite |
| CA3058095A1 (en) | 2017-05-08 | 2018-11-15 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
| WO2018206535A1 (en) | 2017-05-08 | 2018-11-15 | Novozymes A/S | Carbohydrate-binding domain and polynucleotides encoding the same |
| EP3622064B1 (en) | 2017-05-08 | 2025-05-14 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
| EP3401385A1 (en) | 2017-05-08 | 2018-11-14 | Henkel AG & Co. KGaA | Detergent composition comprising polypeptide comprising carbohydrate-binding domain |
| WO2018220116A1 (en) | 2017-05-31 | 2018-12-06 | Novozymes A/S | Xylose fermenting yeast strains and processes thereof for ethanol production |
| AU2018275794A1 (en) | 2017-06-02 | 2019-12-05 | Novozymes A/S | Improved yeast for ethanol production |
| WO2018224544A1 (en) | 2017-06-08 | 2018-12-13 | Novozymes A/S | Compositions comprising polypeptides having cellulase activity and amylase activity, and uses thereof in cleaning and detergent compositions |
| WO2018224035A1 (en) | 2017-06-09 | 2018-12-13 | Novozymes A/S | Polypeptide, use and method for hydrolysing protein |
| EP4026908A1 (en) | 2017-06-20 | 2022-07-13 | Albumedix Ltd | Improved protein expression strains |
| EP3642339B1 (en) | 2017-06-22 | 2025-09-10 | Novozymes A/S | Xylanase variants and polynucleotides encoding same |
| DK3645555T3 (da) | 2017-06-28 | 2022-03-07 | Novozymes As | Polypeptider med trehalaseaktivitet og polynukleotider, der koder for disse |
| US20200181542A1 (en) | 2017-06-30 | 2020-06-11 | Novozymes A/S | Enzyme Slurry Composition |
| KR102683528B1 (ko) | 2017-07-24 | 2024-07-10 | 노보자임스 에이/에스 | 습식 제분에서의 gh5 및 gh30 |
| CA3070281A1 (en) | 2017-08-08 | 2019-02-14 | Novozymes A/S | Polypeptides having trehalase activity and the use thereof in process of producing fermentation products |
| US20210130744A1 (en) | 2017-08-24 | 2021-05-06 | Henkel Ag & Co. Kgaa | Detergent composition comprising xanthan lyase variants ii |
| EP3673056A1 (en) | 2017-08-24 | 2020-07-01 | Henkel AG & Co. KGaA | Detergent compositions comprising gh9 endoglucanase variants ii |
| WO2019038058A1 (en) | 2017-08-24 | 2019-02-28 | Novozymes A/S | GH9 ENDOGLUCANASE VARIANTS AND POLYNUCLEOTIDES ENCODING SUCH VARIANTS |
| CN111344404A (zh) | 2017-08-24 | 2020-06-26 | 诺维信公司 | 黄原胶裂解酶变体以及编码其的多核苷酸 |
| AU2018322748B2 (en) | 2017-08-29 | 2024-05-02 | Novozymes A/S | Baker's yeast expressing anti-staling/freshness amylases |
| HUE072278T2 (hu) | 2017-08-31 | 2025-11-28 | Novozymes As | D-pszikóz-3-epimeráz aktivitású polipeptidek és ezeket kódoló polinukleotidok |
| WO2019046703A1 (en) | 2017-09-01 | 2019-03-07 | Novozymes A/S | METHODS OF ENHANCING GENOME EDITION IN FUNGI |
| US20200196633A1 (en) | 2017-09-01 | 2020-06-25 | Novozymes A/S | Animal Feed Additives Comprising Polypeptide Having Protease Activity and Uses Thereof |
| CN111050566A (zh) | 2017-09-01 | 2020-04-21 | 诺维信公司 | 包含具有蛋白酶活性的多肽的动物饲料添加剂及其用途 |
| WO2019047199A1 (en) | 2017-09-11 | 2019-03-14 | Danisco Us Inc. | GLUCOAMYLASE AND METHODS OF USE THEREOF |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
| MX2020003779A (es) | 2017-09-27 | 2020-08-03 | Procter & Gamble | Composiciones detergentes que comprenden lipasas. |
| CN118910005A (zh) | 2017-09-27 | 2024-11-08 | 诺维信公司 | 脂肪酶变体和包含此类脂肪酶变体的微囊组合物 |
| US11746310B2 (en) | 2017-10-02 | 2023-09-05 | Novozymes A/S | Polypeptides having mannanase activity and polynucleotides encoding same |
| CN111373036A (zh) | 2017-10-02 | 2020-07-03 | 诺维信公司 | 具有甘露聚糖酶活性的多肽和编码它们的多核苷酸 |
| WO2019070883A1 (en) | 2017-10-04 | 2019-04-11 | Novozymes A/S | POLYPEPTIDES WITH PROTEASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME |
| WO2019083818A1 (en) | 2017-10-23 | 2019-05-02 | Novozymes A/S | IMPROVING EXPRESSION OF PROTEASE BY CO-EXPRESSION WITH PROPEPTIDE |
| WO2019081724A1 (en) | 2017-10-27 | 2019-05-02 | Novozymes A/S | VARIANTS OF DNASE |
| PL3476936T3 (pl) | 2017-10-27 | 2022-04-11 | The Procter & Gamble Company | Kompozycje detergentu zawierające odmiany polipeptydowe |
| DE102017125560A1 (de) | 2017-11-01 | 2019-05-02 | Henkel Ag & Co. Kgaa | Reinigungszusammensetzungen, die dispersine iii enthalten |
| DE102017125559A1 (de) | 2017-11-01 | 2019-05-02 | Henkel Ag & Co. Kgaa | Reinigungszusammensetzungen, die dispersine ii enthalten |
| DE102017125558A1 (de) | 2017-11-01 | 2019-05-02 | Henkel Ag & Co. Kgaa | Reinigungszusammensetzungen, die dispersine i enthalten |
| MX2020004716A (es) | 2017-11-06 | 2020-11-06 | Janssen Biotech Inc | Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23. |
| KR20200095472A (ko) | 2017-11-10 | 2020-08-10 | 디펜신 테라퓨틱스 에이피에스 | 조산아에서의 점막 방어 및 장/폐 기능의 성숙화 |
| EP3707252A1 (en) | 2017-11-10 | 2020-09-16 | Novozymes A/S | Temperature-sensitive cas9 protein |
| CN111989400B (zh) | 2017-11-14 | 2024-05-24 | 丹尼斯科美国公司 | α-淀粉酶、组合物和方法 |
| WO2019096903A1 (en) | 2017-11-20 | 2019-05-23 | Novozymes A/S | New galactanases (ec 3.2.1.89) for use in soy processing |
| KR20200097251A (ko) | 2017-11-24 | 2020-08-18 | 디펜신 테라퓨틱스 에이피에스 | 디펜신에 의한 이식편 대 숙주 질환의 예방 및 치료 |
| US11725197B2 (en) | 2017-12-04 | 2023-08-15 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| FI3720955T3 (fi) | 2017-12-08 | 2023-09-05 | Novozymes As | Alfa-amylaasivariantteja ja niitä koodaavia polynukleotideja |
| ES2954431T3 (es) | 2017-12-08 | 2023-11-22 | Novozymes As | Variantes de alfa-amilasa y polinucleótidos que codifican las mismas |
| WO2019125804A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Nucleases and methods for making and using them |
| WO2019122083A1 (en) | 2017-12-22 | 2019-06-27 | Novozymes A/S | Wheat milling process and gh8 xylanases |
| MX2020007914A (es) | 2018-01-29 | 2020-10-28 | Novozymes As | Microorganismos con uso de nitrogeno mejorado para produccion de etanol. |
| US20210123033A1 (en) | 2018-02-08 | 2021-04-29 | Novozymes A/S | Lipases, Lipase Variants and Compositions Thereof |
| US20210071155A1 (en) | 2018-02-08 | 2021-03-11 | Novozymes A/S | Lipase Variants and Compositions Thereof |
| US20190264140A1 (en) | 2018-02-28 | 2019-08-29 | The Procter & Gamble Company | Methods of cleaning |
| JP7516250B2 (ja) | 2018-03-05 | 2024-07-16 | ヤンセン バイオテツク,インコーポレーテツド | 抗il-23特異的抗体を用いたクローン病の治療方法 |
| US11525151B2 (en) | 2018-03-09 | 2022-12-13 | Danisco Us Inc. | Glucoamylases and methods of use, thereof |
| EP3765185B1 (en) | 2018-03-13 | 2023-07-19 | Novozymes A/S | Microencapsulation using amino sugar oligomers |
| WO2019185726A1 (en) | 2018-03-29 | 2019-10-03 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
| CN112105729B (zh) | 2018-04-09 | 2024-05-14 | 诺维信公司 | 具有α-淀粉酶活性的多肽以及编码它们的多核苷酸 |
| US11566239B2 (en) | 2018-04-19 | 2023-01-31 | Novozymes A/S | Stabilized cellulase variants |
| CN112272701B (zh) | 2018-04-19 | 2024-05-14 | 诺维信公司 | 稳定化的纤维素酶变体 |
| WO2019224184A1 (en) | 2018-05-21 | 2019-11-28 | Ipsen Biopharm Limited | Suppression of bone cancer-induced allodynia |
| BR112020022593A2 (pt) | 2018-05-31 | 2021-02-09 | Novozymes A/S | método para tratar polpa de dissolução, polpa de dissolução, fibra têxtil ou celulose derivatizada, e, uso de uma monoxigenase lítica de polissacarídeo. |
| GB201809135D0 (en) | 2018-06-04 | 2018-07-18 | Sec Dep For Health | Methods for detecting anitviral-drug resistant virus |
| WO2019243376A1 (en) | 2018-06-18 | 2019-12-26 | Ipsen Biopharm Limited | Intramuscular injection of botulinum toxin for the treatment of vulvodynia |
| SG11202012529VA (en) | 2018-06-27 | 2021-01-28 | Boehringer Ingelheim Rcv Gmbh | Means and methods for increased protein expression by use of transcription factors |
| WO2020002575A1 (en) | 2018-06-28 | 2020-01-02 | Novozymes A/S | Polypeptides having pectin lyase activity and polynucleotides encoding same |
| CA3105609A1 (en) | 2018-07-04 | 2020-01-09 | Danisco Us Inc | Glucoamylases and methods of use, thereof |
| WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
| CN112601818A (zh) | 2018-07-25 | 2021-04-02 | 诺维信公司 | 用于生产乙醇的表达酶的酵母 |
| GB201812261D0 (en) | 2018-07-27 | 2018-09-12 | Micropharm Ltd | Therapies for treating oral mucositis |
| GB201812262D0 (en) | 2018-07-27 | 2018-09-12 | Micropharm Ltd | Therapies for treating proctitis |
| GB201813884D0 (en) | 2018-08-24 | 2018-10-10 | Sec Dep For Health | Culture media |
| US11473076B2 (en) | 2018-08-31 | 2022-10-18 | Novozymes A/S | Animal feed additives and compositions comprising an S8 serine protease |
| HUE063462T2 (hu) | 2018-09-24 | 2024-01-28 | Janssen Biotech Inc | A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel |
| GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| JP7604365B2 (ja) | 2018-09-28 | 2024-12-23 | イプセン バイオファーム リミテッド | 細胞ベースのクロストリジウム神経毒アッセイ |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| CN113056476A (zh) | 2018-10-03 | 2021-06-29 | 诺维信公司 | 具有α-甘露聚糖降解活性的多肽以及编码它们的多核苷酸 |
| WO2020070461A1 (en) | 2018-10-04 | 2020-04-09 | Secretary of State for Health and Social Care | Immunoassay for detection of streptococcus pneumoniae serotypes |
| WO2020076697A1 (en) | 2018-10-08 | 2020-04-16 | Novozymes A/S | Enzyme-expressing yeast for ethanol production |
| EP3874051A1 (en) | 2018-10-31 | 2021-09-08 | Novozymes A/S | Genome editing by guided endonuclease and single-stranded oligonucleotide |
| MA55149A (fr) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
| US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
| WO2020123463A1 (en) | 2018-12-12 | 2020-06-18 | Novozymes A/S | Polypeptides having xylanase activity and polynucleotides encoding same |
| WO2020128864A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
| EP3898962A2 (en) | 2018-12-21 | 2021-10-27 | Novozymes A/S | Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| WO2020160126A1 (en) | 2019-01-31 | 2020-08-06 | Novozymes A/S | Polypeptides having xylanase activity and use thereof for improving the nutritional quality of animal feed |
| CN113840837A (zh) | 2019-03-14 | 2021-12-24 | 詹森生物科技公司 | 用于产生抗tnf抗体组合物的方法 |
| EP3938390A1 (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
| MA55283A (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | Procédés de production de compositions d'anticorps anti-tnf |
| KR20210141990A (ko) | 2019-03-14 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법 |
| MX2021011328A (es) | 2019-03-18 | 2021-12-10 | Janssen Biotech Inc | Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23. |
| BR112021018731A2 (pt) | 2019-03-21 | 2021-12-21 | Novozymes As | Variantes de alfa-amilase e polinucleotídeos codificando as mesmas |
| CA3131705A1 (en) | 2019-03-27 | 2020-10-01 | Umc Utrecht Holding B.V. | Engineered iga antibodies and methods of use |
| CN113785039B (zh) | 2019-04-03 | 2024-06-18 | 诺维信公司 | 具有β-葡聚糖酶活性的多肽、编码其的多核苷酸及其在清洁和洗涤剂组合物中的用途 |
| US12247237B2 (en) | 2019-04-10 | 2025-03-11 | Novozymes A/S | Polypeptide variants |
| MX2021012289A (es) | 2019-04-12 | 2021-11-12 | Novozymes As | Variantes de glucosido hidrolasa estabilizadas. |
| WO2020229191A1 (en) | 2019-05-15 | 2020-11-19 | Novozymes A/S | Temperature-sensitive rna-guided endonuclease |
| GB201907016D0 (en) | 2019-05-17 | 2019-07-03 | Ipsen Biopharm Ltd | Screening method to determine suitability for participation in a clinical trial |
| EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA |
| US20200385453A1 (en) | 2019-06-04 | 2020-12-10 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody |
| GB201908155D0 (en) | 2019-06-07 | 2019-07-24 | Univ Warwick | Leader sequence |
| EP3986996A1 (en) | 2019-06-24 | 2022-04-27 | The Procter & Gamble Company | Cleaning compositions comprising amylase variants |
| US20220251528A1 (en) | 2019-06-24 | 2022-08-11 | Novozymes A/S | Alpha-Amylase Variants |
| EP3994255A1 (en) | 2019-07-02 | 2022-05-11 | Novozymes A/S | Lipase variants and compositions thereof |
| GB201909619D0 (en) | 2019-07-04 | 2019-08-21 | Univ Oxford Innovation Ltd | Methods for diagnosing multiple sclerosis |
| EP4004211A1 (en) | 2019-07-25 | 2022-06-01 | Novozymes A/S | Filamentous fungal expression system |
| WO2021018751A1 (en) | 2019-07-26 | 2021-02-04 | Novozymes A/S | Enzymatic treatment of paper pulp |
| MX2021015821A (es) | 2019-07-26 | 2022-02-03 | Novozymes As | Microorganismos con transporte de nitrogeno mejorado para la produccion de etanol. |
| GB201911063D0 (en) | 2019-08-02 | 2019-09-18 | Tarian Biologics Ltd | Formulations |
| GB201911064D0 (en) | 2019-08-02 | 2019-09-18 | Tarian Biologics Ltd | Therapy |
| MX2021015818A (es) | 2019-08-06 | 2022-02-03 | Novozymes As | Proteinas de fusion para mejorar la expresion de enzimas. |
| CN114364795A (zh) | 2019-08-22 | 2022-04-15 | 巴斯夫欧洲公司 | 淀粉酶变体 |
| EP4031661A1 (en) | 2019-09-16 | 2022-07-27 | Novozymes A/S | Polypeptides having beta-glucanase activity and polynucleotides encoding same |
| GB201913804D0 (en) | 2019-09-25 | 2019-11-06 | Prostate Cancer Res Centre | Fusion polypeptides |
| GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| EP4038170A1 (en) | 2019-10-03 | 2022-08-10 | Novozymes A/S | Polypeptides comprising at least two carbohydrate binding domains |
| CA3158982A1 (en) | 2019-12-10 | 2021-06-17 | Monica TASSONE | Microorganism for improved pentose fermentation |
| GB201918313D0 (en) | 2019-12-12 | 2020-01-29 | Lift Biosciences Ltd | Cells for treating cancer |
| GB201918341D0 (en) | 2019-12-12 | 2020-01-29 | Lift Biosciences Ltd | Cells for treating infections |
| US20230049145A1 (en) | 2019-12-12 | 2023-02-16 | Fresenius Kabi Deutschland Gmbh | Glycosylated polypeptides |
| EP4077622A1 (en) | 2019-12-19 | 2022-10-26 | The Procter & Gamble Company | Cleaning compositions comprising polypeptides having alpha amylase activity |
| WO2021123184A2 (en) | 2019-12-19 | 2021-06-24 | Novozymes A/S | Alpha-amylase variants |
| CN114761551B (zh) | 2019-12-19 | 2025-09-12 | 诺维信公司 | 木聚糖酶变体和编码其的多核苷酸 |
| EP4077656A2 (en) | 2019-12-20 | 2022-10-26 | Novozymes A/S | Polypeptides having proteolytic activity and use thereof |
| WO2021148278A1 (en) | 2020-01-24 | 2021-07-29 | Novozymes A/S | Mutants of a filamentous fungal cell having increased productivity in the production of a polypeptide |
| EP4097226A1 (en) | 2020-01-31 | 2022-12-07 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
| GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| WO2021152123A1 (en) | 2020-01-31 | 2021-08-05 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
| WO2021163015A1 (en) | 2020-02-10 | 2021-08-19 | Novozymes A/S | Process for producing ethanol from raw starch using alpha-amylase variants |
| WO2021163030A2 (en) | 2020-02-10 | 2021-08-19 | Novozymes A/S | Polypeptides having alpha-amylase activity and polynucleotides encoding same |
| MX2022009515A (es) | 2020-02-10 | 2022-09-02 | Novozymes As | Variantes de alfa-amilasa y polinucleotidos que las codifican. |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| EP4110909A1 (en) | 2020-02-26 | 2023-01-04 | Novozymes A/S | Polypeptide variants |
| GB202003611D0 (en) | 2020-03-12 | 2020-04-29 | Univ Oxford Innovation Ltd | Stabilised viral fusion proteins |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| TW202426039A (zh) | 2020-03-16 | 2024-07-01 | 英商艾普森生物製藥有限公司 | 肢體痙攣之治療 |
| EP4133066A1 (en) | 2020-04-08 | 2023-02-15 | Novozymes A/S | Carbohydrate binding module variants |
| US12509670B2 (en) | 2020-04-17 | 2025-12-30 | Danisco Us Inc. | Glucoamylase and methods of use thereof |
| CN115516071A (zh) | 2020-04-21 | 2022-12-23 | 诺维信公司 | 包含具有果聚糖降解活性的多肽的清洁组合物 |
| CA3181949A1 (en) | 2020-05-05 | 2021-11-11 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| GB202006803D0 (en) | 2020-05-07 | 2020-06-24 | Imperial College Innovations Ltd | Method for identifying RNA binding protein binding sites on RNA |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| TWI916375B (zh) | 2020-06-25 | 2026-03-01 | 英商梅迪繆思有限公司 | 軸突損傷之預防 |
| GB2596820A (en) | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| AU2021308574A1 (en) | 2020-07-13 | 2023-03-09 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody |
| GB202010934D0 (en) | 2020-07-15 | 2020-08-26 | Ipsen Biopharm Ltd | Controlling operation of a bioreactor vessel |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| WO2022013574A1 (en) | 2020-07-17 | 2022-01-20 | Imperial College Innovations Limited | Hybrid double antigen sars-cov-2 antibody detection assay |
| GB202011902D0 (en) | 2020-07-30 | 2020-09-16 | Imperial College Innovations Ltd | Antinobacillus pleuropneumoniae vaccines |
| WO2022024065A1 (en) | 2020-07-30 | 2022-02-03 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody |
| EP4200424A1 (en) | 2020-08-18 | 2023-06-28 | Novozymes A/S | Dispersins expressed with amylase signal peptides |
| JP7885201B2 (ja) | 2020-08-25 | 2026-07-06 | ノボザイムス アクティーゼルスカブ | ファミリー44キシログルカナーゼの変異体 |
| EP4204548A1 (en) | 2020-08-28 | 2023-07-05 | Novozymes A/S | Polyester degrading protease variants |
| WO2022049403A1 (en) | 2020-09-07 | 2022-03-10 | Imperial College Innovations Limited | Sars-cov-2 antibody detection assay |
| CN116829592A (zh) | 2020-09-11 | 2023-09-29 | 免疫医疗有限公司 | 治疗性b7-h4结合分子 |
| US20230365639A1 (en) | 2020-09-14 | 2023-11-16 | Aesculus Bio Aps | Defensin fragment derived lipopeptides for treatment of drug-resistant microorganisms |
| CA3192419A1 (en) | 2020-09-15 | 2022-03-24 | Adam Byrne | Treatment of idiopathic pulmonary fibrosis |
| GB202015618D0 (en) | 2020-10-01 | 2020-11-18 | Ipsen Biopharm Ltd | Method for producing beta-trypsin |
| CN116507725A (zh) | 2020-10-07 | 2023-07-28 | 诺维信公司 | α-淀粉酶变体 |
| US20230407273A1 (en) | 2020-10-13 | 2023-12-21 | Novozymes A/S | Glycosyltransferase variants for improved protein production |
| GB202016349D0 (en) | 2020-10-15 | 2020-12-02 | Imp College Innovations Ltd | Proteome analysis in pulmonary hypertension |
| EP4237525A1 (en) | 2020-10-28 | 2023-09-06 | Novozymes A/S | Use of lipoxygenase |
| WO2022090361A2 (en) | 2020-10-29 | 2022-05-05 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
| AU2021370998A1 (en) | 2020-11-02 | 2023-05-25 | Novozymes A/S | Glucoamylase variants and polynucleotides encoding same |
| US20240271175A1 (en) | 2020-11-02 | 2024-08-15 | Novozymes A/S | Leader peptides and polynucleotides encoding the same |
| GB202017673D0 (en) | 2020-11-09 | 2020-12-23 | Imperial College Innovations Ltd | Treatment of pulmonary arterial hypertensive |
| WO2022106404A1 (en) | 2020-11-18 | 2022-05-27 | Novozymes A/S | Combination of proteases |
| WO2022106400A1 (en) | 2020-11-18 | 2022-05-27 | Novozymes A/S | Combination of immunochemically different proteases |
| US20240052000A1 (en) | 2020-12-15 | 2024-02-15 | Novozymes A/S | Mutated host cells with reduced cell motility on |
| WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
| WO2023288294A1 (en) | 2021-07-16 | 2023-01-19 | Novozymes A/S | Compositions and methods for improving the rainfastness of proteins on plant surfaces |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| EP4284905A1 (en) | 2021-01-28 | 2023-12-06 | Novozymes A/S | Lipase with low malodor generation |
| WO2022171780A2 (en) | 2021-02-12 | 2022-08-18 | Novozymes A/S | Alpha-amylase variants |
| WO2022175440A1 (en) | 2021-02-18 | 2022-08-25 | Novozymes A/S | Inactive heme polypeptides |
| EP4294917A1 (en) | 2021-02-22 | 2023-12-27 | Basf Se | Amylase variants |
| EP4047088A1 (en) | 2021-02-22 | 2022-08-24 | Basf Se | Amylase variants |
| GB202102832D0 (en) | 2021-02-26 | 2021-04-14 | Ip2Ipo Innovations Ltd | Retroviral vectors |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| EP4305146A1 (en) | 2021-03-12 | 2024-01-17 | Novozymes A/S | Polypeptide variants |
| EP4305062A1 (en) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
| US20240060061A1 (en) | 2021-03-15 | 2024-02-22 | Novozymes A/S | Dnase variants |
| MX2023005793A (es) | 2021-03-15 | 2023-05-29 | Procter & Gamble | Composiciones de limpieza que contienen variantes de polipeptido. |
| EP4060036A1 (en) | 2021-03-15 | 2022-09-21 | Novozymes A/S | Polypeptide variants |
| EP4308607A2 (en) | 2021-03-18 | 2024-01-24 | MedImmune Limited | Therapeutic binding molecule that binds to ccr9 |
| WO2022199418A1 (en) | 2021-03-26 | 2022-09-29 | Novozymes A/S | Detergent composition with reduced polymer content |
| GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| JP2024513191A (ja) | 2021-03-30 | 2024-03-22 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
| CN117396217A (zh) | 2021-03-30 | 2024-01-12 | 益普生生物制药有限公司 | 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗 |
| US20240180197A1 (en) | 2021-04-12 | 2024-06-06 | Novozymes A/S | Method for producing a meat analogue product |
| GB202105277D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Signal peptides |
| GB202105278D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Cell therapy |
| GB202105276D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Delivery of gene therapy vectors |
| CN117355608A (zh) | 2021-05-27 | 2024-01-05 | 诺维信公司 | 转录调节物和编码其的多核苷酸 |
| US20250011809A1 (en) | 2021-05-27 | 2025-01-09 | Cell Therapy Catapult Limited | Viral vector production |
| BR112023025624A2 (pt) | 2021-06-07 | 2024-02-27 | Novozymes As | Célula de levedura recombinante, célula hospedeira recombinante, composição, cocultura, métodos de produção de um derivado de uma célula hospedeira recombinante e de produção de um produto de fermentação, e, uso de uma célula hospedeira recombinante |
| CA3220135A1 (en) | 2021-06-16 | 2022-12-22 | Novozymes A/S | Method for controlling slime in a pulp or paper making process |
| IL309996A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Production methods for the production of anti-TNF antibody compositions |
| CN117730090A (zh) | 2021-07-13 | 2024-03-19 | 诺维信公司 | 重组角质酶表达 |
| MA66538B1 (fr) | 2021-09-16 | 2026-03-31 | Ipsen Biopharm Limited | Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale |
| CA3228712A1 (en) | 2021-09-23 | 2023-03-30 | Nicolae GRIGORE | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| US20240417709A1 (en) | 2021-10-12 | 2024-12-19 | Novozymes A/S | Endoglucanase with improved stability |
| CA3234874A1 (en) | 2021-10-15 | 2023-04-20 | Martijn Scheffers | Glucoamylase variants and methods for use thereof |
| US20250000816A1 (en) | 2021-11-11 | 2025-01-02 | Nutri-Gentix Limited | Nutritional compositions |
| AU2022392458A1 (en) | 2021-11-22 | 2024-05-02 | Ipsen Biopharm Limited | Treatment of pain |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| WO2023104846A1 (en) | 2021-12-10 | 2023-06-15 | Novozymes A/S | Improved protein production in recombinant bacteria |
| WO2023118871A1 (en) | 2021-12-21 | 2023-06-29 | Imperial College Innovations Limited | Pseudotyped lentiviral vectors |
| WO2023118436A1 (en) | 2021-12-22 | 2023-06-29 | Novozymes A/S | Method of producing a milk-based product |
| WO2023118565A1 (en) | 2021-12-23 | 2023-06-29 | Novozymes A/S | Reduction of residual dna in microbial fermentation products |
| EP4475850A1 (en) | 2022-02-09 | 2024-12-18 | Imperial College Innovations Limited | Treatment of telangiectasia |
| EP4476240A1 (en) | 2022-02-10 | 2024-12-18 | Novozymes A/S | Improved expression of recombinant proteins |
| WO2023161245A1 (en) | 2022-02-22 | 2023-08-31 | Novozymes A/S | Oral care composition comprising enzymes |
| CN118660951A (zh) | 2022-03-02 | 2024-09-17 | 诺维信公司 | 木葡聚糖酶用于改善洗涤剂的可持续性的用途 |
| JP2025509233A (ja) | 2022-03-08 | 2025-04-11 | ノボザイムス アクティーゼルスカブ | デアミダーゼ阻害剤及びデアミダーゼドメインを有する融合ポリペプチド |
| EP4242303A1 (en) | 2022-03-08 | 2023-09-13 | Novozymes A/S | Fusion polypeptides with deamidase inhibitor and deamidase domains |
| KR20240159839A (ko) | 2022-03-09 | 2024-11-06 | 아스트라제네카 아베 | FRα에 대한 결합 분자 |
| EP4490517A1 (en) | 2022-03-11 | 2025-01-15 | Astrazeneca AB | A scoring method for an anti-fr alpha antibody-drug conjugate therapy |
| AU2023253826A1 (en) | 2022-04-11 | 2024-11-21 | Boehringer Ingelheim International Gmbh | Combination treatment |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| CN119053708A (zh) | 2022-05-17 | 2024-11-29 | 诺维信公司 | 用于减少游离脂肪酸的方法 |
| EP4544036A1 (en) | 2022-06-21 | 2025-04-30 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
| WO2023247514A1 (en) | 2022-06-22 | 2023-12-28 | Novozymes A/S | Recombinant mannanase expression |
| WO2023247664A2 (en) | 2022-06-24 | 2023-12-28 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
| EP4547210A1 (en) | 2022-06-30 | 2025-05-07 | Novozymes A/S | Mutanases and oral care compositions comprising same |
| JP2025525309A (ja) | 2022-07-15 | 2025-08-05 | ノボザイムス アクティーゼルスカブ | デアミダーゼ阻害剤活性を有するポリペプチド |
| WO2024033133A2 (en) | 2022-08-11 | 2024-02-15 | Basf Se | Enzyme compositions comprising an amylase |
| JP2025526654A (ja) | 2022-08-11 | 2025-08-15 | ビーエーエスエフ ソシエタス・ヨーロピア | プロテアーゼ、マンナナーゼ及び/又はセルラーゼを含む酵素組成物 |
| GB202212472D0 (en) | 2022-08-26 | 2022-10-12 | Ip2Ipo Innovations Ltd | Retroviral vectors |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| CN119948159A (zh) | 2022-09-15 | 2025-05-06 | 诺维信公司 | 真菌信号肽 |
| GB202213936D0 (en) | 2022-09-23 | 2022-11-09 | Imperial College Innovations Ltd | Introns |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214445D0 (en) | 2022-09-30 | 2022-11-16 | Imp College Innovations Ltd | Gene therapy |
| EP4593873A1 (en) | 2022-09-30 | 2025-08-06 | Ipsen Biopharm Limited | Clostridial neurotoxin for use in a treatment of bladder pain syndrome |
| GB202214720D0 (en) | 2022-10-06 | 2022-11-23 | Path Spray Ltd | Compositions for detecting biological agents |
| WO2024118901A2 (en) | 2022-11-30 | 2024-06-06 | Novozymes A/S | Carbonic anhydrase variants and polynucleotides encoding same |
| CN120989059A (zh) | 2022-12-05 | 2025-11-21 | 诺维信公司 | 蛋白酶变体以及编码其的多核苷酸 |
| WO2024120767A1 (en) | 2022-12-05 | 2024-06-13 | Novozymes A/S | Modified rna polymerase activities |
| WO2024121191A1 (en) | 2022-12-06 | 2024-06-13 | Novozymes A/S | Method for producing a meat analogue product involving protein-deamidase |
| EP4629838A1 (en) | 2022-12-08 | 2025-10-15 | Novozymes A/S | Polypeptide having lysozyme activity and polynucleotides encoding same |
| EP4629835A1 (en) | 2022-12-08 | 2025-10-15 | Novozymes A/S | Fiber-degrading enzymes for animal feed comprising an oil seed material |
| EP4634355A1 (en) | 2022-12-14 | 2025-10-22 | Novozymes A/S | Improved lipase (gcl1) variants |
| CN120322453A (zh) | 2022-12-14 | 2025-07-15 | 诺维信公司 | 高强度液体蛋白酶配制品 |
| WO2024126811A1 (en) | 2022-12-16 | 2024-06-20 | Boehringer Ingelheim Rcv Gmbh & Co Kg | Means and methods for increased protein expression by use of a combination of transport proteins and either chaperones or transcription factors |
| EP4634395A1 (en) | 2022-12-16 | 2025-10-22 | Basf Se | New ethylenediamine-n,n'-disuccinic acid (edds) synthases |
| EP4638725A1 (en) | 2022-12-19 | 2025-10-29 | Novozymes A/S | Carbohydrate esterase family 3 (ce3) polypeptides having acetyl xylan esterase activity and polynucleotides encoding same |
| CN120283060A (zh) | 2022-12-19 | 2025-07-08 | 诺维信公司 | 用于使用纤维降解酶和工程化酵母生产发酵产物的工艺 |
| CN120380140A (zh) | 2022-12-19 | 2025-07-25 | 诺维信公司 | 具有阿魏酸酯酶和/或乙酰木聚糖酯酶活性的碳水化合物酯酶家族1(ce1)多肽和编码其的多核苷酸 |
| WO2024133344A1 (en) | 2022-12-20 | 2024-06-27 | Novozymes A/S | A method for providing a candidate biological sequence and related electronic device |
| EP4389864A1 (en) | 2022-12-20 | 2024-06-26 | Basf Se | Cutinases |
| WO2024133497A1 (en) | 2022-12-21 | 2024-06-27 | Novozymes A/S | Recombinant protease for cell detachment |
| AU2023410701A1 (en) | 2022-12-21 | 2025-05-22 | Novo Nordisk Pharmatech A/S | Microbial proteases for cell detachment |
| EP4389865A1 (en) | 2022-12-21 | 2024-06-26 | Novozymes A/S | Recombinant protease for cell detachment |
| EP4389886A1 (en) | 2022-12-22 | 2024-06-26 | Novozymes A/S | Lactase enzymes and method of producing a milk-based product |
| CN120435539A (zh) | 2023-01-23 | 2025-08-05 | 诺维信公司 | 清洁组合物及其用途 |
| TW202448517A (zh) | 2023-02-16 | 2024-12-16 | 瑞典商阿斯特捷利康公司 | 用治療性結合分子治療癌症的組合療法 |
| CN120417880A (zh) | 2023-02-22 | 2025-08-01 | 诺维信公司 | 包含转化酶的口腔护理组合物 |
| GB202303328D0 (en) | 2023-03-07 | 2023-04-19 | Imperial College Innovations Ltd | Synthetic promoters |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
| GB202307439D0 (en) | 2023-05-18 | 2023-07-05 | Ipsen Biopharm Ltd | Treatment of a headache disorder with botylinum neurotoxin a |
| AU2024303961A1 (en) | 2023-06-13 | 2025-12-11 | Novozymes A/S | Processes for producing fermentation products using engineered yeast expressing a beta-xylosidase |
| EP4735563A1 (en) | 2023-06-28 | 2026-05-06 | Novozymes A/S | Detergent composition comprising lipases |
| AU2024289271A1 (en) | 2023-07-05 | 2025-11-27 | Novozymes A/S | Foamable dairy products |
| WO2025008364A1 (en) | 2023-07-05 | 2025-01-09 | Novozymes A/S | Methods for obtaining plant-based ready-to-drink coffee or tea beverages |
| EP4273249A3 (en) | 2023-07-07 | 2024-05-22 | Novozymes A/S | Improved expression of recombinant proteins |
| CN121464215A (zh) | 2023-07-10 | 2026-02-03 | 诺维信公司 | 人工信号肽 |
| WO2025032096A1 (en) | 2023-08-09 | 2025-02-13 | Novozymes A/S | Methods for obtaining a plant-based food ingredient |
| AU2024325961A1 (en) | 2023-08-15 | 2026-01-29 | Novozymes A/S | Polypeptides having alkaline phosphatase activity for animal feed |
| CN121620590A (zh) | 2023-09-01 | 2026-03-06 | 诺维信公司 | 稳定的液体脱酰胺酶组合物 |
| EP4777622A1 (en) | 2023-09-13 | 2026-07-22 | Novozymes A/S | Stabilized deamidase compositions |
| EP4780251A1 (en) | 2023-09-19 | 2026-07-29 | Novozymes A/S | Methods for evaluating protein substrate gelling by microbial transglutaminase |
| WO2025068117A1 (en) | 2023-09-26 | 2025-04-03 | Novozymes A/S | Using protein deamidase in processes for obtaining a seed-based dairy alternative beverage with improved stability |
| WO2024240965A2 (en) | 2023-09-29 | 2024-11-28 | Novozymes A/S | Droplet-based screening method |
| CN122029266A (zh) | 2023-10-24 | 2026-05-12 | 诺维信公司 | 木葡聚糖酶用于替代光学增亮剂的用途 |
| WO2025093845A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| AU2023471835A1 (en) | 2023-11-01 | 2026-04-30 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| WO2025103765A1 (en) | 2023-11-17 | 2025-05-22 | Novozymes A/S | Lytic polysaccharide monooxygenases and their use in detergent |
| WO2025111274A2 (en) | 2023-11-20 | 2025-05-30 | Novozymes A/S | Epimerase variants and polynucleotides encoding same |
| CN122270290A (zh) | 2023-11-30 | 2026-06-23 | 诺维信公司 | 包含肽酶或内酯酶的口腔护理组合物 |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
| WO2025132815A1 (en) | 2023-12-20 | 2025-06-26 | Novozymes A/S | Novel cas nucleases and polynucleotides encoding the same |
| WO2025133162A1 (en) | 2023-12-20 | 2025-06-26 | Novozymes A/S | Recombinant protein expression |
| WO2025132872A1 (en) | 2023-12-20 | 2025-06-26 | Novozymes A/S | Modified leguminous protein with improved colloidal stability |
| CN122374461A (zh) | 2023-12-22 | 2026-07-10 | 诺维信公司 | 发酵方法 |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| WO2025140303A1 (en) | 2023-12-28 | 2025-07-03 | Novozymes A/S | Enzymatic treatment of a material comprising corn protein |
| WO2025168806A1 (en) | 2024-02-08 | 2025-08-14 | Novozymes A/S | Polypeptides having carbonic anhydrase activity and polynucleotides encoding same |
| WO2025191164A2 (en) | 2024-03-12 | 2025-09-18 | Novozymes A/S | Use of chymopapain in cell detachment |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
| AU2025239494A1 (en) | 2024-03-22 | 2026-06-25 | Novozymes A/S | Oral care compositions comprising dnases |
| WO2025217017A1 (en) | 2024-04-08 | 2025-10-16 | Novozymes A/S | Compositions and methods for increasing phosphorous availability |
| WO2025226596A1 (en) | 2024-04-24 | 2025-10-30 | Novozymes A/S | Methods for producing secreted polypeptides |
| WO2025229230A1 (en) | 2024-05-03 | 2025-11-06 | Novozymes A/S | Combined carbon capture and soda ash process |
| WO2025233391A1 (en) | 2024-05-09 | 2025-11-13 | Novozymes A/S | Stabilized liquid deamidase compositions |
| WO2025233389A1 (en) | 2024-05-09 | 2025-11-13 | Novozymes A/S | Stabilized liquid deamidase compositions |
| EP4650443A1 (en) | 2024-05-13 | 2025-11-19 | Novozymes A/S | Stabilized liquid deamidase compositions |
| WO2025242320A1 (en) | 2024-05-21 | 2025-11-27 | Novozymes A/S | Stabilized ready-to-drink coffee beverages |
| WO2025247765A1 (en) | 2024-05-30 | 2025-12-04 | Chr. Hansen A/S | Non-heated fermented meat analogue product prepared with vegetable protein transglutaminase and pediococcus strains |
| WO2025257254A1 (en) | 2024-06-12 | 2025-12-18 | Novozymes A/S | Lipases and lipase variants and the use thereof |
| WO2026017381A1 (en) | 2024-07-17 | 2026-01-22 | Novozymes A/S | Optimized bacillus host cells |
| WO2024254620A2 (en) | 2024-08-01 | 2024-12-12 | Novozymes A/S | Protease for diagnostics |
| WO2026057740A1 (en) | 2024-09-12 | 2026-03-19 | Astrazeneca Ab | Treatment of cancer with therapeutic binding molecules |
| WO2026062400A1 (en) | 2024-09-19 | 2026-03-26 | Lift Biosciences Ltd | Preparation of cells |
| WO2026068782A1 (en) | 2024-09-30 | 2026-04-02 | Novozymes A/S | Protease variants and polynucleotides encoding same |
| WO2026076952A1 (en) | 2024-10-08 | 2026-04-16 | Novozymes A/S | Processes for obtaining dairy protein-based ready-to-drink beverages |
| WO2026099414A1 (en) | 2024-11-08 | 2026-05-15 | Novozymes A/S | Method for producing gos syrup |
| WO2026104217A2 (en) | 2024-11-12 | 2026-05-21 | Basf Se | Polypeptides having pectinase activity for use in cleaning compositions |
| WO2026109764A1 (en) | 2024-11-22 | 2026-05-28 | Novozymes A/S | Stabilized solid formulation of antibodies |
| WO2026109480A1 (en) | 2024-11-25 | 2026-05-28 | Novozymes A/S | Gh26 mannanases and their use in detergent |
| GB202417349D0 (en) | 2024-11-26 | 2025-01-08 | Nanosyrinx Ltd | Method of purification |
| WO2026132184A1 (en) | 2024-12-18 | 2026-06-25 | Novozymes A/S | Dispersin variants and their use in animal feed |
| WO2026132220A1 (en) | 2024-12-18 | 2026-06-25 | Novozymes A/S | Gastric stable dispersin variants |
| WO2026131655A2 (en) | 2024-12-18 | 2026-06-25 | Basf Se | Stable mannanase for blends |
| WO2026132030A1 (en) | 2024-12-19 | 2026-06-25 | Novozymes A/S | Cas nucleases and polynucleotides encoding the same |
| WO2026131506A1 (en) | 2024-12-20 | 2026-06-25 | Basf Se | Apolipoproteins for use in cleaning compositions |
| WO2026131444A1 (en) | 2024-12-20 | 2026-06-25 | Novozymes A/S | Alpha-amylases, baking compositions and methods |
| WO2026139262A1 (en) | 2024-12-23 | 2026-07-02 | Basf Se | Polypeptides having chitinase activity for use in cleaning compositions |
| WO2026159189A1 (en) | 2025-01-24 | 2026-07-30 | Novozymes A/S | Method for producing hybrid meat |
| GB202501392D0 (en) | 2025-01-30 | 2025-03-19 | Imperial College Innovations Ltd | Deuterated analogues |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988006630A1 (en) * | 1987-03-02 | 1988-09-07 | Genex Corporation | Method for the preparation of binding molecules |
| JPH02500329A (ja) * | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| WO1989001526A1 (en) * | 1987-08-07 | 1989-02-23 | Genelabs Incorporated | Coincidence cloning method and library |
| CA2016842A1 (en) * | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| CA2016841C (en) * | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| EP0478627A4 (en) * | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
-
1991
- 1991-09-24 IL IL99552A patent/IL99552A0/xx unknown
- 1991-09-27 JP JP51702391A patent/JP3373510B2/ja not_active Expired - Fee Related
- 1991-09-27 EP EP91918234A patent/EP0550645B1/en not_active Revoked
- 1991-09-27 IE IE342591A patent/IE63054B1/en not_active IP Right Cessation
- 1991-09-27 WO PCT/US1991/007149 patent/WO1992006204A1/en not_active Ceased
- 1991-09-27 AT AT91918234T patent/ATE204607T1/de not_active IP Right Cessation
- 1991-09-27 AU AU87318/91A patent/AU667291B2/en not_active Ceased
- 1991-09-27 CA CA002092802A patent/CA2092802A1/en not_active Abandoned
- 1991-09-27 DE DE69132700T patent/DE69132700T2/de not_active Revoked
- 1991-09-27 NZ NZ239988A patent/NZ239988A/en unknown
- 1991-10-01 TW TW080107750A patent/TW314553B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2092802A1 (en) | 1992-03-29 |
| IL99552A0 (en) | 1992-08-18 |
| WO1992006204A1 (en) | 1992-04-16 |
| EP0550645B1 (en) | 2001-08-22 |
| ATE204607T1 (de) | 2001-09-15 |
| DE69132700D1 (de) | 2001-09-27 |
| AU8731891A (en) | 1992-04-28 |
| EP0550645A1 (en) | 1993-07-14 |
| AU667291B2 (en) | 1996-03-21 |
| JP3373510B2 (ja) | 2003-02-04 |
| IE913425A1 (en) | 1992-04-08 |
| DE69132700T2 (de) | 2001-12-06 |
| EP0550645A4 (en) | 1993-09-01 |
| NZ239988A (en) | 1995-06-27 |
| JPH06505145A (ja) | 1994-06-16 |
| IE63054B1 (en) | 1995-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1137941B1 (en) | Protein scaffolds for antibody mimics and other binding proteins | |
| JP3373510B2 (ja) | ヘテロマーリセプターの表面発現ライブラリー | |
| JP6979947B2 (ja) | 近接プローブの作成方法 | |
| JP4829457B2 (ja) | 抗体模倣物および他の結合タンパク質のタンパク質骨格 | |
| JP4369662B2 (ja) | 単量体ドメインのコンビナトリアルライブラリー | |
| JPH06505866A (ja) | 結合タンパク質の最適化 | |
| Urbanelli et al. | Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage | |
| JPH06506836A (ja) | ファージミドを使用するヘテロ二重体受容体ライブラリー | |
| JP2002325594A (ja) | 組換えdna技術によってdna、rna、ペプタイド、ポリペプタイド、または蛋白質を取得するための方法 | |
| Garg | Filamentous bacteriophage: A prospective platform for targeting drugs in phage-mediated cancer therapy | |
| Stiller et al. | Fast and Efficient Fc-Specific Photoaffinity Labeling To Produce Antibody–DNA Conjugates | |
| CN117384287A (zh) | 抗bcma单域抗体及其制备方法与应用 | |
| CN103443277A (zh) | 淀粉样蛋白低聚物结合核酸适体 | |
| Pereboev et al. | Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation | |
| Gomes et al. | Design of an artificial phage-display library based on a new scaffold improved for average stability of the randomized proteins | |
| CN113480603A (zh) | 一种靶向脑胶质瘤细胞的特异性短肽、编码基因及其应用 | |
| KR101755266B1 (ko) | Tale을 포함하는 질환 검출 또는 진단용 조성물 | |
| Haberkorn et al. | Molecular imaging and therapy—a programme based on the development of new biomolecules | |
| CN111647045B (zh) | 一种cd133拮抗多肽及其衍生物与应用 | |
| Sun et al. | Spatially Defined DNA Origami Cell Engagers for T and Natural Killer Cell-Mediated Immune Modulation | |
| CN111647047A (zh) | 一种cd133拮抗多肽及其衍生物与应用 | |
| Shi | Determination of the affinity constants for phage display albumin-binding peptides | |
| Ntemafack et al. | Evolutionary RNA Coliphage Qβ displayed nanotag library and peptide binding materials for biosensing | |
| Hung et al. | Phage display for imaging agent development | |
| JP2007029061A (ja) | ランダムペプチドライブラリーもしくは抗体超可変領域を模倣したペプチドライブラリーと、rna結合タンパク質を用いる試験管内ペプチド選択法を組み合わせた、新規の機能性ペプチド創製システム |